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Cyclodextrins (CDs) are a series of cyclic oligosaccharides composed of 6, 7, 
or 8 D (+)-gluCOSe units linked by α-1,4-linkages and named α-, β-, or γ-CD, 
respectively. Since the first synthesis of polyrotaxane with multiple α-CD rings 
threaded around a polymer chain, CD-based polypseudorotaxanes and polyrotaxanes 
have been receiving increasing attention due to their intriguing supramolecular 
architecture of sliding/dethreading and promising bio-applications. The objective of 
this research was to develop a novel core-shell nanostructures self-assembled from star 
polyrotaxanes, based on star PEG, α-CD, end blocking group with biodegradable 
linkage and cationic polymers, and to investigate the feasibility of their applications to 
biomedical areas such as drug delivery and gene delivery. 
This thesis is divided into five parts. In the first part, we present a literature 
review of drug and gene delivery systems, their developments and challenges, 
followed by a brief summary of recent promising structures as delivery vectors, such 
as core-shell nanostructure (e.g. polymeric micelles), CD-based supramolecular 





In the second part, we demonstrate a supramolecular approach for creating 
biodegradable star polyrotaxane (SPR) by controlled threading of α-CD onto star PEG 
and end blocked with enzyme-triggered degradable linkage. The resulting 
polyrotaxane could further self-assembled into nanoparticles with hydrophilic PEG 
shell and polyrotaxane core. The core-shell nanoaggregates showed high capacity for 
DOX loading with sustained in vitro release for more than 2 months. Furthermore, 
owning to the CD dethreading nature and biodegradable linkage, the SPR 
nanostructure showed enzyme-responsible release properties, which would be 
beneficial to controlled drug delivery.  
In order to meet the conflicting requirements of an ideal drug delivery system, 
disulfide-linkage was introduced on above SPR core-shell nanostructure for reduction-
sensitive drug delivery. The reduction sensitive properties of the polyrotaxanes were 
confirmed. Furthermore, DOX loaded nano-particles exhibited sustained in vitro 
release profile within 30 days even in the presence of DTT, which could be important 
for intravenous delivery to prolong therapeutic effect and reduce cardiotoxicity. In the 
intracellular study, the biodegradable SPR accomplished much faster internalization, 
rapid release of DOX inside cells and higher anticancer efficacy as compared to the 
reduction insensitive control and free DOX. 
Besides drug delivery, we also developed a series of disulfide-containing 
cationic polyrotaxanes as reduction-sensitive gene carriers and investigated their 
applications in gene delivery. Multiple OEI arms with different chain length were 
conjugated onto α-CD rings in the polyrotaxane, which is end blocked with disulfide 
linkage. The degradability and DNA release capability in response to DTT was 





cytotoxicity and higher gene transfection were achieved in contrast to reduction 
insensitive control and polyethylenimine (PEI) 25k. Furthermore, the hindrance effect 
of PEG shell allows the system to be stable in salt and protein solution, and thus 
improve their serum stability.  
In the final part, aiming to increase the serum stability and improve the 
transfection efficiency of PDMAEMA systems with optimal DNA release and 
decreasing cytotoxicity, another reduction-sensitive gene delivery system was 
successfully developed based on star polyrotaxanes, which consists of partially 
threaded α-CD, star PEG and low molecular weight PDMAEMA segments linked to 
the end of PEG arms with disulfide linkage. This research may be helpful as it creates 
a new approach to design a reduction-sensitive delivery system, which achieves rapid 
intracellular release, effective unpacking ability, low cytotoxicity, high transfection 
efficiency and high stability in biological fluids. Moreover, by taking the advantage of 
the core-shell nanostructure, we encapsulated DOX into the center of the star cationic 
polyrotaxane nanoaggregates which could be very promising for the applications in the 
co-delivery of DNA and anti-cancer drugs by achieving a synergistic effect in 
suppressing the proliferation of cancer cells. 
In sum, a series of supramolecular self-assembled nanostructures were 
developed and they can be promising in drug and gene delivery due to many 
advantages, including reduction sensitive degradability, high cell uptake, efficient anti-
cancer ability, serum stability and high transfection efficiency with low cytotoxicity 
and DNA release ability. 
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CHAPTER 1 INTRODUCTION 
This thesis is concerned with some supramolecular self-assembled core-shell 
nanostructures based on star polyethylene glycol (PEG) and α-cyclodextrin (α-CD) 
with their promising applications in drug and gene delivery. In this introductory 
chapter, some background information will be provided, followed by a brief 
introduction to core-shell systems (e.g. micelle), polyrotaxane and bioreductive 
systems as a useful tool for the design of functional nanomaterials for biomedical 
applications, such as drug and gene delivery. Then we will give the scope and 
objective of our research. Finally, a summary of the contents and organization of this 
thesis will be presented. 
1.1 BACKGROUND INFORMATION 
Over the past few decades, drug delivery systems (DDSs) have been 
developed and studied in great depth to improve the curative effect of drugs [1-3]. In 
this method, the administered drug is encapsulated within a material that releases the 
therapeutic in a controlled manner that optimizes the dosage for a specified period of 
time. DDS can ameliorate the problems of conventional administration by enhancing 
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drug solubility, prolonging duration time, reducing side effect, retaining drug 
bioactivity, and so on [4, 5]. For localized treatments, the delivery vehicle is acutely 
retained at the site of delivery, ensuring the local administration of the therapeutic. For 
therapeutics that is delivered through the vasculature, the delivery vehicle increases 
the circulation half-life, and in some cases, targets the therapeutic to a desired tissue. 
A variety of systems have been used as DDSs, such as vesicles [6-8] , nanoparticles [9, 
10], micelles [11, 12], polymer gels [13], alipids [14], etc. At present, stimuli sensitive 
DDSs have been an attractive theme for controlled release. The release behaviors of 
drugs can be easily controlled by surrounding properties, such as pH [15] , 
temperature [16, 17], ionic strength [18] and electric field [19]. 
In addition to DDS, gene delivery systems are also very attractive as a major 
concern component of gene therapy. Gene therapy is the insertion of genes into a 
patient’s cells and tissues to treat a disease, such as a hereditary disease in which a 
deleterious mutant allele is replaced with a functional one [20]. It has drawn a lot of 
attentions in the field of medicine, pharmaceutical sciences and biotechnology due to 
the potentials for treating chronic diseases and genetic disorders such as severe 
combined immunodeficiency [21], cystic fibrosis, and Parkinson’s disease [22]. Gene 
therapy has also been considered as a suitable substitute for conventional protein 
therapy [23] and chemotherapy [24]. 
Although many clinical studies were carried out during the last 20 years, the 
issue of delivery systems has yet to be satisfied. Drug delivery poses great challenges 
to clinicians everywhere. For example, drugs that are administered by the oral route 
suffer from losses resulting from first-pass metabolism, reducing the bioavailability of 
the drug. In these cases, an alternative method of administration is daily intravenous 
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(IV) infusion. This method, however, increases the risk of infections at the site of 
administration and could lead to systemic toxicity, as in the case of chemotherapeutic 
drugs for the treatment of cancer. In the field of gene delivery, the lack of a safe and 
efficient delivery system is a fundamental obstacle to successful clinical application of 
gene therapy. Although viral vectors show excellent transfection efficiencies, their 
association with safety issues such as insertional mutagenesis, immunogenic and 
inflammatory responses has limited their applications in clinical trials. Because of 
these concerns, non-viral vectors especially cationic polymers (polycations) have been 
extensively investigated in the last twenty years, as they can spontaneously condense 
plasmid DNA (pDNA) into structures small enough to enter cells via endocytosis [25]. 
However, the main disadvantages of these polycations are their poor transfection 
efficiency, high toxicity, non-selectivity and in vivo instability.  
Among various designs on the encapsulation structures, core-shell 
nanostructures (e.g. polymeric micelles) with smaller sizes (20-100nm) have shown 
great promise as nanocarriers for efficient drug and gene delivery.[26, 27] Polymeric 
micelles, which are self-assembled from amphiphilic block copolymers, show distinct 
stability in solution. The core-shell structure of the micelle can improve solubility of 
hydrophobic drugs, and protect the incorporated drug from premature degradation [11, 
28, 29]. As a nanosize carrier, micelle can easily permeate into the tumor and induce 
its passive accumulation due to the vascular leakiness and impaired lymphatic 
drainage in solid tumors, which have been known as the enhanced permeability and 
retention (EPR) [30, 31]. So the core-shell nanostructures offer the advantages of 
decreased side effects and improved drug availability. Furthermore, when 
environmentally sensitive (pH, temperature, enzyme, etc) functional groups are 
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introduced into these amphiphilic copolymers, “smart” micelles are formed, and they 
can be used as environmentally controlled drug release system [32-34].  
Since the first synthesis of polyrotaxanes with multiple α-CD rings threaded 
on a polymer [35-37], tremendous interest has been attracted on the studies of these 
series inclusion complexes and their applications on biomaterials [36-40]. 
Cyclodextrins (CDs), also known as cycloamyloses, and cyclomaltoses, are a series of 
natural cyclic oligosaccharides composed of 6, 7, and 8 D (+)-gluCOSe units linked 
by α-1,4-linkages, and named with α-, β-, and γ-CD, respectively (Fig. 1.1). 
Polyrotaxane is composed of three elements: the macrocycle wheels, the appropriate 
axle, and the bulky end-caps on the terminal of axle. According to the fascinating 
capability of macrocyclic CD rings as host molecules, various guest molecules have 
been investigated to form inclusion complexes with enhanced physical and biological 
properties for drug delivery, and to thread into their cavities to create 
polypseudorotaxanes and polyrotaxanes with controllable size and structure for 
various functional nanomaterials  [37-39, 41-46] 
 
Fig. 1.1 Chemical structure of cyclodextrins with different cavity and height 
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Because of the properties of the low toxicity, sliding, dethreading and easy to 
modification, cyclodextrin-based polyrotaxanes and polypseudorotaxanes have 
inspired interesting and rapid exploitation in life science and biotechnology over the 
past two decades, including drug delivery and gene delivery [40, 47-49]. Specifically, 
cyclodextrin-based biodegradable polypseudorotaxane hydrogels could be promising 
as injectable drug delivery systems for sustained and controlled drug release [50-52]. 
Polyrotaxanes with drug/ligand-conjugated CDs threaded on a polymer chain with 
biodegradable end group could be useful for controlled and multivalent targeting 
delivery due to the mobility of CDs [53, 54]. This kind of polyrotaxane is fascinating 
and very promising for drug-conjugating delivery due to several unique structural 
characteristics. Firstly, CDs bear many hydroxyl groups that could be easily modified 
by chemical reactions, allowing for the conjugation of bioactive agent on the CD rings; 
Secondly, self-assembled polyrotaxanes display the highly mobility of CDs as a result 
of the CD rotating around the polymer chain. This flexibility is expected to enhance 
multivalent ligand-receptor interaction, and is promising for applications such as 
targeting drugs, drug-mediated drug delivery and tissue engineering [55]. Thirdly, 
CDs can dethread through the polymer chain when the end is capped through 
biodegradable linkage, which insures the release of drug into the cell [47].  
In the field of gene delivery, based on the design of CD containing polymer 
with low cytotoxicity [56, 57], a new class of CD-containing gene carriers was 
developed based on cationic polyrotaxanes where multiple cationic CDs are threaded 
onto a polymer chain and capped by bulky ends [58-61]. By taking advantage of the 
CD’s ability to slide and rotate along the polymer axle, this system might be able to 
generate well-matched DNA complexes, and thus accomplish the gene transfection 
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with a minimum amount of cationic polyrotaxanes. As a result, the cationic 
supramolecular gene delivery vectors showed good DNA binding ability, low 
cytotoxicity, and high gene transfection efficacy that is similar to PEI (25K) at the 
optimized N/P ratio and molecular weight. 
In the past decades, reduction-sensitive biodegradable polymers have emerged 
as an attractive class of biomedical materials as the delivery systems for both 
biotherapeutics (pDNA, siRNA, peptides and pharmaceutical proteins) as well as low 
molecular weight drugs. Usually, bio-reducible disulfide linkage was introduced to 
these materials in the main chain, side chain, or in the cross-linker. The disulfide 
bonds are subject to rapid degradation under a reductive environment via thiol-
disulfide exchange reactions [62]. In eukaryotic cells, glutathione tripeptide (GSH) is 
the major redox [63]. Under different intracellular environment, GSH maintain 
distinct and non-equilibrium level [64]. For example, in cell surface or blood fluids, 
the concentration of GSH is low (approximately 2-20 μM). So the disulfide linkage is 
sufficiently stable under the conditions in the circulation as well as in extracellular 
matrices. However, in the cytosol, the disulfide bond may be prone to rapid 
degradation in minutes to hours due to the high concentration of GSH (0.5-10mM) 
[65]. Therefore, reduction-sensitive gene carriers in principle could meet the 
conflicting requirements of an ideal delivery system, i.e. high stability in circulation 
while rapid degradation inside targeted cells [66]. 
Therefore, disulfide-containing systems are very attractive for the 
development of drug and gene delivery. In the cancer therapy, it is often more 
desirable to accomplish rapid drug release after vectors arriving at the pathological 
site, which may enhance the therapeutic efficacy as well as reduce the probability of 
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drug resistance in cells. Due to the stimuli-responsive properties of disulfide linkage, 
reduction-sensitive polymers have received a tremendous amount of interest for 
intracellular drug delivery. In gene therapy, the rapid degradation due to the disulfide 
linkage on the one hand could lead to polyplex dissociation and efficient intracellular 
release of DNA or siRNA, on the other hand, they may result in low toxicity by 
avoiding accumulation of high molecular weight polycations inside cells, and finally 
increasing the transfection efficiency [67].  
1.2 OBJECTIVE AND SCOPE OF STUDY 
In view of the above review, in spite of many studies on the formation of 
polypseudorotaxanes and polyrotaxanes reported so far, the application of 
supramolecular self-assembled core-shell nanostructures in drug and gene delivery 
system has not been developed sufficiently till now:  
(1) Although supramolecular hydrogels and drug-conjugated polyrotaxane have 
been developed for drug delivery, little is known about the dual self-assembly 
behavior of polyrotaxane and their application to sustained and reduction-
sensitive intracellular drug release;  
(2) Non-vial gene carriers are challenged with a set of obstacles before and after 
entering cells, including stability in biological fluids, stimuli DNA release 
inside cells, low cytotoxicity and high gene transfection efficiency [68]. 
Recently, CD-containing gene carriers have been synthesized for gene delivery. 
However, little research has been done on introduction of disulfide bond and 
PEG shell with their related supramolecular structures for bioreducible and 
shell sheddable intracellular gene delivery to improve DNA release ability and 
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serum tolerance ability, to decrease cytotoxicity and to enhance gene 
transfection efficiency. 
(3) In spite of many studies on poly(2-dimethylamino) ethyl methacrylate) 
(pDMAEMA) based gene vectors reported so far, there are few studies on 
bioreducible and shell detachable star polyrotaxane with pDMAEMA, not to 
mention their self-assembly behaviors and their applications to reduction-
sensitive intracellular gene delivery, drug delivery and gene/drug codelivery.  
The main aim of this research was to develop a novel core-shell biodegradable 
nanostructure self-assembled from supramolecular architectures based on star PEG, α-
CD and biodegradable linkage, and to investigate the feasibility of their application to 
biomedical areas such as drug delivery and gene delivery. The specific objectives of 
the study were: 
• To synthesize a novel star polyrotaxane derived from controlled threading of 
α-CD onto star PEG and to study their dual supramolecular self-assembly 
behavior, which leads to the formation of core-shell nanostructures, and to 
explore its potential as a candidate in sustained, stimuli-responsive and 
efficient anti-cancer drug delivery. 
• To design a series of core-shell nanostructures self-assembled from star 
polyrotaxanes with reduction-sensitive end group, which should be helpful to 
meet the conflicting requirements of an ideal drug delivery system, i.e. high 
stability in circulation while rapid degradation inside targeted cells; 
• To develop a series of disulfide-containing cationic polyrotaxanes as 
reduction-sensitive and shell sheddable gene carriers with the aim of 
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increasing serum stability, facilitating unpacking ability of pDNA or siRNA, 
decreasing cytotoxicity and improving transfection efficiency. 
• To synthesize and evaluate the potential applications of the shell detachable 
and biocleavable polyrotaxane based on PDMAEMA for redox-responsive 
gene delivery and further investigate their self-assembly behavior, which may 
lead to core-shell nanostructures for gene/drug co delivery. 
This research should provide a series of new carriers for delivery systems and 
the results of the present study may extend the applications of these dual 
supramolecular self-assembled nanostructures to the field of drug and gene delivery. 
Furthermore, this research should be helpful to create a new approach to design a 
reduction-sensitive delivery system by introducing disulfide linkage into 
polyrotaxanes, which could achieve rapid intracellular release, low cytotoxicity, high 
transfection efficiency and effective unpacking ability. 
This thesis mainly focuses on the study of star polyrotaxanes self-assembled 
nanostructures based on star PEG, α-CD, biodegradable end groups and cationic 
polymers, such as OEI and pDMAEMA. Other supramolecular structures such as 
rotaxanes, catenanes and polycatenanes and their applications are not considered. 
Furthermore, the possibility of using these supramolecular nanoaggregates as carriers 
in drug delivery and gene therapy was evaluated through in vitro experiments. The in 
vivo animal tests of the synthesized materials are very complicated and involve many 
biological issues, but these are not central of this study and hence are beyond the 
scope of this study.  
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1.3 ORGANIZATION OF THE THESIS  
Based on the objectives outlined previously, the key is the preparation of novel 
functional materials for drug and gene delivery. In the following chapters, the detailed 
research on preparation processes for supramolecular self-assembled nanostructures 
and their drug and gene delivery capabilities will be reported. Project design and 
hypothesis are shown in Scheme 1.1. Encompassing the objectives outlined previously, 
this thesis is divided into the following chapters:  
 
Scheme 1.1 Project design and hypothesis of the thesis 
Chapter 2: Literature review on the topic of drug and gene delivery systems, their 
development and challenges. Brief summary of recent promising materials and 
structures for drug and gene delivery, such as core-shell nanostructures (e.g. 
polymeric micelles), CD-based supramolecular structures and environmentally 
sensitive and biodegradable vectors, was also presented. 
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Chapter 3: Report on the synthesis of triggered enzymatic biodegradable star 
polyrotaxanes based on star PEG and α-CD, their dual self-assembly behavior and 
their applications as drug delivery systems. 
Chapter 4: Highlight on the utilization of disulfide bond on the polyrotaxane self-
assembled nanostructures for stimuli-responsible drug delivery, which should be 
helpful to meet the conflicting requirements of an ideal drug delivery system, i.e. high 
stability in circulation while rapid degradation inside targeted cells; 
Chapter 5: Research on the reduction sensitive and shell sheddable gene delivery 
based on core-shell nanostructures formed by polyrotaxanes with star PEG, 
oligoethylenimine (OEI) conjugated α-CD and disulfide linkage. This nanostructure 
was explored as an efficient gene carrier with increasing serum stability, facilitating 
DNA release ability, low cytotoxicity and high transfection efficiency. 
Chapter 6: Demonstration of the application of disulfide linkage and low MW 
PDMAEMA on polyrotaxanes to form a shell detachable and biocleavable core-shell 
nanostructures for their promising applications in redox-responsive gene delivery. 
Chapter 7: Further exploration on the dual self-assembly behavior of the star reductive 
polyrotaxanes based on PDMAEMA, which could be very useful as vectors for drug 
delivery and gene/drug codelivery. 
Chapter 8: Conclusion on the work done with possible future endeavours.  
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CHAPTER 2 LITERATURE REVIEW 
2.1 DRUG DELIVERY SYSTEMS AND GENE THERAPY  
2.1.1 Overview of drug delivery systems 
Over the past few decades, drug delivery systems (DDSs) have been 
developed and studied in great depth to improve the curative effect of drugs [1-3]. In 
this method, the administered drug is encapsulated within a material that releases the 
therapeutic in a controlled manner that optimizes the dosage for a specified period of 
time. DDS can ameliorate the problems of conventional administration by enhancing 
drug solubility, prolonging duration time, reducing side effect, retaining drug 
bioactivity, and so on [4, 5]. For localized treatments, the delivery vehicle is acutely 
retained at the site of delivery, ensuring the local administration of the therapeutic. 
For therapeutics that is delivered through the vasculature, the delivery vehicle 
increases the circulation half-life, and in some cases, targets the therapeutic to a 
desired tissue. A variety of systems have been used as DDSs, such as vesicles [6-8] , 
nanoparticles [9, 10], micelles [11, 12], polymer gels [13], alipids [14], etc. At present, 
stimuli sensitive DDSs are an attractive theme for controlled release. The release 
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behaviors of drugs can be easily controlled by surrounding properties, such as pH 
[15] , temperature [16, 17], ionic strength [18] and electric field [19]. 
Nano-sized vehicles, which enable the encapsulation of various materials, 
have been extensively studied. For bioengineering applications, these capsules with 
the ability of encapsulation and delivery of drugs into cells open the door to the 
intracellular therapies such as gene therapy [20]. Future success of gene therapy will 
greatly depend on the understanding the genetic origins of disease and on the methods 
of delivering large numbers of specific drugs into a cell without disturbing the normal 
cellular process. The nano-scale multifunctional polymeric capsules which enable the 
encapsulation of various materials have great potentials in drug encapsulation, drug 
delivery and controlled release, and thus can be employed to solve the problems in the 
current intracellular medicinal therapies. 
2.1.2 Gene therapy and gene delivery systems 
Gene therapy refers to the delivery of a therapeutic gene of interest into the 
targeted cells or tissues with consequent temporary or “permanent” expression of the 
transgene [21]. Over the past two decades, it has gained much attention as a potential 
for treating disease caused by mutation or genetic defects, genetic disorders such as 
cystic fibrosis, combined immunodeficiency [22] and Parkinson’s disease [23]. Gene 
therapy has also been considered as a suitable strategy for conventional protein 
therapy [24] and chemotherapy [25]. 
In clinical application, although over 400 clinical cases were carried out 
during the last 20 years [26], the issue of gene delivery has yet to be satisfied, the lack 
of a safe and efficient delivery vector is a fundamental obstacle to successful gene 
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therapy. To date, viral and non-viral gene carriers are two different strategies under 
investigation for introducing DNA into cells or tissues. Virus vectors, including 
retroviruses and adenoviruses, are regarded as the most effective vehicles for gene 
delivery[27]. The majority of gene therapy clinical trials have relied on viral vectors. 
However, they are challenged on many fundamental drawbacks, such as toxicity, 
immunogenicity, and limitations with respect to scale-up procedures[28]. Most 
importantly, recombinant viral vectors exists the possibility to revert to a wild-type or 
replication-competent virus[29], although they are regarded as non-replicative and 
non-pathogenic.   
Non-viral vectors, compared with the viral counterparts, are relative safer, 
have greater flexibility and facile to large-scale production [30]. They consist of three 
categories: (i) naked DNA delivery, (ii) cationic liposomes and (iii) cationic polymers 
[31]. So far, cationic polymers and cationic liposomes are the most studied and used 
chemical vectors. However, in comparison with viral vectors, non-viral gene carriers 
are significantly less efficient due to the problems of low cell surface selectivity and 
internalization, low targeting to specific intracellular compartments and numerous of 
cellular barriers and immune defense mechanisms. To succeed, the ideal synthetic 
DNA delivery system should possess the following properties: ease of assembly (e.g., 
it should use modular components that can be “packaged” in vitro); efficient delivery 
leading to total transfection (i.e., DNA should be physically delivered to the majority 
of intended cells); stabilization of DNA before and after uptake (e.g., using nontoxic 
biocompatible materials); capability of bypassing or escaping from endocytotic 
pathways (e.g., by incorporating viral components); efficient decomplexation or 
 
Chapter 2: Literature Review 
20 
“unpackaging” (e.g. intracellular controlled  release); efficient nuclear targeting; and 
high, persistent, and adjustable expression of therapeutic levels of proteins[32]. 
Cationic polymers are the major type of the nonviral gene vectors investigated 
in the past decade. They are generally possessed positive charged groups such as 
primary, secondary, tertiary and quaternary amines. This high density of positive 
charges allows the cationic polymers to form stable complexes with non-viral DNA. 
The formed polyplexes (polymer/DNA complexes) are positive charges, which could 
bind cells followed by endocytosis mediated by anionic proteglycans on the cell 
surface. These polymers vary widely in their structures, which range from linear to 
highly branched molecules that influence their complexation with nucleic acids and 
their transfection efficiency. Due to the easy modification, the cationic polymers are 
promising to meet the multiple functions required for safe and efficient gene delivery 
[33]. The polycations frequently used in gene delivery and transfection include, 
polyetheyleneimine [34], poly (L-lysine) [35], dendrimers [36], polybrene [37], 
gelatin [38], CD-containing polymers [39], and poly(2-dimethylaminoethyl 
methacrylate) (pDMAEMA) [40]. Although these gene vectors have been developed 
for over two decades, they are still limited in clinical application due to the poor 
efficiency, high toxicity and low in vivo stability. 
2.2 POLYMERIC MICELLES FOR DRUG AND GENE DELIVERY 
During the past decade, core-shell nanostructures have demonstrated their 
utility in delivery drugs and are currently recognized as promising formulations for 
enhancing the efficacy of drugs [41, 42]. Among these vectors, polymeric micelles are 
the most studied structures. A polymeric micelle is a supramolecular assembly of 
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block copolymers, having a characteristic core-shell structure; the drug-loaded core is 
surrounded by hydrophilic outer shells [43]. These polymeric micelles show distinct 
stability in solution. The core-shell structure of the micelle can improve solubility of 
hydrophobic drugs, and protect the incorporated drug from premature degradation [11, 
44, 45]. As a nanosize carrier, micelle can easily permeate into the tumor and induce 
its passive accumulation due to the vascular leakiness and impaired lymphatic 
drainage in solid tumors, which have been known as the enhanced permeability and 
retention (EPR) [46, 47]. So the micelles offer the advantages of decreased side 
effects and improved drug availability.  
Therefore, polymeric micelles with smaller sizes (20-100nm), which are self-
assembled from amphiphilic block copolymers have shown great promise as 
nanocarriers for efficient drug delivery [48, 49]. Indeed, several micellar formulations 
encapsulating antitumor drugs are now undergoing clinical trials [50]. Furthermore, 
when environmentally sensitive (pH, temperature, enzyme, etc) functional groups are 
introduced into these amphiphilic copolymers, “smart” micelles are formed, and they 
can be used as environmentally controlled drug release system. Recently, there has 
been a strong incentive to develop polymeric micelles with smart functions such as 
target ability to specific tissues and chemical or physical stimuli-sensitivity. Such 
smart polymeric micelles are assumed to enhance the efficacy of the loaded drugs as 
well as to minimize side effects beyond current drug delivery formulations [51-53]. 
2.2.1 Polymeric micelles for drug delivery 
Amphiphilic block copolymers are commonly used to construct micellar 
assemblies. In aqueous solution, the hydrophobic parts of these block copolymers 
aligned together to the centre and hydrophilic parts aligned towards the outside 
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environment to form the polymeric nanocapsules structures. After that, covalent 
bonds will be formed in the outside shell of this capsule to stabilize the whole system 
to make it more suitable for further applications. And the hydrophobic interior 
property of this capsule gives this system the ability to contain hydrophobic drug 
inside its cavity, which refers to drug delivery (Fig. 2.1) [54]. The majority of block 
copolymers have hydrophilic blocks of polyethylene glycol (PEG) [55]. This well 
studied, FDA-approved polymer is biocompatible. PEG demonstrates notable 
antifouling properties, and micelles having an outer shell of this polymer are able to 
resist protein adsorption and cellular adhesion. The nonfouling nature of PEG 
increases the residence time of circulation in blood and minimizes the detection by the 
immune system [56, 57].  
 
Fig. 2.1 Polymeric micelles as drug carriers 
As a typical example, polycaprolactone (PCL) and polylactic acid (PLA) are 
commonly used as the hydrophobic portion to form micelle structure with PEG. They 
have been utilized for amphotericin B, pioglitazone, 9-nitro-20(S)-camptothecin (9-
NC), and methotrexate (MTX) [58-60]. The self-assembly of block copolymers is 
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often spontaneous and can be performed in the presence of small molecules, leading 
to micelles encapsulated with drugs that have diameters up to hundreds of nanometers. 
Since the therapeutic is present during the self-assembly process, drugs are loaded 
easily. For example, PEG–PCL micelles have been used to encapsulate rapamycin, a 
small antibiotic, to form micelles that are less than 100 nm in diameter. Rapamycin 
can be encapsulated at concentrations of >1 mg ml-1, which is exceptionally higher 
than the solubility of the free drug in water  [58]. MTX, an anticancer and anti-
rheumatoid arthritis agent, can be sequestered in micelles of PEG–PLA block 
copolymers in a similar manner. These micellar structures have diameters that range 
from 50 to 200 nm, with loading capacities of 12% by weight and encapsulation 
efficiencies as high as 50% [59]. 
The pH-sensitive micelles are very useful to therapeutic function by 
responding to low pH conditions in the endosomal or lysosomal compartment of the 
cells.  Kataoka et al. at have recently developed micelle-forming PEG-b-P (Asp-Hyd-
DOX) copolymer, which are prepared by chemically conjugating doxorubicin (DOX) 
to the side chain of PEG-b-poly (aspartic acid) copolymers via an acid-labile 
hydrazone bond [61, 62]. Such pH-sensitive polymeric micelles significantly released 
active DXR under low pH conditions corresponding to late endosomes and lysosomes. 
Consequently, the micelles effectively suppressed tumor growth in mice over a broad 
range of injection doses while the toxicity remained extremely low, which is in 
marked contrast to free DOX with a narrow therapeutic window [62]. Similarly, PEG-
b-poly (L-histidine) copolymers possessing pKa values around a physiological pH, 
which act as amphiphilic copolymers to form polymeric micelles under a 
physiological pH condition while showing a hydrophilicity, biodegradability and 
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fusogenic activity at the lower pH conditions [63]. This micelle showed an 
accelerated release of DOX with lower pH. 
2.2.2 Polymeric micelles for gene delivery 
The efficient gene vectors should be a key technology in the forefront of 
modern medicine owing to their potential use for the treatment of intractable disease 
and tissue engineering. In addition to the delivery of hydrophobic drugs, micelle 
carriers can be utilized for the delivery of DNA. Inverted micelles have been designed 
to bind to and package DNA for delivery. Inverted micelles are composed of a 
hydrophilic outer shell (e.g PEG) and a polycationic inner core that can favorably 
interact with negatively charged DNA [64, 65]. Polylysine, polyethylenenimine (PEI) 
and polyphosphoramidate (PPA) have been used for the inner core. The diblocks 
alone in solution do not self-assemble, but when the polyanionic DNA is added, it 
binds the polycation blocks, decreasing the overall net charge, followed by micelle 
formation. The micelles protect the DNA from the enzymatic and hydrolytic 
degradation during delivery. When encountered by cells, the loaded micelles are 
endocytosed, the DNA is released, and the cells become efficiently transfected [64]. 
For example, Kataoka et al. reported the in vivo demonstration of this approach, and 
the gene for luciferase was encapsulated into PEG-polylysine inverted micelles, 
which exhibited sustained gene expression in the mice liver over 3 days [66]. 
DNA delivery is not limited only to inverted micelles. Micelles composed of 
hydrophobic cores and polycationic exteriors can also be used. For instance, micelles 
were formed, which consist of polypeptides with polyalanine as a hydrophobic block 
and polylysine/polyhistidinie as hydrophilic block that condense DNA on their outer 
corona. Even though DNA is bound to the outer shell of the micelle, it is still 
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protected from enzymatic degradation. Furthermore, these micelles were found to be 
noncytotoxic and capable of delivering genes to HEK293, HepG2, and 4T1 cancer 
cell lines [67]. Generally, the delivery of DNA-carrying micelles can be enhanced by 
decorating peptide, a protein that target the vehicle to a specific binding site [68, 69].   
Recently, micelles capable of dual delivery of DNA and other therapeutics 
have also have been designed [70-72]. Specially, poly N-methyldietheneamine 
sebacate and (cholesteryl oxocarbonylamido ethyl) methyl bisethylene ammonium 
bromide sebacate (PMDS-co CES) form micelles with an inner hydrophobic core 
composed of cholesterol surrounded by polycationic polymer. The co-delivery of the 
micelle containing paclitaxel and the plasmid DNA suppressed tumor growth in a 4T1 
mouse breast cancer model more effectively than the delivery of micelles with either 
therapeutic alone [70]. 
2.3 CYCLODEXTRIN BASED POLYROTAXANE FOR DRUG AND GENE 
DELIVERY 
Since the first synthesis of polyrotaxanes with multiple α-CD rings threaded 
on a polymer [73-75], tremendous interest has been attracted on the studies of these 
series inclusion complexes and their applications on biomaterials [74-78]. 
Cyclodextrins (CDs), also known as cycloamyloses, and cyclomaltoses, are a series of 
natural cyclic oligosaccharides composed of 6, 7, and 8 D (+)-gluCOSe units linked 
by α-1,4-linkages, and named with α-, β-, and γ-CD, respectively. Their topological 
structures give a hydrophobic inner cavity with a depth of ca. 7.0 Å, and an internal 
diameter ca. 4.5, 7.0, and 8.5 Å for α -, β-, and γ-CD, respectively. Polyrotaxane is 
composed of three elements: the macrocycle wheels, the appropriate axle, and the 
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bulky end-caps on the terminal of the axle. According to the fascinating capability of 
macrocyclic CD rings as host molecules, various guest molecules have been 
investigated to form inclusion complexes with enhanced physical and biological 
properties for drug delivery (Fig. 2.2), and to thread into their cavities to create 
polypseudorotaxanes and polyrotaxanes with controllable size and structure for 
various functional nanomaterials  [75-77, 79-84] 
 
Fig. 2.2 Demonstration of CD and polyrotaxane: (a) structure of α-CD, (b) general 
synthesis procedure of polyrotaxane [74] 
2.3.1 CD based polyrotaxanes and polypseudorotaxanes for drug delivery 
There have been several recent attempts made to use cyclodextrin based 
polyrotaxanes and polypseudorotaxanes for drug delivery. Because both PEO and 
CDs are known to be biocompatible and CDs have been approved by the FDA as food 
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and drug formulations, it is easily to construct supramolecular inclusion complexes 
between CDs and PEO or its copolymers as a new class of bioabsorbable systems for 
controlled drug delivery. Based on different method for introducing drugs or proteins, 
there have been polypseudorotaxane hydrogels for sustained drug release and drug-
conjugated biodegradable polyrotaxanes for controlled and targeting drug delivery.  
2.3.1.1 Supramolecular hydrogels formed by α-CD and PEO and the copolymers 
Supramolecular hydrogels based on polypseudorotaxanes of CDs and 
polymers is one of the most attractive physical cross-linking hydrogels. Generally, 
they are thixotropic and thermo-reversible, which is a unique property as injectable 
hydrogel drug delivery systems [85-87]. As a typical example, PEG of high molecular 
weights was found to form complexes with α-CD in aqueous solution to give gels in a 
wide range of concentrations [87, 88]. According to the rheological studies, the 
hydrogels displayed decreasing visCOSity when agitated and restored within hours 
after the agitation. This property renders the hydrogel formulations injectable even 
through a fine needle [85]. These unique hydrogel can be applied to injectable and 
bioabsorbable drug delivery systems due to their thixtropic and reversible properties 
[78]. The gels were entrapped by fluorescein isothiocyanate-labeled dextran (dextran-
FITC) and characterized in terms of in vitro release [85]. It was found that the release 
rate decreases sharply with an increase in the molecular weight of PEO up to 35K Da 
and the release rate of gel formed with PEO 35K and 100K is quite sustained.  
In spite of the promising properties of α-CD-PEO hydrogels, it is challenging 
to apply this hydrogel for in vivo drug delivery. Firstly, this hydrogel is not suitable 
for long-term drug release because the physical interaction is weak in aqueous 
environment due to the hydrophilic property of PEO; In addition, the high molecular 
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weight PEO is not biodegradable and it is difficult for filtration through human kidney 
membrane. Therefore, with regarding to the first problem of α-CD-PEO hydrogels, a 
new supramolecular hydrogels self-assembled between α-CD and triblock copolymer 
PEO-PPO-PEO were studied for long-term and controlled release of drugs [13, 82]. 
The gelation was induced by the complex formation between the PEO segments of the 
PEO-PPO-PEO triblock copolymer and partially threaded α-CDs. In addition to the 
injectable and reversible properties, the polypseudorotaxane hydrogel is thermo-
sensitive. Furthermore, unlike the thermo-responsible hydrogels formed only with 
PEO-PPO-PEO triblock copolymers [89, 90], the addition of α-CD largely reduced 
the concentration of the copolymer needed for gel formation [13]. The in vitro 
controlled release properties showed that the hydrogel can achieve the sustained 
release for more than one week with a linear release kinetics [78]. Pluronics have also 
been threaded on hydroxypropyl-β-CD. They showed enhanced solubility of the drug 
and a temperature-dependent sustained release [91]. 
Considering that the high molecular weight PEO is not suitable for filtration 
through human kidney membrane, a biodegradable polymer will be advantageous 
because of the degradation of material into low molecular weight compounds, which 
can be eliminated from the body through natural pathway. PHB is one of the 
biodegradable polymers that can be used for drug delivery. PEO-PHB-PEO triblock 
copolymer was found to form block selective polypseudorotaxanes with α-CD (Fig.2. 
3a) [92, 93]. For hydrogel formation, it was found that the cooperation effect of 
complexation of α-CD with PEO block together with the hydrophobic interaction 
between the middle PHB blocks results in the formation of the supramolecular 
hydrogel with a strong macromolecular network (Fig. 2.3b) [86].  
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Fig. 2.3 (a) The stucture of PEO-PHB-PEO triblock copolymer, and (b) the schematic 
illustratios of the proposed structures of α-CD-PEO-PHB-PEO inclusion complex  
In contrast to most physical hydrogels formed simply by copolymers, the in 
vitro release kinetics studies of dextran-FITC model drug form this α-CD-PEO-PHB-
PEO hydrogel showed that it was suitable for relatively long-term sustained 
controlled release of macromolecular drugs. Specifically, it was found that the α-CD-
PEO-PHB-PEO hydrogels with reasonably high α-CD concentration showed 
excellent controlled release property, sustaining the release of dextran-FITC for more 
than 1 month. This is a large improvement by comparasion with α-CD-PEO 
homopolymer hydrogel [85]. Furthermore, the hydrogels with lower α-CD 
concentrations resulted in a much faster release rate, indicating the complexation 
between α-CD and PEO blocks is important to form a stable supramolecular gel. As 
the same with α-CD-PEO hydrogel, this hydrogel was also found to be thixotropic 
and reversible. Therefore, this new supramolecular hydrogel is promising for 
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relatively long-term sustained controlled delivery of macromolecular drugs as an 
injectable formulation. More importantly, the biodegradable PEO-PHB-PEO 
copolymers will have the advantage that the hydrogel will be bioabsorbable and 
dissociation after drug release, which is a good benefit for the human body [86]. 
Similarly with copolymer PEO-PHB-PEO, another amphiphilic biodegradable 
copolymer PEO-PCL was also studied to form polypseudorotaxane hydrogels with α-
CD. The new supramolecular hydrogels are promising for minimally invasive 
therapeutic delivery application with fine-tuned properties [94, 95].  
Based on similar mechanism whereby α-CD could thread on part of PEO 
segments in a block or homo polymer to form supramolecular physical cross-linked 
structure, an increasing number of polypseudorotaxane-based physical hydrogels are 
appearing in the literature. For example, by mixing α-CD, PEG and PAA in an 
aqueous solution, the competition between host-guest and hydrogen-bonding 
interactions occurs [96]. Moreover, there are a few reports on hydrogel formation 
between α-CD and PEO or PPO-grafted polymers. Supramolecular physical gelation 
can be introduced by a specific host-guest interaction between α-CD and PEO-grafted 
dextrans [97]. Similar thermo- or pH-sensitive polypseudorotaxane hydrogels can be 
formed between α-CD and PEO-grafted chitosan [98], α-CD and PEO-grafted 
hyaluronic acid [99], β-CD and PPO-grafted dextran copolymer [100], and between 
α-CD and highly densely PEO grafted polymer brushes (PBIEM-g-P(PEOMA)) [101]. 
Recently, a water soluble polyrotaxane composed of multiple methylated α-CD rings 
threaded on a high molecular weight PEO chain and end-capped by bulky adamantly 
groups was developed [102, 103]. This Me-PR exhibited thermo-reversible sol-gel 
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transition in water depending on the degree of methylation and a gelation took place 
at high temperature.  
Apart from the physical hydrogel, chemical gel cross-linked by biodegradable 
polyrotaxanes having ester linkages at the terminal of PEG are also reported as good 
example for drug delivery. These supramolecular networks are also called “sliding 
gels” [104-106]. Typically, Yui’s lab prepared biodegradable and temperature-
controlled hydrogels by crosslinking N-isopropylacrylamide (NIPAAm) and 
methacrylate(MA)-introduced polyrotaxane in which α-CDs are threaded onto a PEG 
chain capped with bulky end-groups via ester linkages [107]. These supramolecular 
hydrogels could be useful for biomedical applications because of their 
biocompatibility and thermo-controllable property. 
2.3.1.2 Supramolecular micelles based on cyclodextrin for drug delivery 
Although supramolecular hydrogels or self-aggregates constructed from CDs 
involving inclusion complexes have been intensively investigated not only for their 
theoretical merits but also for their potential drug delivery applications, the self-
assembly micelles formed by amphiphilic copolymer threaded with CDs has not been 
used as a carrier for the controlled drug release. Being different from supramolecular 
hydrogels matrix for drug delivery, the polyrotaxane micelles could self-assemble the 
drug into a nanometer scale particle, which is always an attractive factor for effective 
drug delivery carriers. As a typical example, a kind of novel amphiphilic triblock 
copolymers containing polyrotaxane as a central block was synthesized via the ATRP 
(Fig. 2.4) [108]. Rather than the physically crosslinked hydrogels or the traditional 
PRs yielded as crystalline precipitates from aqueous solution, these triblock 
copolymer with polyrotaxane central block flanked by two hydrophilic brushlike 
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PEGMA oligomers would self-assemble into nano-sized particles with the unique 
core–shell structure in aqueous medium. In this system, PEGMA oligomers create a 
dense non-adhesive hydrophilic coating around the PR central block capable of 
suppressing protein and cell adhesion and extending residence time of the particles as 
carrier for the controlled drug release.  
 
Fig. 2.4 (a) Synthetic pathway of PR-based triblock copolymer via ATRP of PEGMA in 
aqueous medium; (b) Schematic diagram of self-assembly micelles formed by the PR-
based triblock copolymer in aqueous medium 
Amphotericin B (AmB) was selected as a model drug to evaluate the drug 
release property of the polyrotaxane micelle system. Surprisingly, the nano-sized 
micelles were found to effectively solubilize AmB with high drug-loading content and 
drug-loading efficiency as well as long sustainable release profile. By comparison 
 
Chapter 2: Literature Review 
33 
with micelles form by Pluronic PPO-PEO-PPO without CDs, the polyrotaxane 
containing amphiphilic micelles released much slower, which indicated that 
encapsulated AmB may have some interaction with threaded β-CDs, giving longer 
and sustained release time. Moreover, the entrapment into self-aggregates of 
amphiphilic PR-derived triblock copolymers can protect AmB molecules from 
hydrolysis, aggregation and precipitation by minimizing contact with the bulk 
aqueous phase.  
Another micellar structure was constructed by using the process of highly 
threaded pseudopolyrotaxane stacking to drive self assembly. Poly (ethylene oxide)-
blcok poly ((dimethylamino ethylmethacrylate) (PEG-PDMA) polymer is an example. 
α-CD was able to thread over the PEG segment, but not the PDMA segment of this 
polymer axle. The threaded part of the polypseudorotaxanes aggregated, leaving the 
hydrophilic PDMA polymers exposed to solution, thus forming a micellar structure 
[109].  
2.3.1.3 Drug-conjugated biodegradable polyrotaxane for drug delivery 
In addition to hydrogel matrix for drug, CD-based polyrotaxanes could be 
widely applied as drug delivery systems with another strategy, which is by 
conjugating drug or functional proteins in on the CD rings. Polyrotaxane is 
fascinating and very promising for this kind of drug delivery due to several unique 
structural characteristics. Firstly, CDs bear many hydroxyl groups that could be easily 
modified by chemical reactions, allowing the conjugation of bioactive agent on the 
CD rings; Secondly, self-assembled polyrotaxanes display highly mobility of CDs as 
a result of the CD rotating around the polymer chain. This flexibility is expected to 
enhance multivalent ligand-receptor interaction, and is promising for applications 
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such as targeting drugs, drug-mediated drug delivery and tissue engineering [110]. 
Thirdly, CDs can dethread through the polymer chain when the end is capped through 
biodegradable linkage, which insures the release of drug into the cell [111].   
In the field of drug delivery, one of the most crucial issues is how to bind the 
bioactive agents or ligands on receptor sites of proteins on the plasma cell membranes 
effectively and specifically. Over the last decades, the approach of multivalent 
interaction by using multiple ligands with receptor protein was considered as a 
possible solution [112]. However, multivalent ligand-immobilized polymer resulted in 
unsatisfying mainly because of a spatial mismatch between the ligand-polymer and 
receptor [113] (Fig. 2.5a). Thus, as mentioned above, cyclodextrin-based 
polyrotaxanes are advantageous in freely spinning through the polymer chain, which 
opens the opportunity for multivalent interaction with biological systems (Fig. 2.5b). 
 
Fig. 2.5 The effects of mobile CDs in polyrotaxanes on binding receptor proteins in a 
multivalent manner (a) Image of ligand-polyrotaxane conjugate, (b) image of ligand-
immobilized polymer, and (c) possible binding models for Gal-1 and polyrotaxanes. 
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Based on this hypothesis, a polyrotaxane consisting of lactoside-CD-
polyviologen conjugated polyrotaxane was investigated for its ability to inhibit 
galectin-1-mediated T-cell aggulutination. Due to the rotating properties, the 
polyrotaxane showed an enhancement for the agglutination [114]. Similarly, biotin 
was conjugated to α-CD or β-CD which was treaded in PEO or PPO chains and end 
caps with biodegradable L-phenylalanine (Z-Phe). In contrast to biotin-CD conjugate, 
this biotin-polyrotaxane conjugate model significantly switches monovalent binding 
to multivalent binding, and results in a much greater inhibitory potency [115, 116]. 
Furthermore, by conjugating maltose with α-CD-PEO polyrotaxane, Yui’s lab found 
that it exhibits a much stronger inhibitory effect than maltose and the mobility of α-
CD along the PEG chain plays a crucial role in rapid binding of concanavalin A [117-
119].  
Biodegradability is one of the indispensable properties for drug delivery 
systems. As compared to biodegradable hydrogel matrices for drug release, drug-
conjugated biodegradable polyrotaxane can be advantageous in both controlling the 
drug release by degradation rate of terminal group and the number of CDs threaded 
onto the biodegradable polymer, and the dethreading of CDs modified with 
appropriate drugs may enhance drug permeation across biological barriers (Fig. 2.6). 
The first example of biodegradable polyrotaxanes was reported in 1995 [120]. The 
supramolecular assemblies were formed between α-CD and PEO chain, capped with 
L-Phe via biodegradable peptide linkages. When the peptide linkages were 
enzymatically degraded by protease such as papain, the polyrotaxanes would degrade 
to PEO, α-CD and L-Phe. In order to investigate the degradation and CD release 
kinetics of this new drug release system, hydroxyl-propylated (HP) modified 
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polyrotaxanes were synthesized [121]. The in vitro release study shows that HP-α-CD 
can be released when either of two terminal peptides was cleaved, and the rate of 
degradation can be controlled by changing the degree of hydrophobicity of the α-CDs 
in the polyrotaxanes. Furthermore, the oxypropyl groups next to L-Phe moiety can 
enhance the interaction with papain to increase the HP-α-CD release [122]. Thus the 
designed polyrotaxanes are feasible as novel drug carriers in which the degradation of 
terminal moiety can induce the release of drugs. 
 
Fig. 2.6 The schematic illustration of drug-conjugated polyrotaxane and the concept of 
triggered drug release via enzymatic degradations 
The incorporation of drugs to HP-α-CD in the polyrotaxane was accomplished 
in 1999. Theophylline-polyrotaxane conjugates were synthesized by coupling 
theophylline with α-CD that threaded onto PEG chain capped with L-Phe [111]. Upon 
enzymatic degradation of the terminal groups, theophylline-CD conjugates were 
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completely released via dissociation of the supramolecular structure without steric 
hindrance. The bonds between drug and α-CDs can also hydrolysis to release the 
active drugs in cells (Fig. 2.6). In addition, by utilizing different enzymes (papain and 
α-chymotrypsin), sustained release of drug was observed, ranging from 50 h to 250 h. 
Based on the similar technology, another drug, the anti-cancer drug doxorubincin 
(DOX), was also conjugated to polyrotaxane polymer via hydrolyzable linkages, and 
a cell-penetrating low molecular weight protamine (LMWP) peptide was further 
attached to the chain end in order to facilitate the intracellular uptake of tumor cells 
[123]. It was demonstrated that the LMWP-PR-DOX conjugates yielded a sustained 
release of DOX over a period of greater than 4 days and this LMWP-PR-DOX 
conjugate offers a great potential for intracellular drug delivery into tumor cells in 
achieving highly effective and safe drug therapy.  
2.3.2 CD based polyrotaxanes and polypseudorotaxanes for gene delivery 
2.3.2.1 Cyclodextrin-containing cationic polymers for gene delivery 
Gene delivery using polycations is believed as one of the greatest challenges 
for inventing nonviral gene carrier systems instead of toxic virus-based vector 
systems [124]. Because the hydroxyl groups in CD rings offers opportunity for 
multiple modification, CDs were explored for oligonucleotide delivery, which 
enhanced the absorption and resistance to nucleases [125]. The first CD-containing 
cationic polymer for gene delivery was reported in 1999 [126, 127]. Generally, the 
CD-containing cationic polymers showed lower cytotoxicity and efficient gene 
transfection [128, 129]. More importantly, the CD-containing polycations can be 
further modified by inclusion complex formation [130]. Take the pegylation for 
example; PEO-adamantane was used to form complex formations with β-CD 
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modified polyethylenimine (PEI) by the supramolecular interaction between 
adamantane and β-CD. It was found to stabilize the polyplex nanoparticles and result 
in enhanced gene transfection [131, 132]. So far, a number of cationic polymers have 
been modified by grafting CDs on the polymers to study the gene delivery, such as 
linear and branched PEI [133], and polyamidoamine(PAMAM) dentrimer [134, 135]. 
Most recently, a new series of cationic star polymers consisting of α-CD core 
and oligoethylenimine(OEI) arms were synthesized as nonviral gene delivery vectors 
[136]. The α-CD-PEI star polymers could inhibit the migration of pDNA on agarose 
gel as a result of nanoparticles with sizes ranging from 100 to 200 nm. The star 
cationic polymer was found to display lower in vitro cytotoxicity than branched PEI 
(Mw=25K), and the transfection efficiency is excellent, being comparable to or even 
higher than that of branched PEI (25K). With a similar star structure, a kind of 
polycationic amphiphilic cyclodextrins was reported [137]. The structure contains 
both cationic elements and lipophilic tails, which is similar to the lipid structure. The 
nanoparticle stability and transfection efficiency can be rationally modulated by 
judicious tailoring of the molecular topology. 
2.3.2.2 Cyclodextrin-containing cationic polyrotaxane for gene delivery 
Another new class of CD-containing gene carriers was developed based on 
cationic polyrotaxanes where multiple cationic CDs are threaded onto a polymer 
chain and capped by bulky ends. By taking advantage of the CD’s ability to slide and 
rotate along the polymer axle, this system appears to be able to generate well-matched 
DNA complexes, and thus accomplish the gene transfection with a minimum amount 
of cationic polyrotaxanes. It is similar to the concept of multivalent interaction 
discussed earlier. Therefore, CD-containing cationic polyrotaxanes are a promising 
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system for non-viral gene delivery. The first example of this system would be the 
cationic supramolecules composed of multiple OEI-grafted β-CD threaded on a 
Pluronic PEO-PPO-PEO triblock copolymer chain and end capped with 2,4,6-
trinitrobenzene sulfonate (TNBS) (Fig. 2.7) [138]. This system may have the 
following advantages. Firstly, β-CD is known to selectively thread around the PPO 
segments [139], providing low spatial hindrance using spare PEO segments and 
permitting efficient OEI grafting degree. Secondly, due to the free mobility of OEI-
grafted β-CD along both PPO and PEO segments, it is flexible to condense DNA 
efficiently. Thirdly, because shorter length of PEI was used the system showed much 
less toxicity than PEI (25K) in cell cultures. Finally, there are a lot of “flapping” OEI 
chains with many primary and secondary amines, which is beneficial for interaction 
with DNA and cell membranes. As a result, the cationic supramolecular gene delivery 
vectors showed good DNA binding ability, low cytotoxicity, and high gene 
transfection efficacy that is similar to PEI (25K). It even exhibits higher transfection 
efficiency than dimethylaminoethyl(DMAEC)-α-CD polyrotaxane systems [140]. In 
further development, the β-CD-OEI/PEO-PPO-PEO system was reported to display 
high and sustained gene delivery capability in cancer cells in the presence or absence 
of serum [141]. 
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Fig. 2.7 structures of cationic polyrotaxanes with multiple OEI-grafted β-CD rings[138]. 
By utilizing the similar system, a few of cationic polyrotaxanes based on other 
CDs and chains were synthesized, including cationic supramolecules consisting of 
OEI-grafted α-CD threaded on PEO [142] and polyrotaxane consisting of cationic 
OEI-grafted α-CD threaded on PEO-PPO random copolymer [143]. Generally, these 
cationic polyrotaxanes showed strong DNA binding ability, low cytotoxicity, high 
gene delivery capability and they have a high potential as novel non-viral gene 
carriers in clinical gene therapy. In another study, soluble polyrotaxanes were formed 
for gene delivery by threading α-CD molecules over PEO and PCL chains of the 
ternary block copolymer PEO-PCL-PEI. The gene transfection efficiency was of the 
same order of magnitude as PEI (25K) but with much lower toxicity [144]. In addition 
to amino-grafted CD polyrotaxane, LPEI/γCD-based polypseudorotaxanes have also 
been examined for gene delivery [145]. The γ-CD-based polypseudorotaxane had 
improved cellular uptake and lower toxicity. The transfection efficiency of this 
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polypseudorotaxane was comparable to or greater than that of the LPEI, especially at 
higher N/P ratios. 
2.4 ENVIRONMENTALLY SENSITIVE AND BIODEGRADABLE VECTORS 
The most evident problem associated with non-degradable polymeric vectors 
is that they are not easily removed by the physiological clearance systems and, 
therefore, can possibly accumulate within cells or tissues to elicit further cytotoxicity. 
The biodegradable polymers, which exhibit a suitable and controllable degradation 
profile in the body after certain periods of time, have been extensively investigated 
over the past two decades [146]. Recent studies of biodegradable vectors focus on 
various stimuli-triggered responses such as enzymes, pH, redox and temperature. The 
linkages can be divided into protease-catalyzed peptide bond, simple hydrolysis based 
ester bond, pH-triggered hydrazone bond and disulfide bond for reduction with 
reductive agents or enzymes.  
The stimuli-responsive DDS must be degraded only via disease-derived 
stimuli to achieve degradation-controlled release at a desired release rate. In particular, 
biodegradable hydrogels have been proposed as excellent candidates for such 
controlled drug delivery systems because they have several advantages such as 
excellent biocompatibility, high responsiveness to specific degradation, and 
acceptable mechanical strength for implantation [86]. In this system, degradation-
controlled drug release cannot be guaranteed in these hydrogels because of high 
diffusivity of drugs through these polymer matrices. Chemical immobilization of drug 
on biodegradable hydrogel matrix or water-soluble polymer backbone has been a 
general strategy when the drug is introduced into these polymer systems [111]. Such a 
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drug-immobilized polymer system or polymer-drug conjugate is to provide prolonged 
release action of the drug by the hydrolysis or biological scission of the covalent 
bonds.  
In the field of gene delivery, one of the most important difficulties arisen in 
the strategy of using polycations as gene carriers is how to make sure the 
endosomal/lysosomal escape of polyplex and how to release DNA into the cytoplasm, 
finally reaching the nucleus through the nucleus membrane. With regard to this issue, 
the introduction of biodegradable moieties into polycations to dissociate the polyplex 
has been studied recently [147]. Generally the biodegradable vectors demonstrate a 
reduced cytotoxicity and higher or comparable transfection efficiency to an 
unmodified polycation like PLL or PEI, thus the biodegradable polymers shows great 
potential to be used as a gene vector. There are a large variety of biodegradable 
polymeric vectors including Polyesters, Polyurethanes, PLL-based, PEI-based, 
Phosphorus containing polymers, Polysaccharide based, biodegradable nanoparticles 
and Poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA)[148]. 
2.4.1 Enzymatic triggered biodegradable systems for drug and gene delivery 
Among various stimuli-triggered responses, enzyme is one of the widely used 
triggers. Usually, the enzymatic triggered biodegradable systems contain a ester bond, 
which could be simplify hydrolyzed to protease-catalyzed peptide bond under 
enzymes.  
For example, supramolecular assemblies were formed between α-CD and PEO 
chain, capping with L-Phe via biodegradable peptide linkages. When the peptide 
linkages were enzymatically degraded by protease such as papain, the polyrotaxanes 
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will degrade to PEO, α-CD and L-Phe. When the peptide linkages were enzymatically 
degraded by protease such as papain, the polyrotaxanes will degrade to PEO, α-CD 
and L-Phe. In order to investigate the degradation and CD release kinetics of this new 
drug release system, hydroxyl-propylated (HP) modified polyrotaxanes were 
synthesized [121] (Fig. 2.8). After that, drug, theophylline, was conjugated to this 
polyrotaxane for delivery. Upon enzymatic degradation of the terminal groups, 
theophylline-CD conjugates were completely released via dissociation of the 
supramolecular structure without steric hindrance. The bonds between drug and α-
CDs can also undergo hydrolysis to release the active drugs in cells [111]. Similarly, 
polyrotaxane composed of PLLA and α-CD end with z-l-Phe exhibited papain-
triggered hydrolysis [149]. Moreover, in order to examine the enzymatic degradation 
controlling, two different peptide end capped polyrotaxanes, L-phenylalanylglycyl-
glycine terminated and L-tyrosineglycylglycine-glycine terminated polyrotaxane, 
were also synthesized [150, 151]. 
 
Fig. 2.8 Structure (a) and the degradation mechanism (b) of CD/PEO polyrotaxanes 
with Z-L-Phe 
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In gene delivery, due to the flexibility and multivalent interaction, the cationic 
polyrotaxane with biodegradable terminal linkage has received much attraction. If the 
end caps can be cleaved intracellularly, the cationic CDs would dethread and disrupt 
the endosomal membrane because of cholesterol and/or phospholipid inclusion. At the 
same time, the CD release can convert the multivalent interactions into monovalent 
interaction thereby releasing the DNA for transfection (Fig. 2.9) [152, 153]. The 
assumption was first evaluated in Yui’s lab [153]. Aminoethylcarbamoyl (AEC) 
groups were introduced to α-CD which was threaded onto a PEG chain capped with 
Z-l-Phe linking via labile linkage. In contrast to PEI, the gene delivery system showed 
enhanced and tight complex formation even at lower N/P ratio.  
 
Fig.2.9 Strategies of gene delivery using aminoethylcarbamoyl (AEC)-polyrotaxane 
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2.4.2 pH-sensitive biodegradable systems for drug and gene delivery 
Recently, the pH-triggered dethreading of polyrotaxane was also demonstrated. 
α-CD terminated polyrotaxane consisting of β-CD and pluronic was biodegradable 
under acidic conditions due to cleavage of hydrazone bonds in low pH [81]. Similarly, 
it was reported that α-CD-PEG polyrotaxanes also exhibited dethreading in low pH 
environment [154]. Such stimuli-responsive polyrotaxane systems can open up a new 
paradigm of biodegradable materials for biomedical applications. 
Similarly, supramolecular aggregates that possessed pH-induced reversible 
micelle-gel transition were synthesized. The polypseudorotaxane consisted of 
hydrophilic copolymer PEG-b-PLL-HBr copolymer and α-CD [155]. Micellization of 
this hydrophilic copolymer due to the block-specific threading of α-CD molecules 
onto the PEG block yielded supramolecular-structured nanoparticles, which 
undergoes pH-inducible gelation in aqueous media. Firstly, in pH=4.5, the PLL block 
was nonthreaded while the PEG block of PEG-b-PLL was included inside the cavity 
of α-CD, inducing the micelle-like aggregation of the hydrophilic block copolymer to 
nanoparticles around 30 nm. The water soluble supramolecular nanoparticles possess 
an insoluble core consisting of inclusion formation α-CD and PEG and a soluble shell 
of free PLL. When increasing the pH value of the aqueous solution, the solubility of 
the PLL shell of the nanoparticles was changed and above pH 10, PLL became less 
soluble and aggregated in aqueous solution, leading to the gel formation. 
Subsequently it will become micelle solution again when changing to acid condition. 
The driving force for the formation of the supramolecular hydrogel is believed to be 
the synergetic effect of selective complexation between PEG block and α-CD, and the 
pH-inducible hydrophobic interaction between PLL block at pH 10. Such pH 
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switchable and reversible supramolecular hydrogels may find application in 
biomedical fields, such as controlled drug or protein release 
2.4.3 Disulfide-linkage based biodegradable polymers for drug and gene delivery 
In the past decades, reduction-sensitive biodegradable polymers have emerged 
as an attractive class of biomedical materials as the delivery systems for both 
biotherapeutics (pDNA, siRNA, peptides and pharmaceutical proteins) as well as low 
molecular weight drugs. Usually, bioreducible disulfide linkage was introduced to 
these materials in the main chain, side chain, or in the cross-linker.  
The disulfide bonds are subject to rapid degradation under a reductive 
environment via thiol-disulfide exchange reactions [156]. In eukaryotic cells, 
Glutathione tripeptide (GSH) is the major redox [157]. Under different intracellular 
environment, GSH maintain distinct and non-equilibrium level [158]. For example, in 
cell surface or blood fluids, the concentration of GSH is low (approximately 2-20 μM). 
So the disulfide linkage is sufficiently stable under the conditions in the circulation as 
well as in extracellular matrices. However, in the cytosol, disulfide bond may be 
prone to rapid degradation in minutes to hours due to the high concentration of GSH 
(0.5-10mM) [159]. Therefore, reduction-sensitive gene carriers in principle could 
meet the conflicting requirements of an ideal delivery system, i.e. high stability in 
circulation while rapid degradation inside targeted cells [160]. 
For cancer therapy, it is often more desirable to accomplish rapid drug release 
after carriers arrive at the pathological site, which may enhance the therapeutic 
efficacy as well as reduce the probability of drug resistance in cells. Due to the 
stimuli-responsive properties of disulfide linkage, reduction-sensitive polymers have 
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received a tremendous amount of interest for intracellular drug delivery. As a typical 
example, biodegradable micelles with sheddable PEG shells were synthesized based 
on poly (ethylene glycol)-SS-poly (ε-caprolactone) (PEG-SS-PCL) diblock copolymer 
and applied for rapid intracellular release of DOX (Fig. 2.10) [161]. Owning to the 
reductive cleavage disulfide bonds, it was found that the PEG-SS-PCL micelles were 
subject to fast aggregation in the presence of 10 mM dithiothreitol (DTT), which is 
analogous to the intracellular environment such as cytosol. Furthermore, in contrast to 
the reduction insensitive control, the shell-sheddable micelles with disulfide linkage 
showed much faster DOX release under a reductive environment. However, no 
difference in release rate was observed under the non-reductive conditions. The 
micelles also showed faster higher anticancer efficacy in comparison to the insensitive 
control. Therefore, the biodegradable micelles with disulfide-linkage are very 
promising for efficient intracellular drug delivery and to achieve improved anti-cancer 
therapy. Based on this theory, disulfide bonds were introduced to some other polymer 
micelles for stimuli-responsive drug delivery [162-165].   
 
Fig. 2.10 Illustration of reduction-sensitive shell-sheddable biodegradable micelles for 
efficient intracellular release of anticancer drugs [161] 
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In gene therapy, the rapid degradation due to the disulfide linkage on the one 
hand could lead to polyplex dissociation and efficient intracellular release of DNA or 
siRNA, on the other hand, they may result in low toxicity by avoiding accumulation 
of high molecular weight polycations inside cells, and finally increasing the 
transfection efficiency [166]. For example, disulfide bonds were used as cross-linker 
for the formation of low molecular weight PEI to 25K molecular weight PEI. Gosselin 
et. al found that the properties of 25KPEI was improved by introducing SS linkage, 
such as sufficient DNA release, decreased cytotoxicity and high transfection activity 
[167]. More importantly, disulfide linkage could bring a better balance between DNA 
release and DNA protection. A group of bioreducible poly (amido amine)s was 
synthesized with multiple disulfide bonds in the main chain and side chain. The 
results indicates that the bioreducible polycations could allow sufficient DNA 
protection in extracellular environment, rapid DNA intracellular release, markedly 
lower cytotoxicity and enhanced transfection [168].   
Due to the dethreading nature of polyrotaxane, disulfide linkage could also be 
introduced in polyrotaxane. Yui’s group designed a cytocleavable polyrotaxane that 
has supramolecular structure of DMAEC-α-CDs threading onto a PEG chain capped 
with benzyloxycarbonyl tyrosine (Z-Tyr) via disulfide (SS) linkage (Fig. 2.11a) [140, 
169]. The in vitro dissociation experiment showed that the DMAEC-SS-PRX systems 
exhibit sufficient cleavage of SS linkages, as a result of the rapid endosomal escape 
and pDNA release (Fig. 2.11b). Furthermore, by comparison with a variety of 
DMAEC-SS-PRXs with different number of DMAEC groups, it was found that the 
polyplex with lowest number of DMAEC exhibited a much faster pDNA release in 
cytoplasm. Thus the transfection activity was related to an appropriate timing for 
 
Chapter 2: Literature Review 
49 
DNA release and high transfection and stability can be achieve by optimizing 
numbers of DMAEC [170].  
 
Fig. 2.11 (a) Chemical structure of biocleavable polyrotaxane, and (b) image of the 
polyplex formation and terminal cleavage-triggered decondesation of the polyplex 
2.4.4 Polymer with sheddable shell for drug and gene delivery 
Before entering to the target cell, the drug/gene delivery carriers are faced 
with a set of extracellular barriers, including protein adsorption and cellular adhesion. 
Specifically, in gene delivery, the stability of polyplex largely depends on the 
structure and charge. The complexes will aggregate when the charge of the system 
become neutral. In the case of in vivo gene delivery, the polyplex particles could be 
prone to rapid aggregation due to the negatively charged plasma proteins in the serum 
or blood, which affect the stability of the positively charged polyplexes. The 
aggregation could result in nucleic payload release or rapid clearance of the 
 
Chapter 2: Literature Review 
50 
polyplexes by reticuloendothelial system [171]. Therefore, many polyplexes, 
including PEI25K, PDMAEMA systems, cannot maintain their stability and high 
transfection efficiency upon intravenous injection [172].     
Introducing a sheddable shell by attaching hydrophilic polymer is one of the 
most attractive methods to maintain the stability of delivery vehicles against serum. 
Hydrophilic polymers, such as polyethylene glycol (PEG), N-(2-hydroxypropyl) 
methacrylamide (HPMA), could be modified to the polymer vectors and formed a 
“brush” like shell on the surface of the particles [173, 174]. Owing to the steric and 
surface charge shielding effects of the hydrophilic shell, decreased particle to particle 
and particle-protein interaction could be achieved, followed by enhanced stability of 
polyplex against salt-, protein-, and biological non-specific interaction. Basically, the 
effects depend on grafting density, length of the hydrophilic polymer and the method 
of conjugation.  
Because PEG shows many well-known properties, such as high solubility, 
biocompatibility and reduced immunogenicity, it is widely modified to polyplex for 
polymeric or liposomal gene delivery [175-177]. Specifically, PEG shell layer could 
stabilize the aggregation in the interior of micelles and at the same time provide a 
“stealth” layer on the surface which could resist protein adsorption and cellular 
adhesion [178, 179]. For example, supramolecular PEGylated polyplexes were 
formed based on the self-assembly between admantyl modified PEG and chitosan-
grafted-(polyethylenimine-β-CD) [180]. It was found that in contrast to polyplex 
without PEG the PEGylated polyplexes significantly improved their stability under 
physiological conditions. A similar method for introducing PEG was also developed 
by Davis and co-workers [181].  
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Although PEG modifications are widely applied, they may challenged to some 
drawbacks, such as lower transfection efficiency and reduced internalization of 
untargeted polyplexes [182], degradation of DNA by nucleases [183], and lower DNA 
binding ability [184]. Recently, polymer poly(methacryloxyloxyethyl 
phosphorylcholine) (pMPC), which has a similar structure to the polar phospholipid 
group of cell membrane, was developed for the stabilization of polyplex. Similar to 
PEG, the pMPC-based modifications could avoid the aggregation and unfavourable 
interactions in the biological fluids [185, 186]. Licciardi et. al reports that the 
copolymer micelles with hydrophilic MPC shell are biocompatible and could suppress 
the unwanted interactions between drug and plasma protein [185].     
2.5 POLETHYLENEIMINE (PEI) AS GENE DELIVERY VECTORS 
PEI has been one of the most popularly employed cationic gene carriers due to 
its superior transfection efficiency and consistency of transfection in many different 
types of cells. They are often considered as the gold standard of gene transfection. 
The first successful polyethyleneimine-mediated DNA and oligonucleotides transfer 
was conducted in 1995 by Jean-Paul Behr [34]. Since then, numerous publications 
have appeared on studies of PEI as gene delivery vectors. PEI has been derivatized to 
improve the physicochemical and biological properties of polyplexes [187]. There are 
two principal structures for PEI, branched and linear. Branched PEI could be 
synthesized by polymerization under acidic conditions based on aziridine monomers 
while linear PEI can be obtained by polymerization or hydrolyzation of poly (2-
propyl-2-oxazoline) under highly acidic conditions [188, 189].   
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The development of well-known “proton sponge” effect has explained, in 
some part, the high transfection efficiency of PEI. PEI has high cationic charge 
density resulting from every third carbon [190]. In according to theoretical 
calculations, the ratio of primary/secondary/tertiary amines of branched PEI is 1:2:1 
[191]. Due to the high density of amines, the nitrogens of PEI could be protonated and 
the protonation degree is proportional to the pH of the environment. Basically, by 
comparison with physiological pH, less amines remain unprotonated at pH of 5 [192]. 
The unprotonated amines with different pKa values confer a buffering capacity over a 
wide range of pH. The buffering property gives PEI an opportunity to escape from the 
endosome [190], protecting the DNA from degradation in the endosomal 
compartment during the maturation of the endosome to lysosome, facilitating 
intracellular trafficking of DNA [193]. Some studies confirmed, at least partially, 
confirmed this theory. The buffering effect of PEI was supported by the study of 
Sonawane, which found higher chloride concentration and decreased acidification of 
PEI polyplexes in contrast to those of polylysine [194]. It was also found that, the 
transfection efficiency of PEI could be reduced after the removal of protonable 
amines in PEI or by introducing bafilomycin A, an inhibitor of the intracellular proton 
pump, into the system. The results verified the “proton sponge” effect [195, 196]. 
The molecular weight is often considered as one of the most important factors 
that could influence the transfection activity of PEI. Godbey et al. found that when 
increasing the molecular-weight of bPEI for transfection, both transfection efficiency 
and cytotoxicity increased [197-199]. It is probably because the high cation density of 
PEI contributes to the formation of highly condensed particles by interacting with 
DNA but this may confer significant cytotoxicity [200]. The toxicity could be due to 
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the necrosis, which is caused by aggregation and adherence on the cell surface 
[201].Typically, the optimal molecular weight of PEI is between 5~25 kDa [187]. 
Apart from molecular weight, the branched type and size of PEI polyplex could also 
affect the transfection efficiency in vitro. Aggregated polyplexes could increase 
cellular association and improve nuclear access due to membrane rupture [202]. For 
example, linear PEI shows lower complexation capability and larger polyplex 
aggregates than branched PEI [203], but studies with linear PEIs found that LPEI at 
22kDa exhibited even higher transfection efficiency and lower cytotoxicity compared 
to branched PEI [204-206].  
Due to the amine nitrogens, PEI is flexible to be conjugated with functional 
groups to improve their properties. For example, PEI-PEG grafted copolymers 
demonstrated a reduced cytotoxicity while maintaining transfection efficiency [207]. 
Conjugation of a targeting moiety like folate or antibody shows varied transfection 
efficiency in different cells, indicating that transfection efficiency is not based solely 
on the properties of the polymer but also cell type as different internalization might be 
involved [208, 209].  
2.6 POLY(2-(DIMETHYLAMINO)ETHYL METHACRYLATE) (PDMAEMA) 
AS GENE VECTORS 
Due to the biocompatibility of methacrylate polymers, they are also applied to 
the microencapsulation of cells without tissue rejection in cell transplantation [210]. 
The combination properties of methacrylates, such as biocompatibility, relatively easy 
synthesis and functionalization, make them as promising candidates for gene delivery 
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and led to the idea of synthesis of poly (2-[dimethylamino]ethyl methacrylate) 
(pDMAEMA)-based polymers for gene therapy.  
pDMAEMA is a synthetic polymer with tertiary amino groups on the side 
chain (Fig. 2.12). It is water soluble and owning to its positive charged surface, it 
could compact DNA into small particles by electrostatic interaction [211]. Basically, 
the degree of cellular uptake of the polyplex strongly depends on the size and charge 
of pDMAEMA, which is relative to the ratio of the polymer to DNA [212]. At low 
pDMAEMA: pDNA ratios (w/w), the polyplex have a negative charge and relative 
large particle size. When the polymer: plasmid ratios are above 3:1, small and positive 
zeta potential can be observed, which are favorable factors for transfection [213]. It 
was found that the polyplexes with a size around 200 nm and positive zeta potential 
(25mV-30mV) possess the highest transfection activity [214]. In addition to the 
polymer/DNA ratio, the molecular weight of pDMAEMA also adds effect on the 
DNA condensation. It has been reported that the average molecular weight of 
pDMAEMA should be above 100Kg/mol in order to give sufficient condensation of 
pDNA [215]. The PDMAEMA/pDNA complexes show higher transfection efficiency 
than that of DEAE-dextran/DNA and poly(L-lysine) (PLL)/DNA complexes. And 
their cytotoxicity is higher than DEAE-dextran, but lower than PLL [215]. 
Interestingly, in contrast to DEAE-dextran and PLL, the transfection activity of the 
polymer complexes is not affected by serum protein. A recent study showed that 
higher molecular weight PDMAEMA had a greater binding affinity to pDNA than 
lower molecular weight. Furthermore the molecular weight of PDMAEMA was found 
to have an influence on transfection efficiency, and the gene expression increased 
with the increasing molecular weight. However, cellular uptake of polyplexes was 
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determined to be insensitive to PDMAEMA molecular weight [216]. In another study, 
three kinds of PDMAEMA (linear, highly-branched, and star-shaped) were 
synthesized to investigate the gene delivery ability. It was found that the DNA 
compaction and cellular uptake are similar for all three polycations, but the star-
shaped PDMAEMA showed the highest transfection efficiency, which is of similar 
orders as branched PEI [217].  
 
Fig. 2.12 Chemical structure of pDMAEMA 
There have been several attempts made to explain the high transfection 
efficiency of pDMAEMA. Assuming the polyplexes enter cells through endocytosis, 
earlier workers proposed that PDMAEMA acts with a “proton sponge” effect to 
enhance endosome/lysosome escape. At physiological pH, pDMAEMA, which like 
PEI, is partially protonated due to its average pKa value of 7.5. It might result in the 
disruption of endosmes, facilitating the release of DNA into the cytosol [218]. The 
proton sponge effect could also cause the release of cytotoxic lysosomal enzymers 
into the cytosol, and resulting in high cytotoxicity [218]. However, Dubruel’s and 
Jones’s groups found some different results from the above hypothesis [219-221]. For 
example, in Dubruel’s study, the polymethacrylates which containing acid functions 
show buffering properties in analogy with “PEI proton sponge”. But they have a 
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lower transfection efficiency, probably owning to a limited cell uptake. The result 
indicates that the buffering capability of the synthetic polymers is not necessarily the 
crucial factor in the transfection process [219, 220].   
Cytotoxicity, lack of cell specificity and serum-induced aggregation are the 
major obstacles to application of pDMAEMA-based polyplexes to gene delivery. 
Similar with PEI, the molecular weight of the polymer plays an important role to the 
cytotoxicity [201]. Generally, the cytotoxicity of polymer appears to increase with the 
increasing of molecular weight. Membrane disruption, apoptosis and cytotoxicity of 
PDMAEMA increased with their chain length [222]. Therefore, it was suggested that 
one of the most rational ways to decrease cytotoxicity and enhance gene transfection 
efficiency could be achieved by combining low molecular weight transfection 
segments with degradable linkages and forming a combined large molecular weight 
transfection polymer. In addition, because it was reported that higher zeta potential of 
polyplexes could lead to significant cytotoxicity [223], PEGlyation is a well verified 
method to decrease cytotoxicity due to its shielding effect on the surface charge of 
particles [224-226]. Furthermore, PEG shell layer could also stabilize the aggregation 
in the interior of micelles and at the same time provide a “stealth” layer on the surface 
which could resist protein adsorption and cellular adhesion [178, 179]. 
Recently, a group of reduction-responsive polymer and conjugates was 
synthesized based on PDMAEMA for gene delivery [227-229]. Generally, they 
contain disulfide-linkage, which is prone to rapid degradation in reductive 
intracellular environment and cell nucleus. They showed distinct features different 
from their normally hydrolytically degradable counterparts: on the one hand they 
could lead to polyplex dissociation and efficient intracellular release of DNA or 
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siRNA, on the other hand, they may result in low toxicity by avoiding accumulation 
of high molecular weight polycations inside cells, and finally increasing the 
transfection efficiency [158]. For example, based on the structure of PDMAEMA-
PCL-PDMAEMA triblock copolymers for high efficient siRNA delivery [230], Zhu, 
et. al designed reduction-responsive cationic biodegradable micelles by introducing 
SS bonds into the systems. PDMAEMA-SS-PCL-SS-PDMAEMA triblock 
copolymers were prepared through RAFT polymerization. They found that the 
micelles could effectively condense DNA into stable polyplexes under physiological 
salt conditions. However, they are subject rapidly degradation and releasing DNA in 
and intracellular mimicking reductive environment. More importantly, the reduction-
sensitive micelles revealed much lower cytotoxicity than the reduction-insensitive 
control, indicating that the reduction-responsive biodegradable micelles are a 
promising candidate for safe and efficient gene delivery [227].  
In addition to gene delivery, biodegradable PDMAEMA-PCL-PDMAEMA 
triblock copolymer was also prepared for siRNA and paclitaxel codelivery. 
Significant enhanced gene silencing efficiency of the polycations micelles was 
observed as compared to 20K PDMAEMA or 25K PEI. Moreover, due to the 
improved cellular uptake, micelle loaded with paclitaxel displayed higher drug 
efficacy than free drug. These results suggested that cationic biodegradable micelles 
are highly promising for the combinatorial delivery of siRNA and lipophilic 
anticancer drugs [230]. 
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CHAPTER 3 SYNTHESIS OF ENZYMATIC 
BIODEGRADABLE STAR POLYROTAXANES AND 
THEIR SELF-ASSEMBLY BEHAVIOR FOR DRUG 
DELIVERY  
3.1 INTRODUCTION  
Over the past few decades, core-shell nanostructures (e.g. micelles) have 
shown great promise as carriers for efficient drug delivery [1]. They offer the 
advantages of improved drug solubility, drug availability and decreased side effects 
due to the enhanced permeability and retention (EPR) effect [2, 3]. In these core-shell 
structures, PEG is widely modified as the hydrophilic shell due to the properties of 
biocompatibility and reduced immunogenicity, which could stabilize the particle 
aggregation and resist protein adsorption [4]. Usually, the inner core of the 
nanostructures is hydrophobic polymer or inorganic metals (e.g gold) [5, 6], Since the 
first synthesis of polyrotaxane with multiple α-cyclodextrin (CD) rings threaded 
around a polymer chain [7], CD-based polyrotaxanes have been receiving increasing 
attention in drug delivery [8-10]. Due to the threading and dethreading nature of 
polyrotaxanes, recent studies in biodegradable polyrotaxanes focus on various stimuli-
triggered responses such as enzymes and pH [11-13]. 
 
Chapter 3:  Synthesis of Supramolecular Core-Shell Nanostructures as Drug Vectors 
75 
Recently, biodegradable core-shell structures have attracted much interest due 
to that they exhibited a suitable and controllable degradation profile in the body after 
certain periods of time [14]. The biodegradable synthetic polymers such as poly 
(lactic acid-co-glycolic acid) (PLGA), poly (lactic acid) (PLA) and poly (ε-
caprolactone) (PCL) are among the most frequently studied and they displayed 
gradual degradation kinetics inside body with degradation times ranging from days to 
months [15, 16]. However, as efficient drug delivery carriers for cancer therapy, the 
polymers must achieve faster degradation and drug release only after arriving at the 
pathological site. Therefore the development of structures with stimuli-responsive or 
triggered decomposition properties is an important challenge for drug delivery 
systems.  
In spite of many studies on the formation of star polymers reported so far,[17, 
18] little is known about the star polyrotaxane derived from controlled threading of α-
CD onto star PEG (sPEG), not to mention any examples on the dual self-assembly 
behaviour of the star polyrotaxanes, which may lead to core-shell nanostructures. 
Uniquely, the inner core of the structure is formed by polyrotaxanes, which is 
different from traditional core-shell nanostructures [2, 3, 5]. These may potentially 
lead to some specific interactions (e.g. hydrogen bond) between the drug and core.[19, 
20] Furthermore, little research has been done on the further applications of the core-
shell polyrotaxane nanostructures in sustain drug delivery. By comparison with 
covalently conjugating drugs into the polyrotaxane, these new core-shell 
nanostructures could easily load drug with high efficiency via non-covalent 
interactions and it could be achieved simultaneously in aqueous environment without 
impairing the chemical integrity of the drug.  
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In this research, star polyrotaxane (SPR) is successful synthesized. The SPR 
could further self-assembled into nanostructures in water with polyrotaxane core and 
PEG shell (Scheme 3.1). Their self-assembly behavior and biodegradability were 
confirmed. After encapsulating DOX, the polyrotaxanes showed high drug loading 
efficiency and enzymatic-triggered in vitro drug release. And in a further development 
of intracellular study, the DOX loaded SPR was found to accomplish much faster 
internalization, rapid uptake inside cells and significantly higher anticancer efficacy 
as compared to the free DOX control.  
 
Scheme 3.1 Illustration of the preparation of core-shell nanostrucutures dual self-
assemebled form star polymers  
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3.2 MATERIALS AND METHODS  
3.2.1 Materials  
1,3-Dicyclohexyl-Carbodiimide (DCC), hydroxysuccinimide (NHS), 
ethylenediamine, 1,1’-Carbonyldiimidazole (CDI), N-carbobenzyloxy-L-
phenylalanine (Z-L-Phe-OH), doxorubicin (DOX), papain (activity: 14 units/mg), 
ethylenediaminetetraacetic acid (EDTA), 2-mercaptoethanol and sodium hydroxide 
(NaOH) were received from Sigma-Aldrich and used as received. 8-arm polyethylene 
glycol (8-arm PEG: Mn=9468) and trinitrobenzene sulfonic salt (TNBS) were 
purchased from Fluka. α-Cyclodextrin (α-CD) was purchased from TCI. Diethyl 
ether, methanol, dimethylformamide (DMF), 1,4-dioxane and dimethyl sulfoxide 
(DMSO) were purchased from Merck. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), penicillin, and streptomycin were obtained from Sigma. 
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3.2.2 Synthesis methods 
 
Scheme 3.2 Synthesis routes and structures of the biodegradable polyrotaxanes (SPR) 
8-arm PEG (1g, 0.1056 mmol) was heated in a flask at 80 °C in vacuum 
overnight to remove water. When the flask cooled, 10 mL of anhydrous DMF was 
injected under nitrogen and the solution was added dropwise over a period of 6 h 
under nitrogen to 15 mL of anhydrous DMF solution in which 1,1’-
carbonyldiimidazol (CDI) (0.07g, 0.4224 mmol) was dissolved, followed by stirring 
overnight under nitrogen at room temperature. The resulting solution was slowly 
added dropwise over a period of 3 h into 2.4 g (40 mmol) of ethylenediamine, which 
3.2.2.1 Synthesis of 8-arm PEG-bis-(Amine) (PEG-NH2) 
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was dissolved in 10 mL of anhydrous DMF with stirring at room temperature. The 
mixture was further stirred overnight. Excess ethylenediamine and DMF was removed 
by vacuum evaporation in 60 °C. The resulting viscous liquid was dissolved in 2 mL 
methanol and purified by column chromatography on a Sephadex LH-20 column with 
methanol as eluent to give as a viscous yellowish liquid (Yield, 0.72g (72%)) [21].  
8-arm-PEG-bis (Amine) (0.1g, 0.01056 mmol) was added to 13.8 mL of α-CD 
saturated aqueous solution (0.145 g/mL) in centrifuge tubes, followed by alternately 
immersing the tubes in an ultrasonic water bath for 20 min. The reaction mixture was 
further stirred overnight at room temperature. The precipitated inclusion complex was 
isolated by centrifugation, and freeze-dried in vacuum (Yield, 1g) [
3.2.2.2 Synthesis of Polyrotaxanes (PPR-NH2) 
7]. 
Partial polyrotaxane with TNBS end group (PR-TNBS) was prepared in 
aqueous solution, as reported previously [
3.2.2.3 Synthesis of polyrotaxanes (PR-TNBS/PR-Phe) 
22]. Pseudopolyrotaxane (1g, 0.01506 mmol) 
was dissolved in 15 mL DI water to obtain a turbid solution. 1.0g NaHCO3 was added 
to the solution to adjust the pH (~9) and in order to block the ends of IC, 0.4g (3.7 
mol) of sodium salt of 2,4,6-trinitrobenzene sulfonic acid (TNBS) was added. The 
mixture was further stirred overnight at the room temperature. The resulting solution 
was centrifuged and the precipitate was washed with water for 3 times, followed by 
dissolving in DMSO and dialyses against DI water for 4 days (MWCO of dialysis 
tube is 2000). Then the product was further purified by gel chromatography on a 
Sephadex G-75 column with DMSO as eluent. The obtain solution was put in dialysis 
tube (MWCO=2000) and dialysis against DI water for 4 days to remove excess 
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DMSO. Finally, the resulting solution was freeze-dried to obtained yellowish 
polyrotaxane (Yield, 0.6 g (60%)).  
Partial polyrotaxane with Z-L-phenylalanine end groups (PR-Phe) was 
synthesized in two steps, as reported previously [11, 21, 23]. Firstly, N-
Hydroxysuccinimide ester of Z-L-phenylalanine (Z-L-Phe-OSu) was prepared by 
condensation reaction of N-carbobenzy-loxy-L-phenylalanine (Z-L-Phe-OH) with N-
hydroxysuccinimide (NHS), and 1,3-dicyclohexylcarbodiimide (DCC) was used as 
condensing agent, as reported previously [24]. Briefly, 2g DCC (10.02 mmol) was 
dissolved in 10 mL anhydrous 1,4-dioxane and the solution was added by dropwise 
into 20 mL anhydrous 1,4-dioxane, in which Z-L-Phe-OH (1g, 3.34 mmol) and NHS 
(0.768g, 6.68 mmol) were dissolved, followed by stirring the solution overnight under 
nitrogen at room temperature. The mixture was filtered to remove byproduct and the 
filtrate was vapor evaporation to concentrate dioxane. The obtained viscous yellowish 
liquid was washed with excess ether. After centrifuge, the white precipitation was 
recrystallized in the mix solution of dichloromethane and ether. Finally, the crystal 
product was centrifuged and freeze-dried. Yield, 1.3g (73.5%) 
Secondly, the resulting Z-L-Phe-Osu (0.33g, 0.84 mmol) was dissolved in 5 
mL of anhydrous DMSO, followed by the addition of Pseudopolyrotaxane (1g, 
0.01056 mmol). The suspension was stirred at room temperature for 48 h and the 
obtained solution was precipitated in ether as a crude complex. The complex was 
dissolved in DMSO and purified by dialysis and G-75 column the same as the 
purification of PR-TNBS (Yield, 0.12g (60%)).  
3.2.2.4 Self-assembly and DOX encapsulation 
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The solubility of partial polyrotaxane was different based on the threaded 
number of α-CD. Generally, the solubility was decreased with the increase of 
threaded number and threaded arms. For the soluble polyrotaxanes, the core-shell 
nanostructure could be prepared by directly dissolving the polymer in water and 
allowing it to stay overnight to ensure complete dissolution [25]. For TEM and 
particle size measurements, the solution was filtered through a 0.45 μm Whatman 
PVDF filter into a dust-free vial. In the case of the insoluble polyrotaxanes, the 
nanoaggregates could be prepared by dialysis [26, 27]. Specifically, polyrotaxane 
(PR-α 28-TNBS) was dissolved in DMSO with concentration of 2 mg/mL, followed 
by dialysis against DI water for 2 days to remove DMSO (MWCO=2000).  
The soluble polyrotaxane was loaded with Doxorubicin (DOX) followed by 
the method reported before [19]. 5 mg soluble polyrotaxane (PR-α 8-Phe, PR-α 12-
TNBS) was added to 0.5 mg Doxorubicin  hydrochloride (DOX·HCl) and dissolved 
together with 1 mL DI water, and the solution was stirred overnight at room 
temperature. Solution of sodium hydroxide (NaOH) was added to the solution to 
adjust the pH to 8~9 and stirred for 3 h. Because DOX is insoluble in basic condition, 
the unloaded DOX molecular were precipitated and removed by ultracentrifugation. 
The obtained solution with loaded DOX was lyophilized (Yield, 6 mg). 
The insoluble polyrotaxane could be loaded with DOX followed by the 
dialysis method reported before [28-30]. Before loading doxorubicin to the micelle-
like nanoaggregates, DOX·HCl was stirred with twice the number of mole of TEA in 
DMSO overnight to obtain the DOX base. 10mg polyrotaxane (PR-α 20-TNBS and 
PR-α 28-TNBS) was dissolved in 5 mL DMSO with DOX base solution (1 mg DOX 
base) and stirred for 5 h at room temperature. The solution was transferred to a 
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dialysis membrane (MWCO=2000) and dialyzed against NaOH solution (pH=9) for 
24 h (exchange per 4 hrs). The obtained solution was adjust back to pH=5 with HCl 
and then freeze-dried (Yield, 10 mg). 
3.2.3 Measurements and Characterization 
1H-NMR spectra were recorded on a Bruker AV-400 NMR spectrometer at 
400 MHz at room temperature. The 1H NMR measurements were carried out with an 
acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 30° pulse width, 5208 Hz 
spectral width, and 32 K data points. Chemical shifts were referenced to the solvent 
peak (δ=2.49 ppm for d6-DMSO). In this research, the 1H-NMR spectra were used to 
determine the relative amount and the existence of the 8-arm PEG-bis-(Amine), α-
cyclodextrin, TNBS and Z-L-Phe. 
3.2.3.1 Proton Nuclear Magnetic Resonance (1H-NMR) spectra 
Thermogravimetric analyses (TGA) were made using a TA Instruments SDT 
2960. 2~4 mg samples were heated at 20 °C/min from room temperature to 800 °C in 
a dynamic nitrogen atmosphere (flow rate = 70 mL/min). TGA was used mainly for 
the determination of the thermal stability of polymers and the percentages of chemical 
components in the proposed structure based on the decomposition temperature of 
specific chemicals.  
3.2.3.2 Thermal Gravimetric Analysis (TGA) and Differntial scanning calorimetry 
(DSC) 
Differential scanning calorimetry (DSC) measurements were performed using 
a TA Instruments 2920 differential scanning calorimeter equipped with an auto-cool 
 
Chapter 3:  Synthesis of Supramolecular Core-Shell Nanostructures as Drug Vectors 
83 
accessory and calibrated using indium. The following protocol was used for each 
sample: heating from room temperature to 200 °C at 20 °C min-1, holding at 200 °C 
for 2 min, cooling from 200 °C to -30 °C at 5 °C min-1, and finally reheating from -30 
°C to 200 °C at 5 °C min-1. Data were collected during the second heating run. 
Transition temperatures were taken as peak maxima [31]. 
The CAC values were determined by the dye solubilization method [
3.2.3.3 Critical Aggregation concentration (CAC) determination 
32]. The 
hydrophobic dye 1,6-diphenyl-1,3,4-hexatriene (DPH) was dissolved in methanol 
with a stock concentration of 0.6mM. Partial polyrotaxane (PR-Phe) was dissolved in 
water with variable concentration in the range of 0.0001 to 10 mg/mL, while keeping 
the concentration of DPH constant. 1 mL of polyrotaxane aqueous solution was mixed 
with 10 μL DPH stock solution and equilibrated at room temperature overnight. A 
UV-vis spectra in the range of 330-430 nm were recorded at room temperature. And 
the CAC values were determined by the plot of the difference in absorbance at 378 
nm and at 400 nm (A378-A400) versus logarithmic concentration. 
The morphologies of the core-shell structure were imaged on a JEOL JEM-
2010F FasTEM field emission transmission electron microscope, operated at 100 kv. 
The sample for TEM was prepared by directly depositing one drop of sample solution 
onto copper grids, which were coated in advance with supportive Formvar films and 
carbon. The polymer samples were dyed with phosphotungstic salt to increase the 
contrast under the TEM experiment. Then the samples were kept in a vacuum oven 
for 48 h for drying at room temperature before TEM imaging.  
3.2.3.4 Transmission Electron Microscopy (TEM) 
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Size and distribution of the core-shell structure were measured on a DLS 
instrument (Zetasizer Nano ZS, Malvern Instruments Ltd, USA), with a laser light 
wave length of 633 nm at a 173o scattering angle. The results were expressed in 
volume-averaged scales as unimode. The measurement was performed at 25 °C. 
3.2.3.5 Dynamic light scattering (DLS) measurements 
The biodegradability of PR-Phe in the presence or absence of papain was 
investigated by TEM and particle size. 1 mg PR-Phe was dissolved in 1 ml PBS 
containing papain (3 mg, 50 unit), ethylenediaminetetraacetic acid (EDTA, 2 
μmol/mL), and 2-mercaptoethanol (10 μmol/mL) [
3.2.3.6 Biodegradation behavior evaluation 
11, 23]. The solution was shaken 
under 100 rpm at 37 °C for 20 days, and a new dose of papain (20 units/mL) was 
added every 5 days. The degradation behavior and morphology difference of the 
polymer was characterized and observed by TEM and particle size after 1, 4 and 15 
days. In order to make a comparison, the control sample with 1 mg PR-Phe was 
dissolved in 1 mL PBS without papain, and it was characterized with the same 
procedure as above. 
The amount of DOX encapsulated in the polyrotaxane nanoparticles was 
analyzed by fluorescence measurement (excitation at 480 nm) [
3.2.3.7 Characterization of the drug delivery systems 
26]. For determination 
of drug loading content, 1 mL DMSO was added into 1mg DOX-loaded SPR, the 
nanostructures were broken up and the DOX was dissolved in the solution. The 
characteristic emission absorbance of DOX at 588 nm was recorded and compared 
with a standard curve generated DOX/DMSO solutions with different DOX 
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concentrations varying from 0 to 60 μg/mL. Drug loading content (DLC) and drug 
loading efficiency (DLE) were calculated according to the following formula: 
DLC (wt%) = (weight of loaded drug/weight of polymer) 100% 
DLE (wt%) = (weight of loaded drug /weight of drug in feed) 100% 
The morphologies of DOX-loaded polyrotaxane nanoaggregates were 
examined using transmission electron microscope (TEM, JEOL JEM-2010F) and 
particle size, the same procedures as before.   
Release of drugs from the drug-loaded SPR was studied using the dialysis 
method [
3.2.3.8 In vitro drug release study 
19, 33, 34]. 3 mg PR-TNBS/DOX and PR-Phe/DOX were put in dialysis 
membrane tube (MWCO=2000 Da) together with papain (50 unit/mL), followed by 
dialyzing against 15 mL medium of PBS (pH=7.4) containing 
ethylenediaminetetraacetic acid (EDTA, 2 μmol/mL), and 2-mercaptoethanol (10 
μmol/mL) [11, 23]. The release system was shaken under 100 rpm at 37 °C for 60 
days. At designed time intervals, 1 mL release medium was removed and replaced 
with fresh medium. The medium removed was analyzed for its drug content by using 
fluorescence measurement (excitation at 480 nm). The recorded intensity was 
compared with a standard curve containing DOX/PBS solution with concentration 
varied from 0 to 5 μg/mL. In order to make a comparison, free DOX without polymer, 
PR-TNBS/DOX and PR-Phe/DOX were put into dialysis tube without papain, 
followed by dialyzing against blank PBS and they were measured with the same 
procedure above 
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In vitro cytotoxicity tests on the polymer were performed by 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in a 96-well cell 
culture plate [
3.2.3.9 Cell viability assay 
35]. In brief, L929 mouse fibroblasts (MB231 human breast cancer cell 
and Hela cervical cancer cell) were cultivated in DMEM containing 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin at 37 °C, 5% CO2 and 95% relative 
humidity. For cell viability assay, cells were seeded into 96-well plates (NUNC, 
Wiesbaden, Germany) at a density of 1×105 cells/mL. After 24 h, the culture media 
was replaced with serum-supplemented culture media containing serial dilutions of 
the polymers, and the cells were incubated for 24 h, at 37 °C in a humidified 5% CO2 
atmosphere. Control cells were treated with an equivalent volume of DMEM. 10 μL 
of sterile, filtered MTT stock solution in PBS (5 mg/mL) was added to each well, 
reaching a final concentration of 0.5 mg/mL. After 4 h of incubation at 37 °C, the 
MTT solution was removed and the insoluble formazan crystals that formed were 
dissolved in 100 μL of dimethylsulfoxide (DMSO). The absorbance of the formazan 
product was measured at 570 nm using a fluorometer (FLUOstar Optima Microplate 
Fluorometer).  
The cellular uptake and intracellular distribution behaviors of DOX-loaded 
SPR-TNBS and SPR-Phe were followed with fluorescence microscopy using MDA-
MB-231cell line in a 96-well cell culture plate [
3.2.3.10 Intracellular cell uptake and distribution 
26, 33]. MB231 cells were cultured in 
DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin for 
1 day. Then they were seeded in a 96-well plate at a density of 1×105 cells/mL with 
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100 µL medium and cultured at 37 °C, 5% CO2 and 95% relative humidity. After 24 h 
incubation, the medium in 96-well plate was changed with the DOX-loaded polymer 
solution with different DOX concentration. The cells were incubated with DOX-
loaded polyrotaxanes at 37 °C in a humidified 5% CO2-containing atmosphere. After 
10 min, 1 h, 2 h, 24 h and 48 h, the culture media were removed and the cells were 
rinsed three times with DMEM prior to the fluorescence observation. 
3.3 RESULTS AND DISCUSSION 
3.3.1 Synthesis of 8-arm PEG-bis (Amine) 
8-arm PEG-bis (Amine) was synthesized by the CDI reaction. Specifically, the 
hydroxyl groups at the end of 8-arm PEG were activated with CDI, followed by 
reaction with large excess of ethylenediamine to give terminal amino groups. The 
reaction was completed in anhydrous DMF under nitrogen because the polarity of the 
reaction solvent has a strong influence on the conversion. To minimize intermolecular 
crosslinking, the PEG was added to the CDI solution and the molar ratio of 
ethylenediamine to PEG was more than 50 times in the conjugate reaction. In this 
reaction, different amino grafted degree could be accomplished by controlling the 
amount of CDI and four kinds of mole ratio of CDI to PEG in feed were used in this 
experiment (4:1, 12:1, 16:1 and 40:1, respectively). It was found that the degree of 
reaction increased with increasing of CDI concentration and the reaction time. 
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Fig. 3.1 1H-NMR spectrum of (a) 8-arm PEG (Mw=9468, n=25), (b) PEG-11.3%-NH2 
(feeding ratio of CDI/PEG=4:1), (c) PEG-52%-NH2 (feeding ratio=16:1), (d) PEG-96%-
NH2 (feeding ratio=40:1) in d6-DMSO. 
Fig. 3.1 shows the 1H NMR result of 8-arm PEG-bis-(Amine) (molar ratio: 4:1, 
16:1 and 40:1) in comparison with pure 8-arm PEG. In the spectrum, 8-arm PEG (10k) 
is showed as a control (400 MHz, d6-DMSO, 22oC). In the spectrum of 8-arm PEG-
bis-(Amine), the chemical shift of H3 in PEG was change from 3.5 ppm (in pure PEG) 
to 4.05 ppm (in the product), which is attributed to end grafting of ethylenediamine. 
And due to the different end grafting degree, the peak of H2 (-OH of PEG) was 
decreased or disappeared after the reaction. Furthermore, the integration ratios of each 
component are with the similar ratio of the original PEG and ethylenediamine. This 
result confirms the successful conjugation of 8-arm PEG with ethylenediamine.  
By comparing Fig. 3.1 (b), 3.1 (c) and 3.1 (d), it was found that when the 
feeding ratio of CDI to PEG increases, the peak of H3 (which represents the grafted 
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arms in PEG) increases and the peak of H2 (which represents the un-grafted arm) 
decrease. This is because the more CDI used, the more grafted degree will be obtained. 
Therefore, the grafted degree can be indirectly calculated on the basis of integration 
value of H3 and H2. The results are summarized in table 3.1, together with the 
elemental analysis (EA) results. Based on the above result, it was found that although 
large excess CDI were used, fully grafted 8-arm PEG cannot be obtained, probably 
because the CDI reaction is not very effective and the influence of water in CDI. 
Table 3.1 Composition and EA results of 8-arm PEG-bis (Amine) 











C% H% N% C% H% N% 
PEG-11.3%-NH2 4 
11.3% 
(1 arm) 52.84 8.83 0.26 52.69 9.01 0.16 
PEG-28%-NH2 12 
28% 
(2 arm) 52.91 9 0.66 54.68 9.24 0.64 
PEG-52%-NH2 16 
52% 
(4 arm) 53.7 8.97 1.21 54.53 9.23 1.12 
PEG-96%-NH2 40 
96% 
(7.7 arm) 52.63 8.79 2.22 51.98 8.87 2.11 
a Data was all calculated on the basis of 1H NMR in DMSO-D6 
b Theoretical elemental analysis calculated for the corresponding compound.  
c Elemental analysis found. 
3.3.2 Synthesis of partial polyrotaxane 
After grafting ethylenediamine, 8-arm PEG-bis-amine with different grafted 
ratio was allowed to react with saturated solution of α-CD to obtain 
polypseudorotaxane, following similar procedures described in previous report [36], 
in which it was found that α-CD will form an inclusion complex with ratio of EO to 
CD is 2, approximately. Then the end of PEG was blocked to form polyrotaxane with 
two kinds of end groups: TNBS and Z-L-Phe. Following 1H-NMR spectra showed the 
chemical components of the product structures (Fig. 3.2).  
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Fig. 3.2 1H-NMR of (a) 8-arm PEG (Mn=9468), (b) α-CD, (c) PR-α 12-TNBS, (d) PR-α 
65-TNBS and (e) PR-α 8-Phe in d6-DMSO. 
In Fig. 3.2 (c)-(d), the signals for α-CD, the threading 8-arm PEG (δ=3.5) and 
the end capping groups (TNBS, δ=8.95) were all observed. In Fig. 3.2 (e), instead of 
TNBS, the end capping group of Z-L-Phe was observed at δ 7.2-7.4. Furthermore, it 
was observed that the peaks of α-CDs in Fig. 3.2 (b) were clearly sharp, but those of 
polyrotaxanes were broadened (Fig. 3.2 (c)-(e)). These results suggest that the 
mobility of α-CDs in polyrotaxane is restricted by the PEG chain after forming the 
supramolecular structure. These results showed good agreements with our supposed 
structure, which confirming the forming of the polyrotaxane with TNBS and Z-L-Phe 
end groups [21, 37]. 
In Fig. 3.2 (c), the PEG-11.3%-NH2 was used for the inclusion complexation, 
and higher grafted degree PEG-96%-NH2 was used in Fig. 3.2 (d). By comparison, it 
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was found that more threaded α-CDs will be obtained in higher grafted degree 
probably because higher end capping in higher grafted degree, resulting less 
dethreaded α-CDs in DMSO. The average numbers of threaded α-CD in the final 
products could be calculated by comparing the resonance peak of H1 of α-CD (δ=4.79) 
with that of PEG (δ=3.50). And the number of threaded arms can be estimated by 
comparing the peak area of TNBS/Z-L-Phe end and PEG. By calculation, the 
following polyrotaxane was confirmed (Table. 3.2): 
Table 3.2 Composition of polyrotaxane and compared with TGA results 
a  Data was all calculated on the basis of 1H NMR in DMSO-D6 
b  Data was calculated based on TGA.  
By comparison with TNBS end polyrotaxane, the polyrotaxane with Phe end 
threaded less α-CD with the same grafted degree of PEG. This is because in the 
synthesis of polyrotaxane-Z-L-Phe, the reaction was finished in DMSO, which results 
some CD dethreading before the end capping. 











PR-α 12-TNBS  PEG-11.3%-NH2 1 10  12  
PR-α 20-TNBS  PEG-28%-NH2  2 20  20  
PR-α 28-TNBS  PEG-52%-NH2 2 26  28  
PR-α 65-TNBS  PEG-96%-NH2 6.7 62  65  
PR-α 8-Phe PEG-28%-NH2 1 8 9 
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3.3.3 TGA and DSC assessment  
 
Fig. 3.3 TGA of (a) 8-arm PEG, (b) α-CD, (c) PR-α 20-TNBS and (d) PR-α 65-TNBS 
The thermal stability of the polyrotaxane was evaluated using 
thermogravimetric analysis (TGA) and compared with free α-CD and the starting 
polymers. Fig. 3.3 shows the weight loss curves for polyrotaxanes by comparing with 
8-arm PEG and α-CD. As shown in Fig. 3.3, PR-α 20-TNBS shows an initial weight 
loss of 55.04% and second weight loss of 28.91% on heating with onset of thermal 
decomposition at 229 °C and 365 °C, respectively. This two-step thermal degradation 
could be attributed to the first decomposition of α-CD and the second one to naked 
PEG component mainly. The similar thermal decomposition could also be found in 
PR-α 65-TNBS (Fig. 3.3(d)). However, the onsets of the decomposition of α-CD and 
PEG in the polyrotaxane are observed at 269 °C and 373 °C, respectively, which are 
higher than those of the CD and PEG blocks in PR-α 20-TNBS. Therefore, by 
comparison with pure PEG and α-CD, it could be concluded that the PEG and CD 
blocks was stabilized by the formation of polyrotaxane. Furthermore, the more α-CD 
threaded, more stable ICs could be obtained. The higher decomposition temperatures 
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of polyrotaxane are due to the contribution of complex formation to thermal stability 
of both α-CD and PEG [31, 38]. Although the TGA method may not be as accurate as 
the 1H NMR due to the partially overlapping of the two weight loss steps, the two-step 
weight loss behavior can also be used to estimate the ratio between α-CD and PEG in 
the polyrotaxanes (Table 3.2). The results further confirmed the 1H NMR result and 
the proposed polyrotaxane compositions.  
 
Fig. 3.4 DSC curves (second heating run at 20 °C /min) for (a) 8-arm PEG, (b) 10K-PR-α 
12-TNBS, (c) 10K-PR-α 20-TNBS and (d) 10K-PR-α 65-TNBS. 
The thermal properties of the obtained polyrotaxanes, corresponding 8-arm 
PEG in the solid state were investigated by DSC. Fig. 3.4 shows the DSC curves for 
three kinds of partial polyrotaxane and pure 8-arm PEG. In 8-arm PEG curve (Fig. 
3.4a), heating process display one melting peak (endothermic peak) at 43.2oC and one 
exothermic peak at 21oC on the cooling trace. It attributes to the melting and 
recrystallization of PEG crystals. However, no obvious melting peak was observed in 
PR-α 20-TNBS and PR-α 65-TNBS because the polymer chain is closely included in 
the channels formed by CDs in the polyrotaxane. Interestingly, in PR-α 12-TNBS, 
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there is a clear endothermic peak which is due to the melting of PEG crystallites. The 
results indicated that PEG is partially covered by α-CD and most likely many PEG 
arms were uncomplexed by α-CD. In the polyrotaxanes, there is a trend that both 
fusion temperature and enthalpy change increase with and decrease number of 
threaded α-CDs. This is in accordance with the fact that the polyrotaxanes with less 
threaded CDs have more uncomplexed portion of PEG chains [31]. 
3.3.4 CAC determination 
It was found that the solubility of the polyrotaxanes decreased with the 
increasing number of threaded α-CDs. Among the synthesized 5 kinds of 
polyrotaxanes, PR-α 8-Phe, PR-α 12-TNBS, PR-α 20-TNBS is soluble in water and 
the solubility is PR-α 8-Phe > PR-α 12-TNBS > PR-α 20-TNBS. While PR-α 28-
TNBS and PR-α 65-TNBS is insoluble. Considering the influence of TNBS in UV 
spectra and fluorescence, PR-α 8-Phe was selected to determine the CAC of the 
partial polyrotaxane.  
 
Fig. 3.5 (a) UV-vis spectra changes of DPH with increasing PR-α 8-Phe concentration in 
water at 25 °C. (b) CAC determination by extrapolation of the difference in absorbance 
at 378 nm and 400 nm 
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This experiment was conducted by varying the aqueous polymer concentration 
in the range of 0.0001 mg/mL to 10 mg/mL, while keeping the concentration of DPH 
constant. DPH shows a higher absorption coefficient in a hydrophobic environment 
than in water. Thus, with increasing polymer concentration, the absorbance at 344, 
358 and 378 nm increased (Fig. 3.5a). The point where the absorbance suddenly 
increases corresponds to the concentration at which core-shell nanostructures are 
formed. When the micelle-like nanoaggregates is formed, DPH partitions 
preferentially into the hydrophobic core formed in the aqueous solution [39, 40]. The 
CAC was determined by extrapolating the absorbance at 378 nm minus the 
absorbance at 400 nm (A378-A400) versus logarithmic concentration (Fig. 3.5b). It was 
found that the CAC values for polyrotaxane PR-α 8-Phe are 0.8 mg/mL.  
3.3.5 Particle Size and TEM observation of self-assemblies 
 
Fig. 3.6 Particle size distribution (intensity distribution) and TEM images of the self-
assembly of PR-α 12-TNBS (a), PR-α 20-TNBS (b) and PR-α 28-TNBS (c). 
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To convince the self-assembly behavior and characterize the size and 
morphology of the polyrotaxane particles, TEM and DLS experiment was conducted. 
Fig. 3.6 shows the size and morphologies of the nanoaggregates formed by partial 
polyrotaxanes with different numbers of threaded α-CDs. Among the four kinds of 
polyrotaxanes synthesized, PR-α 12-TNBS and PR-α 20-TNBS form nanoparticles by 
directly dissolved in water (conc.=1 mg/mL). PR-α 28-TNBS nanoaggregates were 
formed by dialysis method. While insoluble PR-α 65-TNBS cannot form 
nanoaggregates by dialysis, probably because more than half of the PEG arms were 
covered by CD and the hydrophobic environment dominated in the systems 
attributing to the precipitate which cannot be stable in water as form of nanoparticles. 
These nanoaggregates were imaged with staining of the polymer shell with 
sodium salt of phosphotungstic acid. As shown in the TEM images of Fig. 3.6, 
spherical core-shell nanostructures are observed in the three kinds of polyrotaxanes. 
Their average size is around 20~150 nm, which have been confirmed by particle size 
and size distribution determined by DLS measurement. The smaller size observed by 
TEM as compared to that determined by DLS is most likely due to shrinkage of the 
PEG shell [25]. The small sizes of particles may enable them to prolong circulation in 
blood and slower elimination by the reticuloendothelium system (RES) [29]. In Fig. 
3.6a, a bimodal size distribution was evidenced in PR-α 12-TNBS. It suggested that 
there coexist polymer aggregates and unassociated single polyrotaxane in the aqueous 
solution. It may be because only little CDs exist in PR-α 12-TNBS, and the dominated 
hydrophilic segment content prevents the self-assembly, resulting in some 
uncomplexed single polyrotaxane molecules. With increased number of CDs, the size 
distribution became monomodal due to the increase of hydrophobic segments. 
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Furthermore, by comparison Fig. 3.6(a)-(c), it could be found that with increase in the 
number of threaded α-CDs, the formed micelle-like aggregates tend to be larger (from 
27 nm to 168 nm), showing that the presence of more CDs as the polyrotaxane core 
increases the particle volume. Therefore, the particle size and size distribution of the 
formed structure could be changed by controlling the threaded number of CDs in the 
partial polyrotaxanes. 
3.3.6 Biodegradation behavior characterization 
In our experiment, in addition to synthesize partial polyrotaxane with TNBS 
end, another terminal group (Z-L-Phe) was introduced in the systems with enzymatic 
biodegradable linkage. The most attractive character of such polyrotaxane will 
involve the control of drug release utilizing the enzymatic-triggered dissociation of 
supramolecular structure. Thus regulating the degradability of the polyrotaxane would 
be important before loading drug in the systems. In our approach, TEM and DLS were 
used to characterize the biodegradation behavior of the systems.  
 
Fig. 3.7 TEM images of PR-α 8-Phe nanoparticles in PBS solution with (a) and without 
papain (b) after 0, 4 and 15 days (concentration 1 mg/mL)  
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Fig. 3.8 The size change of PR-α 8-Phe nanoparticle in PBS with (a) and without papain 
(b) determined by DLS measurement 
The size and morphology change of the PR-α 8-Phe nanoparticle in response 
to papain, which can cleave the Phe-Gly peptide linkages, in PBS was followed by 
TEM and DLS measurement (Fig. 3.7 and Fig. 3.8). Notably, as shown in Fig. 3.7a, 
the SPR self-assembled nanostructures degraded into small pieces with irregular 
morphologies after 4 days in the presence of papain and the average size of 
nanoparticle decreased from 53 nm to 35 nm. The size of nanoaggregates became 
smaller with more small pieces after 15 days in the presence of papain. In contrast, no 
change in particle morphology was discerned after 15 days in the absence of papain 
under otherwise the same conditions (Fig. 3.7b). The result confirmed the effects of 
dissociation of the supramolecular structure by enzymatic cleavage of the peptide 
linkages on the particle degradation behavior of PR-α 8-Phe in the presence of 
protease papain [11]. This was further verified by the DLS measurement regarding to 
the change of size distribution. In Fig. 3.8a, in the presence of papain, with increasing 
the time, large aggregates decreased and smaller aggregates increased, indicating the 
polyrotaxane was degraded into small pieces. However, no such changes were 
observed in the absence of papain (Fig. 3.8b).  
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3.3.7 Drug loading content determination and morphologies observation 
DOX is one of the most potent anticancer drugs and used widely in the 
treatment of different types of solid malignant tumors [41, 42]. DOX is known to 
interact with DNA by intercalation and inhibition of macromolecular biosynthesis. It 
is crucial, therefore, to delivery and release DOX in the cytoplasm and/or right into 
the cell nucleus. In this chapter, we use DOX as the model molecule to evaluate the 
potential application of the core-shell nanostructures as drug carrier. 
 
















PR-α 12-TNBS 14.551μg 1.455% 10% 14.55% 
PR-α 20-TNBS 18.462μg 1.846% 10% 14.77% 
PR-α 28-TNBS 12.25μg 1.225% 10% 15.31% 
 
 
















PR-α 12-TNBS 48.99 μg 4.899% 10% 78.38% 
PR-α 8-Phe 91.67 μg 9.16% 16.7% 73.3% 
Pure DOX (control) 47.14 µg - - 4.71% 
a Loading content (wt%) = (weight of loaded drug/weight of polymer) 100% 
b Loading efficiency (wt%) = (weight of loaded drug /weight of drug in feed) 100% 
Because of the different solubility in water, two methods were used to load 
drug in our experiment. Dialysis method was used for the insoluble polyrotaxanes and 
dissolve method was used for soluble polyrotaxanes. Table 3.3 and 3.4 show the drug 
loading efficiency of star polyrotaxanes with different numbers of threaded CDs. The 
results showed that the drug loading efficiencies for three polyrotaxanes were 
approximately 14%~15%. The loading content increases with increasing of threading 
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CDs. This can be explained that the more hydrophobic part in the polymer chain 
makes it possible to have more interaction points in the formed structure, giving rise 
to a higher loading content [27, 43]. In table 3.4, the drug content loaded by dissolve 
method is much more than the dialysis method, maybe because the dialysis process 
will cause drug losing (drug release rate>drug loading rate). Pure DOX was used as 
control to verify the dissolve method. With the same procedure in the absence of 
polyrotaxanes, only 4.71 wt% free DOX were found in the final product. In contrast, 
in the presence of polyrotaxane, approximately 78 wt% DOX was observed. The 
result confirmed the high drug load efficiency and capacity of the polyrotaxane. In 
addition to the hydrophobic interaction, the high drug load efficiency may be 
attributed to the hydrogen-bond interaction between hydroxyl group of CDs and 
amide group of DOX under neutral and basic conditions [19].  
 
Fig. 3.9 Morphology and size distribution of DOX loaded PR-α 12-TNBS (a) and PR-α 
8-Phe (b)  
TEM photographs and size distribution of the PR nanoaggregates after loading 
drugs are shown in Fig. 3.9. In Fig. 3.9a, the drug loaded PR-α 12-TNBS have an 
average size of 105±5 nm, and comparing with the aggregates without drug (27±4 
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nm), the particle sizes become larger when the drug is incorporated, showing that the 
presence of DOX in the polyrotaxane core of the nanoparticle increased volume [27, 
29]. Furthermore, after loading drugs, the size distribution of PR-α 12-TNBS changed 
from bimodal to monomodal, and the morphologies became more regular. Therefore, 
the entrapping of drugs into the PR core contributes not only to the increase in the size 
of the nanoparticles but also to the unimodal size distribution. The drugs also 
enhanced the hydrophobic interaction and helped the self-assembly. Similar 
phenomenon has also been observed in DOX loaded PR-α 8-Phe in Fig. 3.9b. 
3.3.8 In vitro drug release behaviors 
The controlled-drug release behavior of DOX from polyrotaxane 
nanoaggregates (PR-α 12-TNBS and PR-α 8-Phe) were investigated using a dialysis 
tube (MWCO=2000) in pH7.4 PBS at 37 °C in the presence or absence of papain, 
with the similar initial drug loading efficiency and the same drug loading content. 
(a) DOX loaded PR-α 8-Phe                                      (b) DOX loaded PR-α 12-TNBS 
Fig. 3.10 In vitro release profile of DOX from polyrotaxane aggregates in PBS at pH 7.4 
and 37 °C, in presence or absence of papain. (a) DOX loaded PR-α 8-Phe; (b) DOX 
loaded PR-α 12-TNBS; Photograph shows the TEM images of 35 days release of PR-α 8-
Phe with papain. 
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Fig. 3.10 shows the release profiles at 37 °C of different DOX loaded 
polyrotaxanes. In Fig. 3.10b, PR-α 12-TNBS exhibited sustained and slow DOX 
release into surrounding PBS, with rapid release of 20% of the drug in the first 24 h, 
and cumulative release of 30% of the drug by 18 days, after which there was a slow 
linear release of 75% of the drug by 57 days. DOX loaded PR-α 8-Phe in the presence 
or absence of papain also exhibit the similar release profile (Fig. 3.10a). On the basis 
of the results, a release mechanism based on progressive surface erosion of PR 
nanostructures can be hypothesized. We hypothesize that the DOX release from the 
nanoparticle could be divided to 3 phases. In the first stage of 24 h release, the DOX 
in the exterior of particle, which was not loaded tightly in PEG shell, was released 
because of passive diffusion. Form 1 days to 18 days, the DOX was tightly loaded in 
the center of particles because of hydrophobic and hydrogen-bond interaction. There 
existed a balance between the drug load interaction and drug diffusion to the bulk 
solution, which resulted in very slowly release rate in this time period. In the final 
stage, the nanoaggregates collapsed eventually because of the higher osmotic pressure 
and the drug in the center of particle was released slowly with linear release. The 
similar release profile has also been observed from other micelle/nanoparticle based 
drug delivery systems [34, 44]. By comparing Fig. 3.10a and 3.10b, it was found that 
PR-α 8-Phe exhibited a higher bust release rate than PR-α 12-TNBS, maybe because 
less threaded CDs resulted in weaker hydrogen-bond interactions and loser drug 
loading.  
In comparison with free DOX without polymers, the polyrotaxane based drug 
delivery systems exhibited a sustained and long term DOX release lasting about 60 
days. The sustained release could be attributed not only to the hydrophobic interaction 
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between drug and the partial polyrotaxane, more importantly, it could also be due to 
the hydrogen-bond interaction between hydroxyl group of CDs and amide group of 
DOX under neutral and basic conditions [19]. It is worthy of note that a sustained 
release rate is importance for intravenous delivery when a targeting in specific area of 
the body is attained. In fact, when the nanocarrier reaches its pharmacological target 
by accumulating in solid tumors through EPR effect [45, 46], its eventual ability to 
slowly release its drug content in extracellular compartment can be considered highly 
beneficial to prolong therapeutic effect [44]. The long induction time ensures 
sufficient time for the particles to accumulate in the small vasculature before the drug 
is released [47]. Importantly, due to the stability and the ability to retain the entrapped 
drug molecule of our system, sustained release could decrease the concentration of 
free drug in circulations, resulting in a decreased accumulation of the drug in the heart 
tissues and reduced cardiotoxicity, which is a serious drawback for DOX as anti-
cancer therapy [48, 49]. 
Remarkably, by comparing the release profiles in Fig. 3.10a, it was found that 
PR-α 8-Phe released DOX rapidly in the presence of papain in contrast to that without 
papain. This is in line with the previous observation that PR-α 8-Phe were degraded 
into small pieces in response to papain. In contrast, no drug release difference was 
observed within 60 days for the reduction insensitive PR-α 12-TNBS nanoaggregates 
under the same conditions (Fig. 3.10b). Therefore, it is evident that fast drug release 
from PR-α 8-Phe is triggered by reduction of Z-L-Phe linkage. Interestingly, unlike 
other triggered-biodegradable drug release profile [50], the release rate of the PR 
nanostructures was sustained even in the presence of papain (Fig 3.10a). It probably 
because even the particles were degraded into small pieces by papain, it still could 
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compact and load drugs to prevent it from releasing suddenly. The phenomenon could 
be observed by TEM images in Fig. 3.10a. This unique property could be highly 
beneficial to prolong the therapeutic effect and decrease the cardiotoxicity. 
3.3.9 In vitro cytotoxicity 
Blank PR-α 8-Phe and PR-α 12-TNBS were evaluated for their cytotoxicity 
against L929 cells with an MTT assay. As shown in Fig. 3.11(a), both drug carrier 
with different end groups did not exhibit detectable cytotoxicity at all concentrations 
up to 1 mg/mL. Therefore, the polymer was expected to be safe for biomedical 
applications. After loading DOX, the L929 cells exhibited a dose-responsive viability 
due to the cytotoxicity of DOX (Fig. 3.11b). It indicated that our polyrotaxane 
nanoparticles could successfully delivery DOX into cells.   
 
 
(a) Blank Polyrotaxane  
 
(b) DOX-loaded PR 
Fig. 3.11 The cytotoxicity of (a) blank polyrotaxane and (b) DOX-loaded PR against 
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(a) DOX loaded PR in MB231 cells 
 
(b) DOX loaded PR in Hela cells 
 
(c) Blank polymer in MB231 cells 
Fig. 3.12 The cytotoxicity of star PR with or without DOX loading against cancer cells 
after 24h incubation. (a) MB231 cells with DOX loading; (b) Hela cells with DOX 
loading; (c) MB231 cells without DOX loading. Data represent mean ± standard 
deviation (n=3). 
The in vitro anticancer activity of the DOX loaded polyrotaxane was 
performed on MB231 and HeLa cancer cells. Cytotoxicity of DOX delivered by the 
polyrotaxane (PR-α 8-Phe and PR-α 12-TNBS) was compared against free DOX in 
these two cell lines using MTT method. As shown in Fig. 3.12 (a)-(b), similar dose-
response viability was observed in both MB231 and Hela cells for all three DOX 
formulas, suggesting our polyrotaxanes could successfully delivery DOX into the 
cancer cell. Remarkably, both DOX loaded PRs exhibited significantly higher potent 
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cytotoxicity could be attributed to higher cell uptake when delivered by the core-shell 
nanostructures (detail showed in Fig. 3.13). It could also due to the ability of our 
carriers to release the drug slowly to cells which could permit their prolonged arrest in 
mitosis. Furthermore, for drugs acting at a specific phase of cell cycle (eg. when DOX 
blocks cell cycle progress at the metaphase/anaphase transition), the capability of the 
delivery system with sustained drug release can allow DOX to act on a higher number 
of cells in a specific phase of cell cycle as compared to a bolus administration [44]. 
Additionally, there was no cellular toxicity caused by the blank polyrotaxane (Fig. 
3.12c) at the studied concentration range, eliminating the possibility that polymers 
themselves were responsible for the cytotoxicity.  
3.3.10 Intracellular uptake and distribution 
 
Fig. 3.13 Cellular uptake and internalization of (a) Free DOX, (b) DOX-loaded PR-α 12-
TNBS and (c) DOX-loaded PR-α 8-Phe in MB231 cells at 10 min, 1 h, 2 h, 24 h and 48 h 
followed by fluorescence microscopy. (DOX Concentration=3μg/mL, left: fluorescence 
light; right: overlay of fluorescence light and bright light). Scale length=100µm.  
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DOX exhibited its own fluorescence with an excitation and emission 
wavelengths of 480 and 580 nm, respectively. The cellular uptake and internalization 
behavior of DOX loaded PR-α 8-Phe and PR-α 12-TNBS were followed with 
fluorescence microscopy using MB231 cell line, by comparing with free DOX. As 
shown in Fig. 3.13 (b) and (c), PR/DOX could be rapidly uptaken by the cells and the 
uptake increases with time. Notably, in contrast to free DOX without transport 
carriers (Fig 3.13a), the PR/DOX complexes exhibited much a faster and higher cell 
uptake, as reflected by the higher intensity of fluorescence within the exposed cells. 
Furthermore, the nanoparticles were able to internalize into the cells, as the red 
fluorescence were seen to be overlaid inside the cells, which implicated that the drugs 
were successfully internalized and delivered into the cells. The high internalization of 
our carriers may due to the small size and core-shell nanostructures with water soluble 
PEG shell, which increased the cell-impermeability and stability of DOX [29]. The 
sustained drug release also prolonged the therapeutic effect of the drugs and increased 
the residence time within MB231 cells. In addition, in contrast with free DOX, much 
less viable cells were found for DOX loaded polymer after 48 h incubation. And the 
MTT studies reveal that smaller number of viable cells was found for PR/DOX, 
indicating a greater drug efficacy for our shell-sheddable drug carriers (Fig. 3.12).   
Furthermore, this CD-based core-shell nanostructure with hydrophilic shell 
could be very useful in vivo situation. Geze et al. studied the biodistribution of β-CD 
nanoparticles in mice after intravenous administration [51]. It was found that as the 
other uncoated particulate nanocarriers, they were rapidly cleared from the blood 
compartment in the reticulo-endothelial system, particularly in liver and spleen 
macrophages. Therefore, DOX-loaded polyrotaxane which present a hydrophilic 
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coating would be great interest in this sense due to the long-circulating properties as 
compared to other structures [44].  
3.4 CONCLUSIONS 
A novel star polyrotaxane is successful synthesized by controlled threading of 
α-CD on star PEG, and blocking the end of the polymer with both enzymatic 
biodegradable linkage. The SPR could further self-assembled into nanostructures in 
water with polyrotaxane core and hydrophilic PEG shell with particle size around 20-
150 nm. The enzymatic biodegradability of the nanoparticles was confirmed by TEM 
and particle size. The nano-sized particles provide high capacity for DOX loading 
with sustained in vitro release for more than 2 months. Furthermore, PR-phe/DOX 
exhibited a faster release, suggesting their stimuli-responsible properties, which 
would be benefic to the controlled drug delivery.  
Remarkably, the PR/DOX was capable of fast cell internalization and cell 
uptake to yield significantly enhanced drug efficacy as compared to free DOX. And 
the DOX-loaded polyrotaxane which present a hydrophilic coating would be great 
interest in vivo due to the long-circulating properties as compared to other structures. 
Taken together, our star polyrotaxanes boast many favorable properties of drug carries, 
which include excellent biocompatibility and triggered-biodegradability, adequate 
drug loading capacity, sustained and controlled drug release, higher cell uptake and 
highly anti-cancer efficacy.  
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CHAPTER 4 DUAL SUPRAMOLECULAR SELF-
ASSEMBLED NANOSTRUCTURES BASED ON STAR 
POLYMERS FOR STIMULI-RESPONSIVE DRUG 
RELEASE 
4.1 INTRODUCTION  
For cancer therapy, reduction-sensitive biodegradable polymers with disulfide 
linkage have emerged as a fascinating class of biomedical materials for drug delivery. 
The disulfide linkages are sufficiently stable under physiological conditions; In the 
cytosol, however, due to the high levels of glutathione they may be subject to rapid 
degradation. Therefore, reduction-sensitive drug carriers in principle could meet the 
conflicting requirements of an ideal drug delivery system, i.e. high stability in 
circulation while rapid degradation inside targeted cells.[1, 2] 
Since the first synthesis of polyrotaxane with multiple α-CD rings threaded 
around a polymer chain [3, 4], CD-based polypseudorotaxanes and polyrotaxanes 
have been receiving increasing attention due to their intriguing supramolecular 
architecture of sliding/dethreading and promising bio-applications [5-8]. Due to the 
threading and dethreading nature of polyrotaxanes, recent studies in biodegradable 
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polyrotaxanes focus on various stimuli-triggered responses such as enzymes[9-11], 
pH, redox[12], and temperature. 
In our previous studies, star enzymatic biodegradable polyrotaxanes were 
successfully synthesized by controlled threading of α-CD onto star PEG (sPEG) and 
their dual self-assembled behaviours to core-shell nanostructures were further 
confirmed. This unique core-shell structure with PR core may potentially lead to some 
specific interactions (e.g. hydrogen bond) between the drug and core, which is 
different from traditional core-shell nanostructures.[13-15] And the core-shell 
polyrotaxane nanostructures were found to be advantages in sustain drug delivery 
with triggered drug release, higher cell uptake and enhanced drug efficacy. 
In this chapter, with the aim of meeting the conflicting requirements of an 
ideal drug delivery system, i.e. high stability in circulation while rapid degradation 
inside targeted cells, we further developed a reduction-sensitive biodegradable system 
for rapid intracellular drug release based on the similar polyrotaxane self-assembled 
nanostructures. Disulfide linkage was introduced to the core-shell nanostructures self-
assembled from SPR (Scheme 4.1). This new SPR nanostructure shows great 
potential to be used as drug carriers with the advantages of reduction-sensitive 
biodegradability, improved solubility, low side effects, high drug load efficiency with 
sustained drug release, improved cell uptake and high anti-cancer efficiency. 
Furthermore, due to the stability and the ability to retain the entrapped drug molecule 
of our system, sustained release could also decrease the concentration of free drug in 
circulations, resulted in a decreased accumulation of the drug in the heart tissues and 
reduced cardiotoxicity, which is a serious drawback for DOX as anti-cancer 
therapy.[16, 17]  
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Scheme 4.1 Illustration of bio-reductive SPR and the intracellular drug release 
4.2 MATERIALS AND METHODS 
4.2.1 Materials  
DCC, NHS, ethylenediamine, cystamine dihychloride, TEA, CDI, Z-L-Phe-
OH, DOX, dithiothreitol (DTT) and NaOH were received from Sigma-Aldrich and 
used as received. 8 arm star PEG (Mn=9468) were purchased from Fluka. α-CD was 
purchased from TCI. Diethyl ether, methanol, DMF, 1,4-dioxane and DMSO were 
purchased from Merck. Penicillin, streptomycin and MTT were obtained from Sigma. 
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4.2.2 Synthesis Methods  
 
Scheme 4.2 Synthesis method and structures of bio-reductive SPR 
8-arm PEG (1g, 0.1056 mmol) was heated at 80 °C overnight, followed by 
adding of 10 mL of anhydrous DMSO. Then the solution was added dropwise under 
nitrogen to 15 mL of anhydrous DMSO solution in which CDI (0.07g, 0.8448 mmol) 
was dissolved. Then the mixture was stirred overnight under nitrogen at R.T. The 
resulting solution was added dropwise into 3.8 g (16.896 mmol) of cystamine 
dihychloride, which was dissolved in 10 mL DMSO together with TEA (4.71 ml, 
33.792 mmol), followed by stirring overnight. DMSO was removed by vacuum 
evaporation in 65 °C and the resulting viscous liquid was dissolved in mix solvent of 
4.2.2.1 Synthesis of PEG-SS-NH2 and PEG-NH2 
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DI water and dichloride methane. The organic layer was collected and it was further 
purified by column chromatography on a Sephadex LH-20 column with methanol as 
eluent to give as a viscous yellowish liquid (Yield, 0.72g (72%)) [18-20]. The 
synthesis of PEG-NH2 are the same with the previous protocols (3.2.2.1) [21]. 
The synthesis procedure is the same with the protocols presented in 3.2.2.2.  
4.2.2.2 Synthesis of Polyrotaxanes (PPR-SS-NH2 and PPR-NH2) 
Partial polyrotaxane with Z-L-phenylalanine end groups (PR-SS-Phe) was 
synthesized in two steps, as reported previously [
4.2.2.3 Synthesis of polyrotaxanes (PR-SS-Phe/PR-Phe) 
21-23]. The synthesis procedure is 
the same with the protocols presented in 3.2.2.3.  
The solubility of polyrotaxane was decreased with the increase of CD threaded 
numbers. The polyrotaxane PR-α 8-SS-Phe and PR-α 8-Phe are soluble in water, and 
the micelle-like nanoaggregates could be prepared by directly dissolving the polymer 
in water and allowing it to stay overnight to ensure complete dissolution [
4.2.2.4 Self-assembly and DOX encapsulation 
24]. In the 
case of the insoluble polyrotaxane (PR-α 20-SS-Phe), the core-shell nanostructures 
could be prepared by dialysis [1, 25]. The procedures are the same with protocols in 
3.2.2.4 
DOX was loaded into the polyrotaxane nanoaggregates followed by the 
method reported before [26]. 10 mg soluble polyrotaxane (PR-α 8-SS-Phe and PR-α 
8-Phe) was added to 1 mg DOX·HCl and dissolved together with 1 mL DI water, and 
the solution was stirred overnight at room temperature. Solution of sodium hydroxide 
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(NaOH) was added to the solution to adjust the pH to 8~9 and stirred for 3 h. Because 
DOX is insoluble in basic condition, the unloaded DOX molecular were precipitated 
and removed by ultracentrifugation. The obtained solution was then lyophilized.  
The drug loading of insoluble polyrotaxane (PR-α 20-SS-Phe) was achieved in 
two steps. Firstly, 10 mg polyrotaxane was dissolved in DMSO and dialyzed against 
DI water for 2 days to form micelle-like aggregates. Secondly 1 mg DOX·HCl was 
added into the resulted nanoparticle solution and stirred overnight at R.T. After 
adjusting the pH to 8~9, unloaded DOX molecular were centrifuged and removed. 
Then the solution with loaded DOX was freeze-dried (Yield, 10 mg). 
4.2.3 Measurements and Characterization 
The procedures are the same with protocols in 3.2.3.1   
4.2.3.1 Proton Nuclear Magnetic Resonance (1H-NMR) spectra 
The CAC values were determined by the dye solublization method [
4.2.3.2 Critical micellization concentration (CAC) determination 
27]. 
Partial polyrotaxane (PR-α 8-SS-Phe and PR-α 8-Phe) was characterized. The 
procedures are the same with presented protocols in 3.2.3.3.  
The procedures are the same with presented protocols in 3.2.3.4 and 3.2.3.5.  
4.2.3.3 Transmission Electron Microscopy (TEM) and Dynamic light scattering (DLS)  
30 mg polyrotaxane (PR-α 20-SS-Phe) was added in 6 mL PBS containing 
DTT (10 mM), followed by shaking under 100 rpm at 37 °C for 6 days. Then the 
4.2.3.4 Biodegradation behavior evaluation-size exclusion chromatogram (SEC) 
 
Chapter 4: Bioreductive Nanostructures for redox-responsive drug delivery 
119 
result solutions were freeze-dried and size exclusion chromatography (SEC) was 
carried out with a Sephadex G-75 column using DMSO as eluent. Fractions were 
collected per 1.5 mL and their optical rotation were recorded at wavelength 589 nm 
with cell length 10 cm and response 2s [1, 28, 29]. (Control: Polyrotaxane was added 
in 6 ml PBS without DTT and it was characterized with the same procedure above). 
2 mg PR-α 20-SS-Phe was dissolved in 1 ml DMSO and dialysis against DI 
water for 2 days (MW=2000). Then DTT (10 mM) was added to the resulted 
nanoaggregates solution, followed by shaking under 100 rpm at 37 °C for 6 days. The 
degradation behavior and morphology difference of the polymer was characterized 
and observed by TEM and Particle size after 0, 1 and 6 days. In order to make a 
comparison, the control sample of PR-α 20-SS-Phe nanoparticles was formed and 
treated without DTT, and it was characterized with the same procedure above. [
4.2.3.5 Biodegradation behavior evaluation-TEM and DLS 
1, 30] 
The amount of DOX encapsulated in the polyrotaxane nanostructures was 
analyzed by fluorescence measurement (excitation at 480 nm) [
4.2.3.6 Characterization of the drug delivery systems 
1]. The procedures are 
the same with presented protocols in 3.2.3.7.  
Release of drugs from the drug-loaded polyrotaxanes was studied using the 
dialysis method [
4.2.3.7 In vitro drug release study 
11, 26, 31]. 3 mg DOX loaded polyrotaxane nanoaggregates were 
put in dialysis membrane tube (MW=2000 Da), followed by dialyzing against 15 mL 
medium of PBS (pH=7.4) containing DTT (10 mM) [28, 30]. The release system was 
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shaken under 100 rpm at 37 °C for 60 days. At designed time intervals, 1 mL release 
medium was removed and replaced with fresh medium. The removed medium was 
analyzed for its drug content with fluorescence measurement (excitation at 480 nm). 
The recorded intensity was compared with a standard curve containing DOX/PBS 
(containing DTT) solution with concentration varied from 0 to 5 μg/mL. In order to 
make a comparison, polyrotaxanes were put into dialysis tube without DTT, followed 
by dialyzing against blank PBS and they are measured with the same procedure above. 
The procedures are the same with presented protocols in 3.2.3.9.  
4.2.3.8 Cell viability assay 
The procedures are the same with presented protocols in 3.2.3.10.  
4.2.3.9 Intracellular cell uptake and distribution 
4.3 RESULTS AND DISCUSSION 
4.3.1 Synthesis of polyrotaxane (PR-SS-Phe and PR-Phe) 
Scheme 4.1 shows the synthesis procedures of partial polyrotaxane. Firstly, 8-
arm PEG-SS-NH2/PEG-NH2 was synthesized by the CDI reaction. Specifically, the 
hydroxyl groups at the end of 8-arm PEG were activated with CDI, followed by 
reaction with large excess of cystamine/ethylenediamine to give terminal amino 
groups. Next, PEG-SS-NH2/PEG-NH2 was allowed to react with saturated solution of 
α-CD to obtain polypseudorotaxane, following similar procedures described in 
previous report [32], in which it was found that α-CD will form an inclusion complex 
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with ratio EO/CD of 2, approximately. Then the end of PEG was blocked to form 
polyrotaxane with Z-L-Phe.  
 
Fig. 4.1 1H-NMR spectrum of (a) 8-arm PEG (Mw=9468, n=25), (b) PEG-11.3%-NH2 
(feeding ratio of CDI/PEG=4:1), (c) PEG-48%-SS-NH2 (feeding ratio=8:1), (d) PEG-
67%-SS-NH2 (feeding ratio=24:1) in d6-DMSO.  
Fig. 4.1 shows the 1H NMR result of 8-arm PEG-SS-NH2/PEG-NH2 in 
comparison with pure 8-arm PEG. In contrast to Fig. 4.1(b), Fig. 4.1(c)-(d) exhibited 
unique peak of δ=2.7~2.8, which was attributed to the SS-linkage. Furthermore, due 
to the end grafting of cystamine/ethylenediamine, the chemical shift of H3 in PEG was 
change from 3.5 ppm (in pure PEG) to 4.05 ppm (in the product). And by comparing 
Fig. 4.1 (b)-(d), it was found that with the increase of feed ratio, the integration ratio 
of H2 (-OH of PEG) was decreased after the reaction. The results confirm the 
successful conjugation of 8-arm PEG with cystamine/ethylenediamine. Quantitative 
comparisons between the integral intensities of peaks H3 and peak H2 were used to 
derive the grafted ratio of the polymer and the results are summarized in Table 4.1. 
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Fig. 4.2 1H-NMR of (a) 8-arm PEG (Mn=9468), (b) α-CD, (c) PR-α 8-Phe, (d) PR-α 8-SS-
Phe and (e) PR-α 20-SS-Phe in d6-DMSO.  
Fig 4.2 shows the 1H NMR of polyrotaxane in comparison with pristine α-CD 
and 8-arm PEG. In Fig. 4.1(c)-(e), the signals for α-CD, 8-arm PEG and the end 
capping groups (Z-L-Phe, δ=7.2-7.4) were all observed. Furthermore, it was found 
that the peaks of α-CDs in polyrotaxanes were broadened; suggesting the mobility of 
α-CDs in polyrotaxane is restricted by the PEG chain after forming the 
supramolecular structure. These results provide us clear evidence for the physically 
interlocked supramolecular structure of 8 arm PEG covered by α-CDs with Z-L-Phe 
end groups [20, 21]. The polyrotaxane compositions could be derived by quantitative 
comparison between the resonance peak due to H1 of α-CD (δ=4.79), the peak due to 
the PEG (δ=3.50) and the peak area of Z-L-Phe end. By calculation, 3 kinds of 
polyrotaxanes are confirmed (Table 4.1). TGA was also further used to estimate the 
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ratio between α-CD and PEG in the polyrotaxanes. And the results were in good 
agreement with the 1H NMR. 
Table 4.1 The polyrotaxane compositions with different threaded number of CDs 
Polyrtoaxanes Grafted ratio of 
Precursor PEG 
α-CD threaded 










PR-α 8-Phe PEG-28%-NH2 1 arm 8 10 
PR-α 8-SS-Phe PEG-48%-SS-NH2 1 arm 8 9 
PR-α 20-SS-Phe PEG-67%-SS-NH2 3 arms 20 21 
a  Data was calculated on the basis of 1H NMR 
b  Data was calculated according to the result of TGA. 
4.3.2 Self-assembly and CAC determination 
 
 
Fig. 4.3 (a) UV-vis spectra changes of DPH with increasing PR-α 8-SS-Phe concentration 
in water at 25 °C. (b) CAC determination by extrapolation of the difference in 
absorbance at 378 nm and 400 nm 
Both PR-α 8-Phe and PR-α 8-SS-Phe were soluble and the core-shell 
nanostructures were formed by directly dissolving in water. Their CAC were 
determined by DPH method [33, 34]. DPH shows a higher absorption coefficient in a 
hydrophobic environment than in water. Thus, with increasing polymer concentration, 
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determined by extrapolating the absorbance at 378 nm minus the absorbance at 400 
nm (A378-A400) versus logarithmic concentration (Fig. 4.3b). It was found that the 
CAC values for water-soluble polyrotaxane PR-α 8-SS-Phe are 0.3 mg/mL. Similarly, 
PR-α 8-Phe showed a CAC of 0.8 mg/mL, which is higher than PR-α 8-SS-Phe (Data 
shown in Fig. 3.5 of chapter 3) 
4.3.3 TEM and Particle Size of the self-assembly 
 
Fig. 4.4 Particle size distribution and TEM images of the self-assembly of PR-α 8-Phe (a), 
PR-α 8-SS-Phe (b) and PR-α 20-SS-Phe (c).(conc.=1 mg/mL). 
To convince the self-assembly and characterize the size and morphology, 
TEM and DLS experiments were conducted. As shown in Fig. 4.4, spherical particles 
were observed in the three kinds of polyrotaxanes. It was found that all three SPR 
nanoparticles exhibited very small size (<120 nm), and the small sizes of 
nanoparticles may enable them to prolong circulation in blood and slower elimination 
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by the reticuloendothelium system (RES) [35]. PR-α 8-SS-Phe was found to form 
nanoaggregates with size of 76 nm and the nanoparticles based on PR-α 20-SS-Phe 
showed higher average sizes of 116 nm. It is probably because the presence of more 
CDs in the polyrotaxane core increased particle volume. Therefore, given the CAC, 
TEM and DLS analytical data as mentioned above, the self-assembly behavior of the 
synthesized partial polyrotaxanes can be confirmed. 
4.3.4 Biodegradation behavior characterization-SEC studies 
In our experiment, terminal group was introduced with disulfide-linkage. The 
most attractive character of such polyrotaxane will involve the control of intracellular 
drug release utilizing the dissociation of supramolecular structure. In our approach, 
size exclusion chromatography (SEC) was used to verify the degradation of the 
polyrotaxane in response to DTT, a reductive environment analogous to that of the 
intracellular compartments such as cytosol and the cell nucleus. 
 
Chapter 4: Bioreductive Nanostructures for redox-responsive drug delivery 
126 
 
Fig. 4.5 Size exclusion chromatograms of polyrotaxane PR-α 20-SS-Phe before treating 
with DTT (a, c), after treating with PBS/DTT (10 mM) or PBS for 6 days (b,d). Pictures 
showed the images of PR-α 20-SS-Phe/H2O mixture (5 mg/mL) before or after treating with 
DTT. 
SEC study was conducted to evaluate the degradation behavior of PR-α 20-
SS-Phe in response to DTT, by using G-75 column with DMSO as eluent. Briefly, 30 
mg PR-α 20-SS-Phe was added in 6 mL PBS water containing DTT (10 mM), 
followed by shaking under 100 rpm at 37 °C for 6 days. Then the result solutions 
were freeze-dried and purified by SEC on a Sephadex G-75 column using DMSO as 
eluent. Fig. 4.5 (a)-(b) show the size exclusion chromatograms of the polyrotaxane 
before and after treating with DTT (10 mM). Before adding DTT (Fig.4.5a), PR-α 20-
SS-Phe was eluted out at higher MW region of the column with a unimodal peak. It 
indicates that the polyrotaxane is pure and the CDs are threaded into the polymer. 
After being stirred for 6 days in the presence of DTT (10 mM) (Fig. 4.5b), the 
unimodal peak was divided into two peaks. The first peak was eluted out at higher 
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MW region. It showed the same position but lower optical rotation in comparison 
with Fig. 4.5(a), suggesting the fraction is the polyrotaxane but with less CD threaded. 
The second peak was eluted out much later in the lower MW region of the column, 
indicating that the fraction is free α-CD. In order to make a comparison, 30 mg PR-α 
20-SS-Phe was added in 6 mL blank PBS (no DTT) and characterized with the same 
procedure. It was found that no change in optical rotation was discerned after 6 days 
in the absence of DTT under otherwise the same conditions (Fig. 4.5c-d). Therefore, 
the results confirm the dethreading behavior of α-CDs after treating with DTT. 
In order to give a visualized picture, the photo images of PR-α 20-SS-
Phe/H2O mixture before or after treating with DTT was presented. Specifically, 
before adding DTT, PR-α 20-SS-Phe was added into water (5 mg/mL) and a turbid 
solution was observed due to the insoluble properties of PR-α 20-SS-Phe (Fig. 4.5a). 
After treating with DTT for 6 days, the solution became clear (Fig. 4.5b), suggesting 
the increase of solubility due to the dethreading of α-CD. In contrast, no change in the 
solubility was observed after 6 days in the absence of DTT under otherwise the same 
conditions (Fig 4.5c-d). 
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4.3.5 Biodegradation behavior characterization-TEM and DLS studies 
 
Fig.4.6 TEM images (a) and size change (b) of polyrotaxane nanoparticels in PBS 
solution with and without DTT (10 mM) after 0, 1 and 6 days (concentration 1 mg/mL). 
The size and morphology changes of PR-α 20-SS-Phe nanostructure in 
response to DTT (10 mM) in PBS were followed by TEM and DLS measurement (Fig. 
4.6). Notably, as shown in Fig. 4.6(a), the SPR nanoaggregates degraded into small 
pieces with irregular morphologies after 6 days in the presence of DTT and the 
average size decreased from 116 nm to 33 nm. In contrast, no change in particle 
morphology was discerned after 6 days in the absence of DTT under otherwise the 
same conditions. The result confirms the effects of dissociation of the supramolecular 
structure by cleavage of the disulfide linkages on the hydrolysis behaviour of PR-α 
20-SS-Phe in the presence of DTT [1]. This was further verified by the DLS 
measurement. In Fig. 4.6(b), with increasing the incubating time, large aggregates 
decreased and smaller aggregates increased, indicating the polyrotaxane 
 
Chapter 4: Bioreductive Nanostructures for redox-responsive drug delivery 
129 
nanoaggregates are degraded into small pieces in the presence of DTT. However, no 
such changes were observed in the absence of DTT under the same condition. 
Similarly, PR-α 8-SS-Phe also showed the same degradation behaviour in response to 
DTT. 
4.3.6 Drug loading efficiency and morphologies observation 
In this chapter, DOX was used as the model molecule to verify the drug 
delivery ability. The SPR nanostructure showed adequate drug loading efficiencies 
around 43%~46% (Table 4.2), which is similar or even higher than the traditional 
micelle structures based on amphiphilic block copolymers.[25, 36] Moreover, because 
of the presence of DOX in the polyrotaxane core, the SPR nanoaggregates showed a 
larger size after loading drugs, which is confirmed by TEM and DLS (Fig. 4.7).[35] 
















PR-α 8-Phe  43.65 μg  4.36 %  10%  43.65%  
PR-α 8-SS-Phe  36.50 μg 3.65% 10% 43.80% 
PR-α 20-SS-Phe  46.35 μg  4.64%  10%  46.35%  
Pure DOX (control) 47.14 µg - - 4.71% 
a Loading content (wt%) = (weight of loaded drug/weight of polymer) 100% 
b Loading efficiency (wt%) = (weight of loaded drug /weight of drug in feed) 100% 
 




Fig. 4.7 Morphology and size distribution of PR-α 8-Phe (a), PR-α 8-SS-Phe(b) and PR-α 
20-SS-Phe (c) before and after loading drugs. 
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4.3.7 In vitro drug release behaviors 
 
Fig. 4.8 In vitro release profile of DOX from polyrotaxanes in PBS at pH 7.4 and 37 °C, 
in presence or absence of DTT: (a) DOX loaded PR-α 8-SS-Phe; (b) DOX loaded PR-α 
8-Phe; (c) DOX loaded PR-α 20-SS-Phe.  
The release of DOX from polyrotaxanes was investigated using a dialysis tube 
in pH7.4 PBS at 37 °C. As shown in Fig. 4.8, the polyrotaxane nanostructures 
exhibited a sustained DOX release lasting about 60 days, in comparison with free 
DOX without polymers. The sustained DOX release from core-shell nanostructures 
was similarly observed in some other cyclodextrin based nanoparticles [31, 37]. 
Based on related researches [26, 38], the long-term release could be attributed not 
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only to the hydrophobic interaction between drug and the polyrotaxane core; more 
importantly, it could also be due to the hydrogen-bond interaction between hydroxyl 
group of CDs and amide group of DOX under neutral and basic conditions, owning to 
the unique structures of star PR. It is worthy of note that a sustained release rate is 
crucial important to prolong therapeutic effect for intravenous delivery when a 
targeting in specific area is attained. [37, 39]  
Remarkably, the results also showed that both PR-α 8-SS-Phe and PR-α 20-
SS-Phe (Fig. 4.8a and c) released DOX faster in the presence of 10 mM DTT in 
contrast to that without DTT (Fig. 4.8b). This is in line with the previous observation 
that the nanoaggregates are degraded into small pieces in response to DTT, a 
reductive environment analogous to that of the intracellular compartments such as 
cytosol and the cell nucleus. In contrast, no drug release difference was observed 
within 30 days for the reduction insensitive PR-α 8-Phe under the same conditions 
(Fig. 4.8b). Therefore, it is evident that faster drug release from star PR was triggered 
by reduction of the disulfide bond. There are some reductive-biodegradable micelles 
triggered by disulfide-linkage for DOX delivery.[30, 36, 40] Interestingly, in our 
systems, rather than rapidly releasing DOX, the nanoaggregates showed sustained 
release profile within 30 days even in the presence of DTT. This unique property 
could be highly beneficial to prolong the therapeutic effect. More importantly, the 
highly stability and sustained drug release of our systems could decrease the 
concentration of free drug in circulations, resulting in a decreased accumulation of the 
drug in the heart tissues and reduced cardiotoxicity, which is a serious drawback for 
DOX as anti-cancer therapy.[16, 17] 
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Fig. 4.9 The cytotoxicity of DOX loaded PR-α 8-SS-Phe/PR-α 8-Phe against cancer cells 
after 6 or 24h incubation: Hela cells after 6 h (a) and 24 h (b) incubation; MB231 cells after 
6 h (c) and 24 h (d) incubation. Free DOX was set as control (n=3) 
Table 4.3 IC50 values (μg/mL) for DOX loaded PR-α 8-SS-Phe/PR-α 8-Phe 
 MB231 (6 h) MB231 (24 h) Hela (6 h) Hela (24 h) 
PR-α 8-SS-Phe/DOX 50 4.9 36.1 2.3 
PR-α 8-Phe/DOX >50 3.7 >50 3.8 
DOX >50  35.97 >50 6.6 
The in vitro anticancer activity of the DOX loaded polyrotaxane was 
performed on MB231 and HeLa cancer cells (Fig. 4.9). As shown in Fig. 4.9, dose-
response viability was observed in both cell lines, suggesting our polyrotaxane could 
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on the cytotoxicity of free DOX [14, 40]. Furthermore, both DOX loaded 
polyrotaxane exhibited similar even higher potent in killing cancer cells than free 
DOX (IC50 values were shown in Table 4.3). The high cytotoxicity could be attributed 
to higher cell uptake when delivered by the polyrotaxanes. It could also be due to the 
capability of the delivery system with sustained drug release, which can allow DOX 
to act on a higher number of cells in a specific phase of cell cycle [37]. More 
importantly, in comparison with PR-α 8-Phe, DOX loaded PR-α 8-SS-Phe exhibited 
higher potent in killing cancer cells than the similar structures without SS linkage, 
indicating that the higher anticancer efficacy is due to the triggered intracellular 
degradation of the nanostructures. Similar phenomenon could also be examined by 
comparing the cytotoxicity of PR-SS-α 20-Phe/DOX and PR-α 8-Phe/DOX on Hela 
cell lines (Fig. 4.10). 
  
Fig. 4.10 The cytotoxicity of DOX loaded PR-α 20-SS-Phe/PR-α 8-Phe against HeLa cells 
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4.3.9 Intracellular uptake and release of DOX 
 
Fig. 4.11 Cellular uptake and internalization of (a) Free DOX, (b) DOX-loaded PR-α 8-
Phe and (c) DOX-loaded PR-α 8-SS-Phe in MB-231 cells at 10 min, 2 h, 4 h, and 24 h 
followed by fluorescence microscopy. (DOX conc.=1 μg/mL). Scale length=100µm. 
The cellular uptake and internalization behavior of DOX loaded PR were 
followed with fluorescence microscopy using MB231 cell line. As shown in Fig. 4.11, 
DOX loaded polyrotaxanes could be rapidly uptaken by the cells and the uptake 
increased with time. Notably, in contrast to free DOX without transport carriers (Fig. 
4.11a), the PR/DOX complexes exhibited a much faster and higher cell uptake. The 
high internalization and cell uptake of our core-shell carriers may be due to the small 
size and water soluble PEG shell, which increased the cell-impermeability and 
stability of DOX [35]. The sustained drug release also could prolong the therapeutic 
effect of the drugs and increase the residence time within MB231 cells. Since it has 
been reported that fluorescence is observed only when DOX is released due to the 
self-quenching effect of DOX in nanoparticles [30, 41], it is clear from these 
fluorescence images that DOX has been efficiently released from PR-α 8-SS-
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Phe/DOX. More importantly, by comparing Fig. 4.11b and 4.11c, PR-α 8-SS-
Phe/DOX showed stronger fluorescence of DOX than that without SS linkage, 
indicating the faster internalization and faster intracellular drug release of the systems 
with disulfide linkage.  
4.4 CONCLUSIONS 
In summary, a novel star polyrotaxane was successfully developed by 
controlled threading of α-CD onto star PEG and end blocked with bioreducible 
linkage. This unique polyrotaxane could self-assemble into core-shell nanostructures, 
which would be applied as a reduction-sensitive drug delivery system. The 
biodegradability of polyrotaxane with disulfide bond in response to DTT was 
confirmed by TEM and particle size. After encapsulating DOX, the nano-sized 
particles showed high drug loading efficiency and sustained in vitro release for more 
than 2 months. Furthermore, the biodegradable SPR exhibited a triggered faster in 
vitro release under a reductive environment in contrast to the reduction-insensitive 
control. In a further development of intracellular study, the biodegradable core-shell 
structures were capable of faster internalization, rapid intracellular uptake and higher 
anticancer efficacy as compared to reduction insensitive control and free DOX. Taken 
together, our SPR nanostructures boast many favorable properties as a drug carries, 
which include excellent biocompatibility and reduction-sensitive biodegradability, 
adequate drug loading capacity, sustained drug release, higher cell uptake and highly 
drug efficacy.  
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CHAPTER 5 REDUCTION-SENSITIVE AND SHELL 
SHEDDABLE NANOSTRUCTURES BASED ON STAR 
POLYROTAXANES FOR GENE DELIVERY  
5.1 INTRODUCTION  
Over the past two decades, gene delivery has gained much attention as the 
potentials for treating disease caused by mutation or genetic defects, genetic disorders 
such as cystic fibrosis, combined immunodeficiency and Parkinson’s disease [1-3]. 
Among various non-viral vectors, PEI has been one of the most popularly employed 
cationic gene carriers due to its superior transfection efficiency and consistency of 
transfection in many different types of cells. They are often considered as the gold 
standard of gene transfection. It was reported that the higher molecular weight PEI 
showed higher transgene expression but it could also lead to significant cytotoxicity 
[4-6], probably due to the necrosis, which caused by aggregation and adherence on 
the cell surface [7, 8]. In contrast, low molecular weight PEI was less toxic but 
showed poor transfection efficiency due to the lower ability to condense DNA [15]. 
Therefore, it was suggested that one of the most rational ways to decrease cytotoxicity 
and enhance gene transfection efficiency could be achieved by combining low 
molecular weight transfection segments with degradable linkages and forming a 
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combined large molecular weight transfection polymer. Recently, a new class of CD-
containing gene carriers was developed based on cationic polyrotaxanes where 
multiple cationic CDs are threaded onto a polymer chain and capped by bulky ends 
[9-12]. By taking advantage of the CD’s ability to slide and rotate along the polymer 
axle, this system seems possible to generate well-matched DNA complexes, and thus 
accomplish the gene transfection with a minimum amount of cationic polyrotaxanes.  
Non-vial gene carriers are challenged with a set of obstacles before and after 
entering cells, including stability in biological fluids, stimuli DNA release inside 
targeting cells, low cytotoxicity and high gene transfection efficiency [13]. In order to 
increase DNA release, bioreducible polymers have emerged as an attractive delivery 
system [14, 15]. These materials usually contain disulfide linkage, which is subject to 
rapid degradation via thiol–disulfide exchange in cytosol [16, 17]. The rapid 
degradation on the one hand could lead to polyplex dissociation and efficient 
intracellular release of DNA or siRNA, on the other hand, they may result in low 
toxicity by avoiding accumulation of high molecular weight polycations inside cells, 
and finally increasing the transfection efficiency [18-20].  
Serum stability is another barrier for gene delivery. In the case of in vivo gene 
delivery, the polyplex particles could prone rapid aggregation due to the negatively 
charged plasma proteins in the serum or blood, which affect the stability of the 
positively charged polyplexes. Introducing a sheddable shell by attaching hydrophilic 
polymer is one of the most attractive methods to maintain the stability of delivery 
vehicles against serum. For example, PEG shell layer could stabilize the aggregation 
in the interior of micelles and at the same time provide a “stealth” layer on the surface 
which could resist protein adsorption and cellular adhesion [21, 22]. Furthermore, 
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PEGlyation is a well verified method to decrease cytotoxicity due to its shielding 
effect on the surface charge of particles [23-25]. 
In this chapter, with the aim of increasing the serum stability and achieving an 
optimal balance between DNA protection and DNA release to maximize transfection, 
we present a novel reduction-sensitive cationic polyrotaxanes for effective gene 
delivery. Herein, star polyrotaxanes were synthesized based on partially threaded α-
CD and star PEG with disulfide-linkage, followed by conjugating multiple 
oligoethylenimine (OEI) arms onto α-CD rings (Scheme 5.1). In contrast to previous 
OEI based cationic polyrotaxane for gene delivery [26, 27], disulfide linkages were 
introduced to polyrotaxane chain, which would allow the system sensitive to 
reduction environment, resulting in sufficiently DNA protection extracellularly, rapid 
degradation and DNA release intracellular, decreased cytotoxicity and enhanced 
transfection efficiency. More importantly, owning to the unique supramolecular 
structure of 8-arm PEG with controlled threaded CDs, the naked PEG arms would 
form a sheddable hydrophilic shell, which could stabilize the polyplex, enhance their 
serum tolerant ability and further decrease the cytotoxicity.  
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Scheme 5.1 Illustration of star polyrotaxanes and intracellular DNA release  
5.2 MATERIALS AND METHODS  
5.2.1 Materials  
Star PEG (Mn=9468) was purchased from Fluka. α-CD was purchased from 
TCI. Linear PEI with a molecular weight of 423 Da, branched PEI with a molecular 
weight of 600 Da, and branched PEI (Mn= 25 kDa) were supplied by Aldrich. NHS, 
DCC, ethylenediamine, TEA, CDI, DTT, Z-L-Phe-OH were received from Sigma-
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Aldrich and used as received. Diethyl ether, methanol, DMF, DMSO were purchased 
from Merck. Penicillin, streptomycin and MTT were obtained from Sigma. 
5.2.2 Synthesis Methods  
 
Scheme 5.2 Synthesis procedure for the cationic polyrotaxane 
The synthesis procedures of PEG-SS-NH2 and PEG-NH2 are the same with the 
methods we presented before. (4.2.2.1) 
5.2.2.1 Synthesis of PEG-SS-NH2 and PEG-NH2 
5.2.2.2 Synthesis of Polyrotaxanes (PPR-SS-NH2 and PPR-NH2) 
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The synthesis procedures of PPR-SS-NH2 and PPR-NH2 are the same with the 
methods we presented before. (3.2.2.2) 
The synthesis procedures of PR-SS-Phe and PR-Phe are the same with the 
methods we presented before. (4.2.2.3) 
5.2.2.3 Synthesis of polyrotaxanes (PR-SS-Phe/PR-Phe) 
The synthesis of OEI-based cationic polyrotaxane is followed by method 
reported before [
5.2.2.4 Synthesis of cationic polyrotaxanes (PR-SS-Phe-OEI/PR-Phe-OEI) 
26]. The resulting polyrotaxane (PR-SS-Phe/PR-Phe) (0.2g, 4.6×10-6 
mol) were dried at 40 °C under vacuum overnight. After the flask cooled, 20 mL of 
anhydrous DMSO was injected and the solution was added dropwise during a period 
of 4 h under nitrogen to 40 mL of anhydrous DMSO solution in which CDI (2.59 g, 
16.55 mmol) was dissolved, and the mixture was stirred overnight under nitrogen at 
room temperature. The product was precipitated in a mixture solution of 
tetrahydrofuran (THF) (300 mL) and Et2O (600 mL), which was further centrifuged 
and washed with THF three times. Then, the precipitate was dissolved in 40 mL of 
anhydrous DMSO, and the solution was added dropwise during a period of 3 h into 
10.5g (24.8 mmol) of OEI423 or 14.9g (24.8 mmol) of OEI600, which was dissolved 
in 40 mL DMSO, followed by stirring the mixture overnight under N2. THF (900 mL) 
was poured into the reaction mixture to precipitate the product. And the resulting 
crude product was purified by SEC on a Sephadex G-50 column using deionized 
water as the eluent. Finally, 0.16 g of yellow solid was obtained (yield, 42%). 
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5.2.3 Measurements and Characterization 
Same with the methods we presented before. (3.2.3.1) 
5.2.3.1 Proton Nuclear Magnetic Resonance (1H-NMR)  
Nitrogen content was recorded on a EA1112 Automatic Elemental Analyzer. 
Samples are further dried in a glass oven overnight before use. 1.92 mg sample is 
loaded into an aluminium sample cup and then placed onto the sampling cartridge. 
The furnace temperature are gradually increased to 950 °C with a constant carrier gas 
flow rate at 140 mL/min. Sulfanilamide is used as standard and analyzed before use.  
5.2.3.2 Elemental analysis 
The plasmid used as report gene was pRL-CMV (Promega, USA), which 
encoding Renilla lucierase, originally cloned from the marine organism Renilla 
reniformis. The plasmid DNA was amplified by using Qiagen Endofree Plasmid 
Mega Kit (Qiagene, Hilden, Germany). The quantity and quality of the purified 
pDNA was assessed by optical density at 260 and 280 nm. The purified pDNA was 
resuspended in TE buffer (10 mM Tris-Cl, oH7.5, 1 mM EDTA). 
5.2.3.3 Plasmid amplification 
All cell lines were purchased from ATCC (Rockville, MD). COS7 and MB231 
cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mg penicillin, 
5.2.3.4 Cells and media 
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100 µg/mL streptomycine at 37°C and 5% CO2.DMEM medium was purchased from 
Gibco BRL (Gaithersburg, MD).  
Gel retardation assay was employed to investigate the DNA binding ability of 
polymers. In general, polymer/DNA complexes were prepared at various N/P ratios 
ranging from 1 to 10 in PBS (pH = 7.4). After 30 min incubation, the complexes were 
mixing with 5μL of 5× gel-loading buffer (BlueJuiceTM, Invitrogen, USA), and then  
electrophoresced on a 0.9% (w/v) agarose gel (Bio-Rad) containing 0.5 ug/mL 
ethidium bromide. Gel electrophoresis was carried out in 1×TAE buffer (40 mM Tris-
acetate, 1 mM EDTA) at 100 V for 30 min in a Sub-Cell system (Bio-Rad 
Laboratories, CA). The location of DNA bands was analyzed on UV illuminator and 
photographed by a GelDoc system (Synoptics Ltd., UK). 
5.2.3.5 Gel retardation experiment 
The particle size and zeta potential of polymer/DNA complexes were 
measured by a Zetasizer Nano ZS (Malvern Instruments Ltd., MA, USA), with a laser 
beam at wavelength of 633 nm (scattering angle: 90°) at 25 °C. 100 µL of polyplexes 
solution containing 3 µg of pDNA were prepared at various N/P ratios from 1 to 50. 
After incubating for 30 min at room temperature, the complexes were diluted to 1 mL 
by 15 mM of KCl solution at the time of measurement. The measurements were 
performed using a capillary zeta potential cell in automatic mode.  
5.2.3.6 Particle size and zeta-potential measurements 
5.2.3.7 Stability of polymer/DNA complexes 
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The salt stabilities of polymer/DNA complexes in PBS were determined by 
dynamic light scattering [28]. Briefly, 100 μL of polyplexes containing 5 μg or 10 μg 
of pDNA were prepared at N/P ratios of 50. After incubating for 30 min at room 
temperature, the complexes were diluted with 800 μL of deionized water and 100 μL 
of 10×PBS solution to generate 1×PBS buffer solution (150 mM PBS). The mixtures 
were incubated at 37 °C and their mean hydrodynamic diameter was measured at 
designed time intervals.  
The protein stabilities of polymer/DNA complexes in 5% (wt) bovine serum 
albumin (BSA) solution were determined by the same method above [29]. The 500 μL 
of polyplex with 10 μg DNA were mixed with an equal volume of 10 wt% BSA 
dissolved in PBS. The mixture was incubated at 37 °C and determined at time interval, 
defined as ti. The average diameter of particles in PBS before BSA treatment, to, was 
also measured. The ratio of particle sizes was calculated as ti/to. 
Polymer/DNA complexes containing 3 µg of pDNA were prepared at various 
N/P ratios from 1 to 50. After 30 min, polymer/DNA polyplexes were treated with 
same volume of 20 mM DTT solution or water. The mixture was incubated at 37 °C 
and determined at time interval, defined as ti. The average diameter of particles in 
water before DTT treatment, to, was also measured by dynamic light scattering. The 
change ratio of particle size was calculated as ti/to. 
5.2.3.8 Biodegradation behavior of polymer/DNA complexes 
The pDNA release ability of polyplex in response to 10 mM DTT was 
evaluated by gel retardation method, followed by the previous report [
5.2.3.9 DNA release ability 
20, 30-32]. 
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Generally, polyrotaxane were mixed with 0.4 µg pDNA at N/P ratio of 50 and 
incubated for 30 min. Then, the polyplex solution was incubated with 10 mM DTT for 
5 h at 37 °C. After incubation, the resulting solution was treated with 1μL of heparin 
sodium salt solution (0-600 μg/mL) to release DNA. After further incubation at room 
temperature for 20 min, the mixed solution was separated into its components by gel 
electrophoresis (35 min at 100 V) (same as the procedure in 5.2.3.4).   
In vitro cytotoxicity tests on the polymer were performed by MTT assay in a 
96-well cell culture plate [
5.2.3.10 Cell viability assay 
33]. In brief, MB231 and COS7 cells were seeded into 96-
well plates at a density of 1×105 cells/mL. After 24 h, the culture medium was 
replaced with serum-supplemented culture medium containing serial dilutions of the 
polymers, and the cells were incubated for 24 h. Next, 10 μL of sterile, filtered MTT 
stock solution in PBS (5 mg/mL) was added to each well. After 4 h of incubation at 
37 °C, the unreacted dye was removed by aspiration and the insoluble formazan 
crystals were dissolved in 100 μL of dimethylsulfoxide (DMSO). The absorbance of 
the formazan product was measured at 570 nm using a fluorometer (FLUOstar 
Optima Microplate Fluorometer).  
MB231 and COS7 cells were seeded onto 24-well plate at a density of 5×104 
per well in 500 μL DMEM medium with 10% FBS 24h prior to transfection. After the 
confluence of the cells reaching to 70-80%, the culture medium was replaced with 
300 μL fresh complete medium (with 10%, 20% and 30% FBS) or serum free medium. 
Polyplexes with different N/P ratios containing 1 μg pDNA were added to each well 
5.2.3.11 In vitro transfection and luciferase assay 
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and were further incubated with cells for 4h. Then the culture media were changed 
back to 500 μL medium containing 10% FBS and cells are incubated for further 20 
hours. At the end of transfection, the cells were washed with PBS three times and 100 
μL of luciferase lysis buffer (Promega, USA) was then added to each well to lysis the 
cells for 30 min. The relative luciferase activity (RLU) was determined by luciferase 
assay kit (Promega, USA) on a single-well luminometer (Berthold lumat LB9507, 
Germany).  The units were normalized to protein content using Coomassie PlusTM 
Protein Assay (Thermo Scientific, USA) and the absorption was measured on a 
microplate reader (Spectra Plus, TECAN) at 570 nm by comparing with standard 
BSA concentration. Results are expressed as relative light units per milligram of cell 
protein lysate (RLU/mg protein). 
Plasmid pEGFP-N1 (Clontech Laboratories Inc., USA) encoding a red-shifted 
variant of wild type green fluorescence protein (GFP) and (FITC) was used to 
examine the GFP expression and FITC expression. Similar with the protocol of in 
vitro luciferase expression, COS7 cells were seeded on 24-well plate at a density of 
5×104 per well in 500 μL DMEM medium with 10% FBS. After 24h, the medium was 
replaced with 300 µL of fresh medium with 10% FBS, in which 20 µL polyplexes 
containing 1µg of pEGFP-N1were added. After 4 h, the transfection medium was 
replaced with medium with 10% FBS and cultured for another 44 hours. At the end of 
transfection, the cells were washed with PBS twice and GFP transfected cells were 
imaged under fluorescent microscope. GFP fluorescence was excited at 488 and 
emission was collected using a 515 nm filter. ImageJ (NIH) was used for comparative 
analysis and quantifying the transfection efficiency. The cells with GFP Expression 
5.2.3.12 In vitro GFP expression 
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above threshold levels were automatically counted from the threshold green channel 
image series using the Analyze Particles function in ImageJ [34]. The GFP expression 
was obtained by dividing the pixel area within the threshold set for the chromogen by 
the total pixel area of the region[35, 36].   
D,L-Buthionine sulfoxamine (BSO), a known GSH inhibitor, was used as 
previously described by Christensen et al [
5.2.3.13 GSH inhibition 
37]. For investigation of cell viability and 
transfection efficiency changed after treating with BSO, cells were pre-treated with 
300 μM BSO solution (diluted by 20 mM stock solution in PBS) for 24 h prior to 
adding complexes solution. The rest procedures were the same as cell viability and 
transfection protocols above. 
Except for cell viability assay, all cell experiments were performed in 
triplicate and the results are expressed as mean ± standard deviation. Student’s t-test 
was used to assess statistical significance of difference between group means. 
5.2.3.14 statistical analysis 
5.3 RESULTS AND DISCUSSION 
5.3.1 Synthesis of cationic polyrotaxanes (PR-SS-Phe/OEI and PR-Phe/OEI) 
Scheme 5.1 (b) shows the synthesis procedures of partial cationic 
polyrotaxane. Firstly, 8-arm PEG-SS-NH2/PEG-NH2 was synthesized by the CDI 
reaction. Specifically, the hydroxyl groups at the end of 8-arm PEG were activated 
with CDI, followed by reaction with large excess of cystamine/ethylenediamine to 
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give terminal amino groups. Next, PEG-SS-NH2/PEG-NH2 was allowed to react with 
saturated solution of α-CD to obtain polypseudorotaxane, following similar 
procedures described in previous report [38], in which it was found that α-CD will 
form an inclusion complex with ratio EO/CD of 2, approximately. Then the end of 
PEG was blocked to form polyrotaxane with Z-L-Phe. Finally, OEIs with different 
MW, linear OEI with MW of 423 and branched OEI600, were grafted to the α-CD 
molecules of polyrotaxanes to give cationic polyrotaxanes. To ensure that there was 
no intra- or intermolecular crosslinking, a large excess of OEI (100 times relative to 
α-CD) was used in the grafting reactions. 
5.3.2 Characterization of cationic polyrotaxanes 
 
Fig. 5.1 1H-NMR spectrum of (a) 8-arm PEG, (b) PEG-48%-NH2, (c) PEG-56%-SS-
NH2, (d) α-CD, (e) PR-α35-Phe and (f) PR-SS-α35-Phe in d6-DMSO. (In PEG-n%-(SS)-
NH2, n means the grafted ratio of terminal amino group; In PR-α n-(SS)-Phe, n means the 
average number of α-CDs threaded on each molecular polymer, calculated by 1H NMR) 
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Fig 5.1(a)-(c) show the 1H NMR result of 8-arm PEG-SS-NH2/PEG-NH2 in 
comparison with pure 8-arm PEG. The unique peak of δ=2.7~2.8 was attributed to the 
SS-linkage. Furthermore, the integration ratio of H2 (-OH of PEG) was decreased 
after the CDI reaction. The results confirm the successful conjugation of 8-arm PEG 
with cystamine/ethylenediamine. By calculation, it was found that the grafted degree 
for PEG-SS-NH2/PEG-NH2 is 48% and 56%, suggesting that about 4 arm of 8-arm 
PEG is grafted with cystamine/ethylenediamine. Fig 5.1(b)-(f) show the 1H NMR of 
polyrotaxane. In Fig. 5.1(e)-(f), the signals for α-CD, the threading 8-arm PEG and 
the end groups (Z-L-Phe, δ=7.2-7.4) were all observed. The polyrotaxane 
compositions (shown in Table 5.1) could be derived by comparison between the 
resonance peak due to H1 of α-CD, PEG (δ=3.50) and Z-L-Phe end.  
 
Fig. 5.2 1H-NMR of (a) α-CD, (b) PR-SS-α 35/OEI423, (c) PR-SS-α 35/OEI600, (d) PR-α 
35/OEI423 and (e) PR-α 35/OEI600 in D2O.  
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Fig. 5.2 shows the 1H NMR spectra of the star polyrotaxanes in comparison 
with pristine α-CD. In the spectra of Fig.5.2b-e, the signals for α-CD, the grafting OEI 
chains, the threading 8-arm PEG, and the Z-L-Phe ends were observed, while the 
peaks were much broadened because of the restriction of the molecular motion by 
molecular interlocking and the grafting of the OEI units [39]. The grafted ratio of 
CD/OEI could be estimated by comparing the integration of the signals for OEI 
(δ=2.5~3.0), PEG (δ=3.5) and threaded ratio of CD/PEG in polyrotaxane (calculated 
based on Fig. 5.1). The elemental analysis of the synthesized cationic polyrotaxane 
was presented in Table 5.2. By calculation, the compositions of the cationic 
polyrotaxane, which determined based on 1H NMR results (Table 5.1), are also in 
good agreement with the elemental analysis results. Therefore, from the results of 1H 
NMR and elemental analysis, it could be conclude that the cationic 8-arm 
polyrotaxane threaded with OEI grafted α-CD and end blocked with disulfide-linkage 
were successful synthesized. 
Table 5.1 The cationic polyrotaxane compositions with OEI grafted-CDs 
 
sample name 
Grafted ratio of 
Precursor PEG a 
α-CD threaded 







of OEI/CD a 
PR-SS-α 35/OEI423 PEG-56%-SS-NH2 3.5 arms 35 2 
PR-SS-α 35/OEI600 PEG-56%-SS-NH2 3.5 arms 35 2.25 
PR-α 35/OEI423 PEG-48%-NH2 3.5 arms 35 2 
PR-α 35/OEI600 PEG-48%-NH2 3.5 arms 35 2.15 
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N% C% H% S% N% C% H% S% 
PR-SS-α 35/OEI423 PEG1CD35SS4OEI70 13.81 44.89 8.18 1.88 14.37 45.02 7.84 1.94 
PR-SS-α 35/OEI600 PEG1CD35SS4OEI78 16.87 45.76 9.12 1.45 16.35 46.12 8.96 1.56 
PR-α 35/OEI423 PEG1CD35OEI70 13.96 44.81 7.45 __ 14.51 45.51 7.81 __ 
PR-α 35/OEI600 PEG1CD35OEI76 16.05 46.88 8.89 __ 16.42 46.64 8.69 __ 
a The compounds are denoted PEGxCDySSzOEIn where x are number of PEG, y are the 
number of threaded CD, z are number of SS linkage, and n are number of OEI repeat units, 
determined by 1H NMR (Table 5.1).  
b Theoretical elemental analysis calculated for the corresponding compound.  
c Elemental analysis found. 
5.3.3 Gel retardation experiment 
 
Fig. 5.3 Electrophoretic mobility of plasmid DNA in the polyplexes formed by (a) PR-α 
35/OEI423, (b) PR-SS-α 35/OEI423, (c) PR-α 35/OEI600, (d) PR-SS-α 35/OEI600 and 
(e)25KPEI at different N/P ratio 
The DNA condensation ability of polycation is a prerequisite for the 
successful gene delivery. In this chapter, gel retardation assay was performed to 
investigate the DNA binding ability of the OEI based cationic polyrotoaxanes. As 
shown in Fig. 5.3, all cationic polyrotaxane exhibited good DNA binding at N/P ratio 
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of 3, where total DNA retardation was detected, showing similar to PEI25k. The 
results show the higher DNA condensation ability of OEI600 based polyrotaxane than 
that of OEI423, which is probably due to their relatively higher charge density and 
high nitrogen content in comparison with OEI423. Furthermore, in comparison with 
PEI25k (Fig. 5.3e), PR-α 35/OEI600 and PR-SS-α 35/OEI600 (Fig. 5.3c-d) exhibited 
better DNA condensation capability even with lower nitrogen content and charge 
density. It is probably because of the OEI-grafted CD rings, which can freely move 
along PEG arms in solution, giving flexibility for efficient complexation with DNA. 
Similar results could also be found in our previous work [9]. 
5.3.4 Particle size and Zeta potential 
 
Fig. 5.4 Particle size (a) and zeta potential (b) of polyplexes formed by PR-SS-α35/OEI, 
PR-α35/OEI and pDNA at various N/P ratios, in comparison with PEI (25k) 
It is generally believed that the particle size and surface charge of polyplexes 
are crucial to endocytosis and gene transfer [23]. Fig. 5.4 shows the particle size and 
zeta potential measurements of cationic polyrotaxane/DNA complexes in comparison 
with PEI (25 kDa) at various N/P ratios. Generally, in Fig. 5.4(a), all polyrotaxanes 
could efficiently condense pDNA into small nanoparticles and the particle size of 
polyplex decreased with an increase of N/P ratio. Their diameters changed 
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dramatically from 300~400 nm to 200 nm as N/P ratio increase from 1 to 10, which is 
similar with the PEI25k/DNA complexes. With further increasing the N/P ratios, their 
particle size changed slightly and remained in the 100–200 nm range. 
Zeta potential is an indicator of the surface charge of polymer/DNA 
nanoparticles, and a positive surface potential of polyplexes is crucial for the 
attachment of anionic cell surface and endocytosis [40]. As shown in Fig. 5.4(b), the 
surface net charge of the complexes of pDNA with cationic polyrotaxanes increased 
sharply from negative to positive as the N/P ratio increased from 1 to 3, and reached a 
plateau at an N/P ratio of 10 and above. The phenomenon is in accordance with the 
results obtained from gel retardation assay, and particle size as discussed earlier. 
When N/P ratio is higher than 10, the zeta potential of the complexes stabilized at 30-
40mV, which could result in a similar affinity to the cell surface.  
5.3.5 Biodegradation behavior of polymer/DNA complexes 
In last two decades, disulfide bond has been highly investigated as a crucial 
linkage for gene delivery vectors due to the rapid disulfide bond cleavage upon the 
interaction with reducing molecules such as, glutathione (GSH), cystein and so forth 
in living cells [41]. This rapid cleavage of disulfide linkage will ensure DNA release 
from complexes efficiently leading to facilitating nuclear import, gene transcription 
and gene expression [42], and also lowering the cytotoxicity of the system. 
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Fig 5.5 Particle size change ratio of polyplexes formed by (a) PR-SS-α35/OEI423, (b) 
PR-α35/OEI423, (c)PR-SS-α35/OEI600, (d) PR-α35/OEI600 and pDNA in the presence 
of 10 mM DTT after 0h, 2h and 5h. 
In order to confirm the degradation and dissociation of our disulfide-
containing systems, the bioreductive cleavage of the disulfide bond in the 
polyrotaxane was mimicked by treating with reducing agent DTT (10mM), which is 
analogous to the intracellular environment such as cytosol. And the particle size 
change of the polyplex with different N/P ratios in response to DTT was determined 
by DLS (Fig. 5.5). The responsive reductive polyplexes PR-SS-α35/OEI were stable 
in physiological solution during 24 h incubation in PBS (part 5.3.11). However, as 
shown in Fig. 5.5, when these complexes were treated with reductive agent, 10 mM 
DTT, the particle size of PR-SS-α35/OEI markedly increased and the increased ratio 
is varied from 1.5 to 2.5 (Fig. 5.5a and 5.5c). Notably, at N/P ratio of 10, after 
incubation with DTT for 5h, the size of polyplex formed by PR-SS-α35/OEI423 and 
PR-SS-α35/OEI600 markedly increased from 186 nm to 291 nm (change ratio=1.6) 
and 90 nm to 221 nm (change ratio=2.5), respectively. In contrast, non-reductive 
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polyplex PR-α35/OEI were sufficiently stable in the presence of DTT and no change 
in particle size was observed (Fig. 5.5b and 5.5c). The increased of particle sizes were 
probably due to the cleavage of the disulfide-bond in the presence of DTT, which led 
to decreased DNA binding ability. This phenomenon is good agreement with other 
disulfide bond based bioreductive gene systems [41, 43, 44]. Therefore, the above 
result confirms the dissociation behavior of the supramolecular structure by cleavage 
of the disulfide linkages upon a reductive intracellular environment. 
5.3.6 DNA release ability 
 
Fig. 5.6 Agarose gel electrophoretic images of the polyplexes (N/P=50) of PR-SS-
α35/OEI600 (a,b) and PR-α35/OEI600 (c,d) with (b,d) or without (a,c) 10 mM DTT. 
(Line 1 shows the bands of control pDNA. Concentrations of heparin at lines 2, 3, 4, 5, 6, 7, 
and 8 were 0, 200, 300, 400, 450, 500 and 600 μg/mL, respectively.) 
To further examine the DNA release ability in the reductive condition, 
condensed polyplexes were subjected to gel retardation and a heparin competitive 
displacement assay was performed in the absence or presence of 10 mM DTT. Fig. 
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5.6(a)-(b) show the gel electrophoretic images of PR-SS-α35/OEI600 before or after 
incubating with DTT for 5h. In the absence of DTT, the critical concentration of 
heparin, at the point of pDNA release, for PR-SS-α35/OEI600 is higher than 600 
μg/mL(Fig. 5.6a), confirming that DNA were compacted tightly by the tested cationic 
polymer. Remarkably, after incubating with DTT for 5h, free DNA bands were 
observed at much lower concentration of heparin (200 μg/mL) (Fig. 5.6b). The results 
suggest that in PR-SS-α35/OEI systems, effective pDNA release was observed in the 
reductive condition, indicating the DNA binding ability of polyrotaxane decreased 
after incubating with DTT. In contrast, no obvious pDNA release was observed on the 
reduction insensitive control under the same condition (Fig. 5.6c-d). In the case of 
PR-α35/OEI600, DNA release ability was not enhanced with DTT and the DNA 
release occurs only when concentration of heparin is 600 μg/mL. These results 
indicate that the pDNA release from PR-SS-α35/OEI polyplexes was induced by the 
SS cleavage, followed by a dissociation of the supramolecular structure of 
polyrotaxanes [31]. Similar results were also found by other groups [44]. These 
findings were thus in accordance with the particle sizes results discussed earlier. 
Similarly, polyplexes formed by PR-SS-α35/OEI423 also exhibited the same results 
(Fig. 5.7). In summary, it is predicted that PR-SS-α35/OEI/DNA system was stable 
extracellularly and could rapid release DNA from the system intracellularly by rapid 
disulfide bond cleavage. 
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Fig. 5.7 Agarose gel electrophoretic images of the polyplexes (N/P=50) of PR-SS-
α35/OEI423 (a,b) and PR-α35/OEI423 (c,d) with (b,d) or without (a,c) 10 mM DTT. 
(Line 1 shows the bands of control pDNA. Concentrations of heparin at lines 2, 3, 4, 5, 6, 7, 
and 8 were 0, 200, 300, 400, 450, 500 and 600 μg/mL, respectively.) 
5.3.7 Cytotoxicity of the cationic polyrotaxanes 
Based on the pioneer findings, we modified our PEI based polyrotaxane with 
the purpose of lowering cytotoxicity using the following strategies: (1) Conjugation of 
low molecular weight PEI chain (OEI423 and OEI600) to CD rings in the 
polyrotaxane to form a large molecular weight star shaped and flexible polymer; (2) 
Introduction of disulfide linkage to polyrotaxane chain to ensure CD dethreading, 
DNA release and lower toxicity; (3) Introduction of PEG hydrophilic shell which 
could decrease cytotoxicity due to its shielding effect on the surface charge of 
particles [23-25]. 
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Fig. 5.8 Cell viability assay with various concentrations of PR-(SS)-α 35-OEI systems 
compared with bPEI (25k) in (a) MB231 and (b) COS 7 cells for 24 h in a serum-
containing medium (n=6). *p<0.01, **p<0.001 
The in vitro cell cytotoxicity of our cationic polyrotaxane systems was 
evaluated by MTT assays in MB231 and COS 7 cell lines, using commercial available 
PEI25k and non-reducible polyrotaxane as control (Fig. 5.8). As shown in Fig. 5.8, all 
investigated polymers exhibited a dose-dependent toxicity effect on both cell lines. It 
is worth noting that all four cationic polyrotaxanes exhibited markedly less toxicity in 
both cultured MB231 and COS7 cells than the PEI control. One possible reason is that 
the introduction of polyrotaxane and lower molecular PEI results in the lower density 
of amino groups and the high density of amino groups in PEI is always considered as 
an important factor leading to high cytotoxicity [45]. Likewise, the cytotoxicity of 
OEI600 based polyrotaxane is higher than that with linear OEI423, which could also 
be attributed to its higher density of amino group. 
More importantly, by comparing the cytotoxicity of disulfide bond contained 
polymer with the non-reductive control, it was valuable to found that polyrotaxane 
with SS linkage showed a remarkable decrease in cytotoxicity over PR-α35/OEI, 
which is the PR-SS-α35/OEI analogue lacking a reductively cleavable disulfide bond. 
The dramatically decreased cytotoxicity is believed to be a direct consequence of the 
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intracellular degradation of the disulfide bond of PR-SS-α35/OEI systems leading to 
CD dethreading with smaller fragments, which results in reduced binding affinity of 
polymers with cellular membranes and reduced interference with cellular signal 
transduction pathway. It is evident that introduction of disulfide linkage is benefit for 
enhancing polymer biocompatibility. Such findings are in accordance with the 
previous reports, demonstrating that the incorporation of bioreductive disulfide bond 
could lower cytotoxicity [18, 46, 47]. From the above cytotoxicity result, we could 
safely come to the conclusion that our modification strategies including conjugation 
of low MW PEI chain to CD rings and introduction of disulfide linkage into the 
polyrotaxane systems are succeed in improving cell viability of PEI. 
5.3.8 In vitro transfection and luciferase assay 
 
Fig. 5.9 Gene transfection efficiency of the polyplexes formed by PR-(SS)-α35/OEI and 
25K PEI in (a) COS7 and (b) MB231 cells in the presence of serum. Luciferase was 
measured at 24h after transfection. Data represent mean±SD (n=3, *p<0.05, **p<0.01). 
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In vitro gene transfection efficiency of the cleavable cationic polyrotaxane was 
assessed using luciferase as a marker gene in MB231 and COS7 cells in the presence 
of serum. Fig. 5.9 shows the luciferase protein expression of the bioreductive 
polyrotaxane PR-SS-α35/OEI compared with non-reductive analogue PR-α35/OEI 
and PEI25k. As presented in Fig. 5.9, it could be seen that the luciferase expression 
mediated by cationic polyrotaxane was greatly dependent on the N/P ratios. Generally, 
the transfection efficiency increased with the increasing of N/P ratios and the optimal 
N/P ratio for the most efficient transfection is around 50. Remarkably, all 
polyrotaxanes showed excellent in vitro gene transfection efficiency, comparable to or 
even higher than that of branched PEI (25 K) at their optimal N/P ratios. In particular, 
the transfection efficiency mediated by PR-SS-α35/OEI423 (N/P=60) was 15 times 
higher than that of PEI (25K) (N/P=10) in MB231 cells (Fig. 5.9b). Furthermore, it is 
worth of note that the reductive polyrotaxane PR-SS-α35/OEI exhibited significant 
higher luciferase expression than the non-biodegradable polyrotaxane control (PR-
α35/OEI). They have significant difference in most N/P ratios. It is hypothesized that 
cytotoxicity was related to gene transfection ability and might be caused by 
electrostatic interactions with negatively charged glycocalyx of the cell surface [4]. 
Since the bioreducible cationic polyrotaxane showed a remarkable decrease in 
cytotoxicity over the non-degradable control (Fig. 5.8), the higher luciferase 
expression of degradable polyrotaxane may have benefited from their lower toxicity 
inside cells, which might enable to enhance the transfection efficiency. 
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Fig. 5.10 Gene transfection efficiency of the polyplexes formed by PR-(SS)-α35/OEI and 
25K PEI in (a) COS7 and (b) MB231 cells in the presence of serum. Luciferase was 
measured at 48h after transfection. Data represent mean±SD (n=3, *p<0.05, **p<0.01). 
We also investigated the luciferase expression level mediated by our cationic 
polyrotaxane after longer transfection time (Fig. 5.10). It was found that the 
polyrotaxane exhibit much better transfection efficiency than PEI, especially after 
long time incubation. It is probably because the transfection efficiency of PEI 
decreased when increasing transfection time, which might be caused by the 
cumulative cytotoxicity of PEI inside cells [28]. While the transfection ability of 
cationic polyrotaxane increased with the increased of incubation time, owing to their 
low cytotoxicity, which may enable them to stay within the cells long enough and 
slowly release the pDNA to enhance luciferase expression. 
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5.3.9 In vitro Green fluorescence protein expression 
 
Fig. 5.11 The fluorescence microscopy images of transfected COS 7 cells mediated by 
pEGFP-N1 complexes form by (a) PR-SS-α35/OEI423, (b) PR-α35/OEI423, (c) PR-SS-
α35/OEI600 and (d) PR-α35/OEI600 at N/P ratio of 30 and 60, comparing with PEI 25K 
at N/P=10. (f) Quantitative comparison of the percentage of cells expressing GFP. 
Student’s unpaired t-test (**p<0.005). (left: fluorescence light; right: bright light). 
We employ another reporter gene pEGFP-N1 plasmid DNA encoding green 
fluorescence protein (GFP) to further visualize transgenetic efficacies of the PR-SS-
α35/OEI carriers with its non-reductive analogue PR-α35/OEI as control. As shown in 
Fig. 5.11, strong fluorescence signal could be observed in delivering EGFP-pDNA 
when transfections were mediated by polyrotaxane systems, exhibiting high levels of 
vector internalization and gene expression. Fluorescence signal increased by the 
increasing of N/P ratio. Both PR-SS-α35-OEI and PR-α35-OEI showed significantly 
higher fluorescence than PEI, indicating higher gene GFP expression efficiency (Fig. 
5.11f). It is in line with the results of luciferase assay. Furthermore, by comparing PR-
SS-α35-OEI and PR-α35-OEI at N/P ratio of 60, a stronger GFP fluorescence 
emission was observed for the bio-reductive vector. As a result, GFP transfection 
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assay showed higher gene transfection efficiencies for PR-SS-α35-OEI systems, and 
this trend agrees well with that measured by luciferase assay (Fig. 5.9).  
5.3.10 GSH inhibition 
 
Fig. 5.12 Effects of BSO (300μM) on luciferase expression levels in COS7 and MB231 
cells. Polyplex formed by PR-(SS)-α35/OEI423 (a,b) and PR-(SS)-α35/OEI600 (c,b) were 
transfected in the presence of serum with/without BSO. Data represent mean±SD (n=3). 
*p<0.05, **p<0.01 
In previous research, we confirmed the degradation behavior and DNA release 
ability of bioreductive polyrotaxane in response to DTT, due to the cleavage of 
disulfide linkage (Fig. 5.5-5.7). And the transfection results and MTT assay further 
showed that the cell viability and gene transfer ability of PR-SS-α35/OEI systems 
were noticeably stronger than the non-reductive analogue PR-α35/OEI control (Fig. 
5.8-5.11). However, we still not sure whether the degradation of the complexes 
occurred intracellularly reducing by glutathione (GSH), and whether the degradation 
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and intracellular reductive environment GSH are responsive for the low cytotoxicity 
and high transfection efficiency. Therefore, in order to further determine the role of 
disulfide linkage of our system in improvement of gene transfection, D,L-Buthionine 
sulfoxamine (BSO), a known GSH inhibitor resulting in depletion of intracellular 
GSH, was used [37, 48]. Fig. 5.12 shows the effects of BSO (300μM) on luciferase 
expression levels in COS7 and MB231 cells. The results showed that when cells were 
pre-incubated with BSO prior to transfection, the transfection efficiency of disulfide-
linkage containing PR-SS-α35/OEI423 (Fig. 5.12a-b) and PR-SS-α35/OEI600 
(Fig.5.12c-d) sharply decreased as compared to the same polyplex without the 
treatment of GSH inhibitor (p<0.01). In contrast, the luciferase expression level of 
non-degradable analogue PR-α35/OEI was not affected by BSO (p>0.05). Therefore, 
it is evident that the observed inhibitions of transfection were not caused by 
cytotoxicity of BSO and the disulfide linkages were cleaved by intracellular GSH. It 
suggests that the degradation did play a role in reductive polyrotaxane transfection, 
presumably through the efficient unpacking of DNA. Furthermore, after treating with 
BSO, no significant differences were observed in the transfection efficiency of PR-
SS-α35/OEI and PR-α35/OEI (p>0.05). This is in consistent with the previous report 
[48, 49], which indicating the intracellular cleavage of the disulfide bond in the PR-
SS-α35/OEI systems by GSH is responsible for their higher transfection efficiency 
observed previous in compared with PR-α35/OEI systems (Fig. 5.9 and 5.10). 
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Fig. 5.13 Effects of BSO (300μM) on cytotoxicity of PR-SS-α35/OEI423 in (a) MB231 
and (b) COS7 cells. Data represent mean ± SD (n=6). **p<0.001 
Since we originally hypothesized that the reductive polyrotaxane would 
facilitate DNA release triggered by the intracellular degradation in response to GSH, 
we expected that the cytotoxicity of the biodegradable polyrotaxane would also be 
affected by the level of intracellular GSH level, which causes the degradation. To test 
this point, cell viabilities were compared between the cells treated with and without 
BSO. As shown in Fig. 5.13, in both cell lines, the cytotoxicity of PR-SS-α35/OEI423 
system significantly increased to the level of its non-degradable analogue PR-
α35/OEI423 upon treatment with BSO (p<0.001). It should also be noted that the 
decreased of cell viability should not be associated with toxicity of BSO, because the 
cytotoxicity of non-reductive PR-α35/OEI423 was not affected by BSO treatment 
(p>0.05). The results showed that the GSH inhibitor led to the inability of polyplex to 
completely degradation, resulting limited DNA release and higher cytotoxicity. 
Evidently, lower the cytotoxicity of complexes is the one of the major contributions of 
disulfide linkage to gene transfection. The results are in accordance with our previous 
hypothesis.  
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5.3.11 Stability of polymer/DNA complexes 
Serum stability is one of the most important barriers for gene delivery. In the 
case of in vivo gene delivery, the polyplex particles could prone rapid aggregation due 
to the negatively charged plasma proteins in the serum or blood, which affect the 
stability of the positively charged polyplexes [50]. In our system, due to the unique 
supramolecular structure of star PEG with partial threaded CDs, the naked PEG arms 
could form a sheddable hydrophilic shell by self-assembly, which could stabilize the 
polyplex. This is one of the major advantages of our systems in contrast to other 
cationic polyrotaxanes formed by linear polymers and cyclodextrins [19, 27]. 
Furthermore, unlike traditional PEGylation via covalent or non-covalent attachment, 
the PEG shell was formed naturally and no more modification is needed, which could 
prevent the drawbacks due to the traditional PEG modification, such as lower 
transfection efficiency and reduced internalization of untargeted polyplexes [51], 
degradation of DNA by nucleases [52], and lower DNA binding ability [53].   
We studied the aggregation behaviors of the polyplex formed by cationic 
polyrotaxane with PEG shell under physiological salt condition (N/P=50) (Fig. 5.14). 
In order to verify the importance of naked PEG arms in our unique PR core-shell 
structure, three control systems are used: PEI25k, α-CD-OEI600 without PEG and 
polyrotaxane based on almost fully threaded 8-arm PEG and cationic α-CD (PR-SS-
α65/OEI600). The last two of which are synthesized with the same procedures as our 
test polyrotaxanes and their structures are confirmed by 1H NMR. The NMR result 
showed that in PR-SS-α65/OEI600 systems, 65 α-CDs are threaded on each polymer 
(~7 PEG arms threaded, 1 arm naked) and the grafted ratio of OEI/CD is two, 
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confirming it as the PR-SS-α35/OEI600 (~3.5 PEG arms threaded, 4.5 arm naked) 
analogue but threading with more CDs. 
 
Fig.5.14 Hydrodynamic size of polyplex formed by PEI, αCD-OEI, PR-SS-α65-OEI and 
PR-(SS)-α35-OEI systems at N/P ratio of 50 with different DNA content as a function of 
time in the presence of 150 mM PBS. (a) DNA content=5μg; (b) DNA content=10μg 
As shown in Fig. 5.14, in the presence of PBS, the hydrodynamic diameters of 
our four test cationic polyrotaxanes remained relatively stable within 24hrs, but the 
complexes formed by polymer without PEG (α-CD-OEI600) or with less naked PEG 
(PR-SS-α65/OEI600) and PEI25k aggregated rapidly in PBS.  In particular, the size 
of polyplexes formed by PR-SS-α35/OEI600 with 10 μg DNA increased from 101.3 
nm to 113.8 nm in 24 hours with PBS incubation, and the size change ratio was 1.13 
(Fig. 5.14b). In contrast, with the increase of CD threaded number and decrease of 
naked PEG arms, the trend of size changes of both α-CD-OEI600 and PR-SS-
α65/OEI600 system were much steeper. The diameters of PR-SS-α65/OEI600 
complexes increased from 164.5 nm to 1749 nm in 24 hours and the size change ratio 
was 10.63. These results demonstrates that the naked PEG in PR-(SS)-α35/OEI 
contributes to the formation of exterior surface with hydrophilic PEG brush layer, 
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which could stabilize the polyplex and prevent aggregation of particles under 
physiological salt conditions.  
 
Fig. 5.15 Evaluation of the change in particle size of polyplexes in PBS that contains 5wt% 
of BSA at 37 °C, as determined by dynamic light scattering: (a) size change ratio (b) 
particle size. (All the N/P ratio of the polymer/DNA complex was fixed at 50.) 
In this chapter, bovine serum albumin (BSA) was selected as the model 
protein to simulate the serum condition. We investigate the stability of the 
polymer/DNA complexes in BSA containing PBS. Fig. 5.15 shows the ratio of size 
change (a) and the size of polyplexes (b) in 5% BSA solution as a function of time. 
Similar with the investigation of salt stability, the particle size of PR-(SS)-
α35/OEI/DNA complex was compared to 3 systems: PEI25k, α-CD-OEI600 without 
PEG and PR-SS-α65/OEI600 (7 arms threaded with CDs). As expected, it was found 
that all the four tested polyrotaxanes with 4.5 naked PEG arms (PR-(SS)-α35/OEI) 
could prevent particle aggregation for 24h in the presence BSA.  The sizes of PR-SS-
α35/OEI600 /DNA complexes increased from 173.7 nm to 202.1 nm in 24 hours, and 
the size change ratio was 1.16. And the size change ratio of other three polyrotaxane 
are all lower than 2. However, without the modification of PEG, the trend of size 
changes of both PEI/DNA and α-CD-OEI/DNA system were much steeper. The ratios 
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of size change at 24 h were 10.4 and 8.4, respectively. Furthermore, there is a trend 
that polyrotaxane with less naked PEG arms is less effective to alleviate BSA-induced 
aggregation. By comparing with polyrotaxanes with 4.5 naked PEG arms, the 
diameter of PR-SS-α65/OEI600 (1 naked arm) complexes increased from 164.5 nm to 
1248 nm in 24 hours and the size change ratio was 7.59. The results are in line with 
the previous salt stability studies. It is confirmed that the shielding effect of PEG 
could hinder the interaction with protein and aggregation of particles. Our 
polyrotaxanes with core-shell nanostructures may be more stable and resistant to 
serum system than other polycationic gene systems, which is important for in vivo 
applications. 
5.3.12 Serum tolerance capacity investigations 
 
Fig. 5.16 Effect of serum contents on the luciferase activities of polymer/DNA complexes 
in (a) COS-7 and (b) MB231 cells. All polyrotaxane were tested at its optimal N/P ratio 
in presence of serum, PEI25k at N/P 10 and polyrotaxane at N/P=30. Data represent 
mean±SD (n=3, *p<0.01, **p<0.001). 
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We have confirmed that the PEG shell could prevent aggregation upon salt 
and protein conditions (part 5.3.11). However, we still do not know whether the 
hydrophilic shell could intracellularly weak the inhibitory effect of serum to 
transfection. To achieve that point, serum tolerance capacity of PR-(SS)-α35/OEI 
systems was investigated. The luciferase gene expression mediated by PR/DNA was 
studied in the medium containing various concentrations of FBS and compared with 
PEI25k (Fig. 5.16). As shown in Fig. 5.16, the increased FBS concentrations exert 
negative effect on gene transfection by PEI25k. In the presence of 30% FBS, 
transfection efficacies were drastically decreased to be less than 1% of those values 
assayed in serum-free medium (p<0.001) in both COS7 and MB231 cells. The low 
transfection efficiencies were possible caused by aggregation of the particles in 
response to serum contained medium, which was verified in the stability studies in 
BSA (Fig. 5.15). In contrast, the polyplex mediated by our four test polyrotaxanes 
with PEG shell interestingly remained high luciferase protein expression level eve in  
30% of FBS (p>0.05), indicated its high serum-resistance capability during 
transfection. The serum tolerance capacity of polyrotaxane system was probably 
because of the particles formed by PR-(SS)-α35/OEI were covered with naked PEG, 
which is hydrophilic and hinder the non-specific interaction of the negative charged 
serum. This property of PEG possibly allows lower binding affinity to serum 
constitutes. This is in consistent with the stability studies. 
5.4 CONCLUSIONS 
Aiming to increase the serum stability and achieving optimal DNA release to 
maximize transfection, a novel reduction-sensitive gene delivery system was 
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successfully developed based on cationic polyrotaxanes with core-shell nanostructures, 
which consists of partially threaded α-CD, star PEG, end blocking polymer with 
disulfide-linkage and multiple OEI arms by conjugating onto α-CD rings. The 
resulted cationic supramolecular structure demonstrated good ability to condense 
DNA into nanoparticles. DLS and gel retardation experiment confirmed their 
degradability and DNA release ability in response to DTT. Remarkably, the results of 
MTT assay and luciferase expression confirmed that the biodegradable polyrotaxane 
with disulfide linkage exhibited significant lower cytotoxicity and higher gene 
transfection efficiency in contrast to reduction insensitive control and 
polyethylenimine (PEI) 25k. They showed excellent in vitro transfection efficiency 
which was comparable to or even higher than that of PEI 25k. Furthermore, in 
according to the glutathione (GSH) inhibition experiment, it was found that cell 
viability and transfection was markedly decreased, confirming that introduction of 
disulfide linkage to the system result in fast intracellular degradation and 
disassociation, efficient DNA release, decreased cytotoxicity and enhanced 
transfection. More importantly, the hindrance effect of PEG shell allows the system to 
be stable in salt and protein solution, and inhibits non-specific protein absorption on 
the particle surface. Moreover, high serum concentration exerts neglect effect on the 
transfection efficiency of this polyrotaxane system, further verifying the PEG shell 
enhances the serum stability of the system. Taken together, our cationic 
nanostructures boast many favorable properties as gene carriers, which include good 
DNA binding ability, reduction-sensitive biodegradability, intracellular DNA release, 
low cytotoxicity, high gene transfection efficiency and high stability in biological 
fluids. 
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CHAPTER 6 SHELL DETACHABLE AND 
BIOCLEAVABLE NANOSTRUCTURES BASED ON STAR 
POLYROTAXANE WITH PDMAEMA FOR REDOX-
RESPONSIVE GENE DELIVERY 
6.1 INTRODUCTION  
pDMAEMA is a synthetic polymer with tertiary amino groups on the side 
chain. It is water soluble and owning to its positive charged surface, it could compact 
DNA into small particles by electrostatic interaction [1] and show higher transfection 
efficiency [2, 3]. Cytotoxicity, lack of cell specificity and serum-induced aggregation 
are the major obstacles for pDMAEMA-based polyplexes to apply in gene delivery 
[4]. Similar with PEI, the molecular weight of the polymer plays an important role to 
the cytotoxicity [5]. Generally, the cytotoxicity of polymer appears to increase with 
the increasing of molecular weight. Membrane disruption, apoptosis and cytotoxicity 
of PDMAEMA increased with their chain length [6]. Therefore, it was suggested that 
one of the most rational ways to decrease cytotoxicity and enhance gene transfection 
efficiency could be achieved by combining low molecular weight transfection 
segments with degradable linkages and forming a combined large molecular weight 
transfection polymer. In addition, because it was reported that higher zeta potential of 
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polyplexes could lead significant cytotoxicity [7], PEGlyation is a well verified 
method to decrease cytotoxicity due to its shielding effect on the surface charge of 
particles [8-10]. 
Recently, a group of reduction-responsive polymer and conjugates was 
synthesized based on PDMAEMA for gene delivery [11-13]. Generally, they contain 
disulfide-linkage, which is prone to rapid degradation in reductive intracellular 
environment and cell nucleus [14, 15]. So they showed distinct feature from the 
normally hydrolytically degradable counterparts: on the one hand they could lead to 
polyplex dissociation and efficient intracellular release of DNA or siRNA [16, 17], on 
the other hand, they may result in low toxicity by avoiding accumulation of high 
molecular weight polycations inside cells, and finally increasing the transfection 
efficiency [18, 19]. Serum stability is another barrier for gene delivery. In the case of 
in vivo gene delivery, the polyplex particles could prone rapid aggregation due to the 
negatively charged plasma proteins in the serum or blood, which affect the stability of 
the positively charged polyplexes. PEG shell layer, could stabilize the aggregation in 
the interior of micelles and at the same time provide a “stealth” layer on the surface 
which could resist protein adsorption and cellular adhesion [20, 21].  
In spite of many studies on the pDMAEMA-based polycations as gene vectors 
reported so far [11-13], little is known about the star pDMAEMA based on reduction-
sensitive polyrotaxanes, not to mention of their dual self-assembly behavior, which 
leads to the formation of core-shell nanostructure and their applications to redox-
responsive gene delivery. In this chapter, we exploit a novel redox-responsive and 
shell detachable nanostructure with hydrophilic PEG shell and cyclodextrin core for 
effective and reductive gene delivery (Scheme 6.1). This nanostructure is derived 
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from star polyrotaxanes based on partially threaded α-CD, star PEG, and end blocking 
cationic polymer pDMAEMA with disulfide linkage, which was prepared via Cu(I)-
mediated ATRP. Uniquely, low molecular weight pDMAEMA segments was linked 
to star PEG and formed a combined large MW transfection polymer with disulfide 
linkages, which would allow the system sensitive to reduction environment, resulting 
in sufficiently DNA protection extracellularly, rapid degradation and DNA release 
intracellular, decreased cytotoxicity and enhanced transfection efficiency. 
Furthermore, owning to the unique supramolecular structure of 8-arm PEG with 
partial threaded CDs, the naked PEG arms would form a sheddable hydrophilic shell, 
which could stabilize the polyplex, enhance their serum tolerant ability. More 
importantly, due to the presence of polyrotaxanes, the star pDMAEMA based 
polyrotaxane could further self-assembled into core-shell nanostructures in water, 
which would be very promising for drug/gene codelivery (Charpter 7). 
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Scheme 6.1 Illustration of star polyrotaxanes based on PDMAEMA and intracellular 
DNA release 
6.2 MATERIALS AND METHODS  
6.2.1 Materials 
Star PEG (Mn=9468) were purchased from Fluka. α-CD was purchased from 
TCI. DMAEMA monomer, 2-bromopropionyl bromide, Cu(I)Br, 1,1,4,7,10,10-
Hexamethyltriethylenetetramine (HMTETA), ethylenediamine, cystamine 
dihychloride, TEA, CDI, DTT, were received from Sigma-Aldrich and used as 
received. Diethyl ether, methanol, tetrahydrofuran (THF), n-hexane and DMSO were 
purchased from Merck. Penicillin, streptomycin and MTT were obtained from Sigma. 
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6.2.2 Synthesis Methods 
 
Scheme 6.2 Synthesis procedure for the star polyrotaxanes 
The synthesis procedures of PEG-SS-NH2 and PEG-NH2 are the same with the 
methods we presented before. (4.2.2.1) 
6.2.2.1 Synthesis of PEG-SS-NH2 and PEG-NH2 
8 arm PEG was converted to the corresponding ATRP macroinitiator by the 
end capping reaction with 2-bromopropionyl bromide in THF [
6.2.2.2 Synthesis of initiator (PEG-SS-Br and PEG-Br) 
22, 23]. In brief, 8-
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arm-PEG-SS-NH2/PEG-NH2 (1g, 0.1056 mmol) was dissolved in 20 mL anhydrous 
THF. Then TEA (118μL, 0.8114 mmol), DMAP (103mg, 0.8114 mmol) and 5 mL dry 
THF containing 2-bromopropionyl bromide (0.18g, 0.8114 mmol) were added 
dropwise during 1h under nitrogen. The reaction was continued for 2h at 0 °C and for 
another 24h at room temperature. After the reaction stopped, the mixture was filtered 
to remove the resultant triethylamine hydrobromide. The solution was precipitated in 
n-hexane and the crude product was dissolved in water and extracted using 
chloroform, following by precipitated in hexane again, centrifuged and dried under 
vacuum to give the purified product (Yield, 0.8g (80%)). 
A typical protocol for amphiphilic PR-based copolymer synthesis via the 
ATRP of PDMAEMA was as follows [
6.2.2.3 Synthesis of polyrotaxane copolymer via ATRP (PR-SS-PDMAEMA and PR-
PDMAEMA) 
22, 24]. In a sealable reactor, 8 arm PEG-SS-
Br (0.25g, 0.0264 mmol) was added to 6.9 mL of α-CD (1g, 1mmol) saturated 
aqueous solution (0.145 g/mL), followed by vigorously stirring at room temperature 
for 24h to form PPR. Then DMAEMA (0.67g, 4.224 mmol) and HMTETA (37 mg, 
0.158 mmol) were added to the resulting PPR suspension. After purged with dry 
nitrogen for 50 min to degas the reaction solution, CuBr (15 mg, 0.1056 mmol) was 
added, followed by three times of degassing using a nitrogen purge. The [PPR-SS-Br]: 
[DMAEMA]:[HMTETA]:[CuBr] relative molar ratios were 1:40:1.5:1 and 1:50:1.5:1, 
respectively. The reactor was sealed and the polymerization was carried out at 25 °C 
for 6h. The experiment was stopped by opening the flask and exposing the catalyst to 
air, and the crude product was directly freeze-dried. Then they were dissolved in 15 
mL DMSO and dialyzed against water for 5 days (MWCO=6000) and freeze-dried. 
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The crude product was again dissolved in water and further purified by column 
chromatography on a Sephadex G-75 column with water as eluent. Finally, the 
purified product was lyophilized and characterized by 1H NMR. Yeild, 0.48g (45%). 
The Synthesis of Polyrotaxane without disulfide-linkage (PR-PDMAEMA) was based 
on 8-arm PEG-Br with the similar procedure as above. 
6.2.3 Measurements and Characterization 
The details were described in section 3.2.3.1 of Chapter 3. 
6.2.3.1 Proton Nuclear Magnetic Resonance (1H-NMR)  
The details were described in section 5.2.3.2 of Chapter 5. 
6.2.3.2 Elemental analysis 
The details were described in section 5.2.3.3 of Chapter 5. 
6.2.3.3 Plasmid amplification 
The details were described in section 5.2.3.4 of Chapter 5. Four cells were 
used: COS7, MB231, Hela and MCF-7 cells. 
6.2.3.4 Cells and media 
The methods of electrophoretic mobility of polymer/DNA complex were 
described in section 5.2.3.5 of Chapter 5. 
6.2.3.5 Gel retardation experiment 
6.2.3.6 Particle size and zeta-potential measurements 
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The details of particle size and zeta potential measurements are described in 
section 5.2.3.6 of Chapter 5. 
The methods of salt stability and protein stability (BSA) studies of polyplexes 
were described in section 5.2.3.7 of Chapter 5.  
6.2.3.7 Stability of polymer/DNA complexes 
Polymer/DNA complexes containing 3 µg of pDNA were prepared at N/P 
ratios of 50. After 30 min, polymer/DNA polyplexes were treated with same volume 
of 20 mM DTT solution or water. The mixture was incubated at 37 °C and determined 
at time interval, defined as ti. The average diameter and zeta potential of particles in 
water before DTT treatment, to, was also measured by dynamic light scattering. The 
change ratio of particle size and zeta potential was calculated as ti/to. 
6.2.3.8 Biodegradation behavior of polymer/DNA complexes 
The procedures of DNA release studies were described in section 5.2.3.9 of 
Chapter 5.  
6.2.3.9 DNA release ability 
The methods of measuring cell cytotoxicity of cationic polymers on MB231, 
Hela, COS7 and MCF7 cells were described in section 5.2.3.10 of chapter 5.  
6.2.3.10 Cell viability assay 
The cytotoxicity of the polymer/DNA complexes at various N/P ratios were 
also measured against different cell lines with the DNA amount of 0.25 μg per well in 
96-well plate. Polymer/DNA complexes were freshly prepared as previously 
 
Chapter 6: Bioreductive and shell detachable based on star PDMAEMA as gene vector 
188 
described. The MTT assay was performed according to the protocol as described in 
the previous section. 
4 cell lines (MB231, Hela, COS7 and MCF7) were seeded onto 24-well plate 
at a density of 5×104 per well in 500 μL DMEM medium with 10% FBS 24h prior to 
transfection. Then the culture medium was replaced with 300 μL fresh complete 
medium with 10% FBS. Polyplexes with different N/P ratios containing 1 μg pDNA 
were added to each well and were further incubated with cells for 4h. Then 200 μL 
medium containing 10% FBS was added and cells are incubated for further 20 hours. 
The measuring method of luciferase expression levels are as the same with the 
protocols described in section 5.2.3.11 of chapter 5.  
6.2.3.11 In vitro transfection and luciferase assay 
The methods of observing in vitro GFP expression of polyplexes on COS7 
cells were described in section 5.2.3.12 of chapter 5. ImageJ (NIH) was used for 
comparative analysis and quantifying the transfection efficiency. The cells with GFP 
Expression above threshold levels were automatically counted from the threshold 
green channel image series using the Analyze Particles function in ImageJ. The GFP 
expression was obtained by dividing the pixel area within the threshold set for the 
chromogen by the total pixel area of the region.   
6.2.3.12 In vitro GFP expression 
The methods of investigation of cell viability and transfection efficiency 
changed after treating with BSO were described in section 5.2.3.13 of chapter 5.  
6.2.3.13 GSH inhibition 
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6.3 RESULTS AND DISCUSSION 
6.3.1 Synthesis of cationic polyrotaxane via ATRP (PRSSP and PRP) 
Scheme 6.1 (b) shows the synthesis procedures of partial cationic 
polyrotaxane based on ATRP of PDMAEMA, which includes 4 steps. (1) Firstly, 8-
arm PEG-SS-NH2/PEG-NH2 was synthesized by the CDI reaction. Specifically, the 
hydroxyl groups at the end of 8-arm PEG were activated with CDI, followed by 
reaction with large excess of cystamine/ethylenediamine to give terminal amino 
groups. (2) Next, 2-bromopropionyl bromide was grafted on the end of PEG arm to 
form corresponding ATRP macroinitiator (PEG-SS-Br). By controlling the feeding 
ratio of 2-bromopropionyl bromide/PEG, partially terminated initiator could be 
achieved (eg. 4 arm grafted). (3) The PPR initiator (PPR-SS-Br) for ATRP was 
obtained by threading α-CDs onto PEG-SS-Br chain, and it was used to polymerize 
DMA. (4) Finally, star polyrotaxane PRSSP was prepared via ATPR of DMAEMA 
using PPR-SS-Br as macroinitiator and the flanking chains of pDMAEMA were 
introduced as the stoppers to prevent CD dethreading. During the end capping process, 
water was used as ATRP solvent to avoid the α-CD rings dethreading [22, 23]. 
Furthermore, according to references regarding polyrotaxane ATRP, the reaction was 
controlled to proceed at room temperature due to the fact that higher temperature 
would cause severe dethreading of α-CDs from the polymeric axle [24, 25].  
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6.3.2 Characterization of cationic polyrotaxanes 
 
Fig. 6.1 1H-NMR spectrum of (a) 8-arm PEG (Mw=9468, n=25), (b) PEG1-(SS-NH2)8, (c) 
PEG1-SS8-Br4, (d) α-CD, (e) PR1-CD12-SS4-PDMA123 and (f) PR1-CD11-SS4-PDMA177 in 
d6-DMSO. (In PRxCDySSzPDMAn, in where x are number of PEG, y are the number of 
threaded CD, z are number of SS linkage, and n are number of DMA repeat units, calculated 
by 1H NMR)  
Fig 6.1(a)-(b) show the 1H NMR result of 8-arm PEG-SS-NH2 in comparison 
with pure 8-arm PEG. In the spectrum, the peaks for the original PEG and cystamine 
are shown. The peak of δ=2.7~2.8 was attributed to the SS-linkage. Due to the end 
grafting of cystamine, the chemical shift of H3 in PEG was change from 3.5 ppm (in 
pure PEG) to 4.05 ppm (in the product, Fig. 6.1b). The results confirm the successful 
conjugation of 8-arm PEG with cystamine. Quantitative comparisons between the 
integral intensities of peaks H3 and peak H2 were used to derive the grafted ratio of 
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the polymer. It was found that the grafted degree for PEG-SS-NH2 is 96%, suggesting 
that all 8 arms of PEG are grafted with cystamine.  
Fig. 6.1(c) shows the 1H NMR of macroinitiator PEG-SS-Br. The signal at 
1.78 ppm was attributed to the methyl group of bromopropionyl-terminated PEG. By 
comparing the integration of the signals for the methyl protons Ha (-CH(CH3)Br, 1.78 
ppm) of the initiation group to those for the H1 of 8 arm PEG in the region of 3.5 ppm, 
the degree of substitution was estimated. The value was calculated to be 4 for the 
purified macroinitiator PEG-SS-Br. 
Fig 6.1 (a), (d), (e) and (f) show the 1H NMR of polyrotaxane in comparison 
with pristine α-CD and 8-arm PEG-SS-NH2. In Fig. 6.1(e) and (f), the signals for α-
CD, the threading 8-arm PEG (δ=3.5) and the end capping polymer PDMAEMA ((-
N(CH3)2, δ=2.21 ppm) were all observed. Furthermore, it was found that the peaks of 
α-CDs in Fig. 6.1(d) were clearly sharp, but those of polyrotaxanes were broadened 
(Fig. 6.1e and f). These results suggest that the mobility of α-CDs in polyrotaxane is 
restricted by the PEG chain after forming the supramolecular structure. These results 
provide us clear evidence for the physically interlocked supramolecular structure of 8 
arm PEG covered by α-CDs ended with PDMAEMA [26, 27]. In Fig. 6.1(f), a higher 
intensities on Ha (δ=2.21 ppm) of PDMAEMA was observed in contrast to Fig. 6.1(e), 
indicating a higher polymerization degree is obtained with increasing the feedings of 
DMA. The CD threaded number could be derived by quantitative comparison 
between the value for the area of the resonance peak due to H1 of α-CD (δ=4.79) and 
the peak due to the PEG (δ=3.50). Moreover, by comparing the integration of the 
signals for the pDMAEMA (-N(CH3)2, around 2.21 ppm) to those for the peak of PEG, 
the degree of polymerization was calculated. By calculation, it was found that about 
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12 CD rings, on average, were threaded on each 8-arm PEG and about 123 (Fig. 6.1e) 
or 177 (Fig. 6.1f) DMA repeat units were formed on the end of PEG (4 arm initiated) 
(Table 6.1). The structure of polyrotaxane without disulfide linkage was also 
confirmed in Fig. 6.2. The resulted cationic polymers exhibited similar peaks with the 
degradable analogue in Fig. 6.1 expecting the peak around 2.7~2.8, which is attributed 
to the disulfide bond. Therefore, it could be concludes that the synthesized polymer in 
Fig. 6.2 is the analogue of PRSSP (Fig. 6.1) lacking disulfide linkage. 
 
Fig. 6.2 1H-NMR spectrum of (a) 8-arm PEG, (b) PEG1-(NH2)8, (c) PEG1-Br4, (d) α-CD, 
(e) PR1-CD12-PDMA123 and (f) PR1-CD11-PDMA177 in d6-DMSO.  
Table 6.1 shows the compositions of PR-based cationic polymer synthesized 
via ATRP of PDMAEMA. According to references about PEG based polyrotaxane 
[28], α-CD will form an inclusion complex with ratio EO/CD of 2. However, in our 
case, though the feed molar ratio of CD/PEG is 40, only 12 CDs were obtained. It is 
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probably because only 4 arm of PEG was initiated, and the steric hindrance of 8-arm 
PEG limited the CD threaded number. In addition, with the increasing of molar ratio 
of DMA in feed, more DMA repeats units are found in the product.  

















per arm  
PRSSP123  1:40:160  1:12:123  4 arms  31  
PRSSP177  1:40:200  1:11:176  4 arms  44  
PRP123  1:40:130  1:12:123  4 arms  31  
PRP177  1:40:180  1:11:177  4 arms  45  
aMolar ratio in feed= [8 arm PEG-Br4]:[α-CD]:[DMAEMA] 
bData was all calculated on the basis of 1H NMR in DMSO-D6 
The elemental analysis of the synthesized cationic polyrotaxane was presented 
in Table 6.2. By calculation, the compositions of the cationic polyrotaxane, which 
determined based on 1H NMR results (Table 6.1), are also in good agreement with the 
elemental analysis results. Therefore, from the results of 1H NMR and elemental 
analysis, it could be conclude that the cationic 8-arm polyrotaxane threaded with OEI 
grafted α-CD and end blocked with disulfide-linkage were successful synthesized. 
















































 5.17  59.85  7.71  __  5.20  59.9  7.73  __  
a The compounds are denoted PEGxCDy(SSz)BrmPDn, in where x are number of PEG, y are 
the number of threaded CD, z are number of SS linkage, m are the number of Br and n are 
number of DMA repeat units, calculated by 1H NMR (Table 6.1).  
b Theoretical elemental analysis calculated for the corresponding compound.  
c Elemental analysis found. 
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6.3.3 Gel retardation experiment 
 
Fig. 6.3 Electrophoretic mobility of plasmid DNA in the polyplexes formed by (a) 
PRP123, (b) PRSSP123, (c) PRP177, (d) PRSSP177 and (e)25KPEI at different N/P ratio 
In this chapter, gel retardation assay was performed to investigate the DNA 
binding ability of the PDMAEMA based cationic polyrotaxanes. Before gel 
electrophoresis, positively charged polyrotaxane was mixed with negatively charged 
pDNA to form complexes at various N/P ratios via electrostatic interaction. As shown 
in Fig. 6.3, all cationic polyrotaxane exhibited good DNA binding at N/P ratio of 2, 
where total DNA retardation was detected. Particularly, PEI25k (Fig. 6.3e) could 
inhibit the migration of the pDNA at N/P ratio of 3 and above, while the four test 
polyrotaxane can retard DNA efficiently at N/P ratio of 2. The results exhibit better 
DNA condensation capability of the PDMAEMA based polyrotaxane than PEI25k. 
Furthermore, no obvious difference in DNA retardation was observed between the 
polyrotaxane PRP (Fig. 6.3a and 6.3c) and PRSSP (Fig. 6.3b and 6.3b), indicating the 
introduction of disulfide bond will not affect the DNA binding ability of the 
polyrotaxane.  
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6.3.4 Particle size and Zeta potential 
 
Fig. 6.4 Particle size (a) and zeta potential (b) of polyplexes formed by PRP, PRSSP and 
pDNA at various N/P ratios, in comparison with PEI (25K) 
It is generally believed that the particle size and surface charge of polyplexes 
are crucial to endocytosis and gene transfer [8]. Formation of nanoparticles could 
facilitate polyplex diffusion, extravasation through vascular fenestration, and cellular 
uptake. Fig. 6.4 shows the particle size and zeta potential measurements of 
PRSSP/DNA and PRP/DNA complexes in comparison with PEI (25 kDa) at various 
N/P ratios. Generally, in Fig. 6.4(a), all polyrotaxanes could efficiently condense 
pDNA into small nanoparticles and the particle size of polyplex decreased with an 
increase of N/P ratio. Their diameters changed dramatically from 400~700 nm to 200 
nm as N/P ratio increase from 1 to 10, which is similar with the PEI25k/DNA 
complexes. With further increasing the N/P ratios, their particle size changed slightly 
and remained in the 100–200 nm range. Furthermore, PRSSP and PRP yielded 
significant larger particles at all N/P ratios as compared to 25kPEI, probably due to a 
looser PEG shell formed by naked PEG arms in the polyrotaxane. 
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As shown in Fig.6.4 (b), the surface net charge of the complexes of pDNA 
with cationic polyrotaxanes increased sharply from negative to positive as the N/P 
ratio increased from 1 to 3, and reached a plateau at an N/P ratio of 10 and above. The 
phenomenon is in accordance with the results obtained from gel retardation assay, and 
particle size as discussed earlier. When N/P ratio is higher than 10, the zeta potential 
of the complexes stabilized at 20mV, which could result in a similar affinity to the 
cell surface. It must be pointed out here that all the four polyrotaxanes with PEG shell 
showed significant lower surface charge of complexes than that of PEI. It may be 
because that the PEG shell led to lower surface charge and exhibited shielding effect 
of polyplex, indicating that the naked PEG arms in the polyrotaxane should be 
preferentially located at the outer layer of complex as the larger particle size and 
lower zeta potential of PRP/DNA or PRSSP/DNA compared with that of PEI. These 
results are also supported by the findings of others [29, 30]. Therefore, the core-shell 
nanostructures self-assembled from our cationic polyrotaxanes could be confirmed. 
6.3.5 Biodegradation behavior of polymer/DNA complexes 
In last two decades, disulfide bond has been highly investigated as a crucial 
linkage for gene delivery vectors due to the rapid disulfide bond cleavage upon the 
interaction with reducing molecules such as, glutathione (GSH), cystein and so forth 
in living cells [31]. This rapid cleavage of disulfide linkage will ensure DNA release 
from complexes efficiently leading to facilitating nuclear import, gene transcription 
and gene expression [32], and also lowering the cytotoxicity of the system. 
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Fig. 6.5 Particle size and zeta potential at various determined time in 10 mM of DTT 
solution at 37 ⁰C. (a) Change ratio of particle size; (b) particle size of polymer/DNA 
complexes ; (c) change ratio of zeta potential and (d) zeta potential of polyplex. (N/P=50) 
In order to confirm the degradation and shell detachment property of our 
disulfide-containing systems, the bioreductive cleavage of the disulfide bond in the 
nanostructures was mimicked by treating with reducing agent DTT (10mM), which is 
analogous to the intracellular environment such as cytosol. And the particle size and 
zeta potential change of the polyplex with different N/P ratios in response to DTT was 
determined by DLS (Fig. 6.5). The responsive reductive polyplexes PRSSP123 and 
PRSSP177 were stable in physiological solution during 24 h incubation in PBS (part 
6.3.11). However, as shown in Fig. 6.5, when these complexes were treated with 
reductive agent, 10 mM DTT for 8h, the size of polyplex formed by PRSSP123 and 
PRSSP177 markedly decreased from 205.6 nm to 81.44 nm (change ratio=0.39) and 
209.2 nm to 107.8 nm (change ratio=0.51), respectively (Fig. 6.5a-b). Zeta potentials 
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also significantly increased from 14.7 mV to 26.1 mV (change ratio=1.78) and 15.1 
mV to 29.7 mV (change ratio=1.96), respectively (Fig. 6.5c-d). In contrast, non-
reductive polyplex PRP123 and PRP177 were sufficiently stable in the presence of 
DTT and no change in particle size or zeta potential was observed. The decreased 
particle sizes of disulfide linkage contained complexes were probably due to cleavage 
of disulfide bond and detachment of PEG shell segment. And it also led to the 
increased zeta potentials because the shielding effect of the PEG layer disappeared 
due to the cleavage of disulfide linkage. This phenomenon is in good agreement with 
other disulfide bond based bioreductive gene systems [12, 30]. Therefore, the above 
result confirms the degradation and shell detachment behavior of our core-shell 
nanostructure based on polyrotaxanes by the cleavage of disulfide linkages upon a 
reductive intracellular environment. 
6.3.6 DNA release ability 
 
Fig. 6.6 Agarose gel electrophoretic images of the polyplexes (N/P=50) of PRSSP123 (a,b) 
and PRP123 (c,d) with (b,d) or without (a,c) 10 mM DTT. (Line 1 shows the bands of 
control pDNA. Concentrations of heparin at lines 2, 3, 4, 5, 6, 7, and 8 were 0, 200, 300, 400, 
500, 600 and 800 μg/mL, respectively.) 
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To further examine the DNA release ability in the reductive condition, 
condensed polyplexes were subjected to gel retardation and a heparin competitive 
displacement assay was performed in the absence or presence of 10 mM DTT. Fig. 
6.6(a) and 6.6(b) show the gel electrophoretic images of PRSSP123 before or after 
incubating with DTT for 5h. In the absence of DTT, the critical concentration of 
heparin, at the point of pDNA release, for PRSSP123 is 800 μg/mL (Fig. 6.6a), 
confirming that DNA were compacted tightly by the tested cationic polymer. 
Remarkably, after incubating with DTT for 5h, free DNA bands were observed at 
much lower concentration of heparin (400 μg/mL) (Fig. 6.6b). The results suggest that 
in PRSSP123 systems, effective pDNA release was observed in the reductive 
condition, indicating the DNA binding ability of polyrotaxane decreased and large 
part of DNA was released after incubating with DTT. In contrast, no obvious pDNA 
release was observed on the reduction insensitive control under the same condition 
(Fig. 6.6c-6.6d). These results confirmed that the pDNA release from PRSSP123 
polyplexes was induced by the SS cleavage, followed by a dissociation and shell 
detachment of the polyrotaxanes nanoaggregates [33]. These findings were thus in 
accordance with the particle sizes results we discussed earlier. Furthermore, 
polyplexes formed by PRSSP177 also exhibited the same results. In summary, it is 
predicted that PRSSP/DNA system was stable extracellularly and could rapid release 
DNA from the system intracellularly by rapid disulfide bond cleavage.  
6.3.7 Cytotoxicity of the cationic polyrotaxanes 
It was reported that linear PDMAEMA only with high molecular weight 
exhibited high transgene expression but it could also lead to significant cytotoxicity. 
In contrast, low molecular weight PDMAEMA was less toxic but exhibit poor 
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transfection efficiency [3, 6, 34]. Based on the findings, we modified our PDMAEMA 
based polyrotaxane with the purpose of lowering cytotoxicity using the following 
strategies: (1) Conjugation of low molecular weight PDMAEMA chain to the end of 
star PEG, which was threaded on CDs, to form a large molecular weight star polymer; 
(2) Introduction of disulfide linkage to polyrotaxane chain to ensure the PDMAEMA 
was intracellularly degraded into small segments, resulting in DNA release and lower 
toxicity; (3) Introduction of PEG hydrophilic shell which could decrease cytotoxicity 
due to its shielding effect on the surface charge of particles [8-10]. 
 
Fig. 6.7 Cell viability assay in (a) MB231 and (b) Hela cells with various concentrations 
of tested polymers in serum -containing medium for 24h, compared with bPEI (25k). 
Mean value ± SD (n=5). **p<0.01 
The in vitro cell cytotoxicity of the bioreductive polyrotaxane was evaluated 
by MTT assays in MB231 and Hela cell lines, using commercial available PEI25k and 
non-reducible polyrotaxane as control (Fig. 6.7). As shown in Fig. 6.7, all investigated 
polymers exhibited a dose-dependent toxicity effect on both cell lines. It is worth 
noting that the polyrotaxane with disulfide linkage PRSSP exhibited markedly less 
toxicity in both cultured MB231 and Hela cells than non-degradable control PRSSP 
and PEI. Generally, cell viability of reductive polymer PRSSP (PRSSP123 and 
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PRSSP177) are above 70% when the concentration increased to 200 μg/mL, while 
viability of PRP, which is the analogue of PRSSP lacking a reductively cleavable 
disulfide bond, markedly decreased to lower than 20% at the same polymer 
concentration. The dramatically decreased cytotoxicity is believed to be a direct 
consequence of the intracellular cleavage of disulfide bond of PRSSP systems leading 
to polyrotaxane degradation with smaller PDMAEMA fragments (MW<7k Da), 
which results in reduced binding affinity of polymers with cellular membranes and 
reduced interference with cellular signal transduction pathway. It is evident that 
introduction of disulfide linkage is benefit for enhancing polymer biocompatibility.  
Moreover, in MB231, it was found that the cytotoxicity of PRSSP177 is 
higher than that of PRSSP123 in high concentration. Since the molecular weight is 
always considered as an important factor for PDMAEMA leading to high cytotoxicity, 
the higher cytotoxicity of PRSSP177 could be attributed to the higher density of 
amino groups in polyrotaxane with higher molecular weight PDMAEMA in contrast 
to PRSSP123. Such findings are in accordance with the previous reports, 
demonstrating that the incorporation of bioreductive disulfide bond could lower 
cytotoxicity of PDMAEMA [11, 12, 19]. 
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Fig. 6.8 Cell viability assay in (a) MB231 and (b) Hela cells with various N/P ratios of 
tested polymer/DNA complexes. Cell viability was expressed as a percentage of the control 
cell culture. Mean value ± SD (n=5), **p<0.01 
In order to determine the non-lethal N/P ratios of the various polyplexes and 
further investigate the effect of disulfide bond on the cytotoxicity of polyplexes after 
interacting with DNA, cytotoxicity of polymer/DNA complexes were evaluated by 
MTT assay. Fig. 6.8 showed the cytotoxicity of polyplex formed by PRP and PRSSP 
at various N/P ratios, by comparing with PEI25k. It was found that at N/P ratio of 10, 
cell viabilities of all tested polyplexes were above 80% with no appreciable 
cytotoxicity and the effect of disulfide bond is the least. However, with the increase of 
N/P ratios, N/P-dependent toxicity effect was observed and the influence of disulfide-
linkage largely increased. Notably, as the N/P ratio increased from 10 to 80, the cell 
viability of polyplex formed by PEI25k and non-biodegradable control PRP sharply 
decreased from 80% to less than 20%. In contrast, cell viability stays near 85% up to 
N/P ratio of 80 for PRSSP123/DNA and PRSS177/DNA complex (expect PRSSP177 
in MB231, which is near 70%). Considering that the only different component in the 
formation between PRSSP/DNA and PRP/DNA polyplexes is the disulfide bond, it is 
evident that the remarkable decreased cytotoxicity of PRSSP systems is mainly due to 
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the reductive of disulfide linkage, leading to polyrotaxane degradation with smaller 
and less-toxic PDMAEMA segments. Furthermore, due to the higher amino density of 
PRSSP177, it showed a higher cytotoxicity in contrast to PRSSP123 (Fig. 6.8a). The 
above results are in line with the cell viability curve of the pure polymer (Fig. 6.7). 
From the above cytotoxicity result, we could safely come to the conclusion that our 
modification strategies including conjugation of low MW PDMAEMA chain to PEG 
arms and introduction of disulfide linkage into the polyrotaxane systems are succeed 
in improving cell viability of PDMAEMA, and resulting a dramatically decreased in 
cytotoxicity over important commercially available reagents PEI25k. 
6.3.8 In vitro transfection and luciferase assay 
Fig. 6.9 Gene transfection efficiency of the polyplexes formed by PRSSP, PRP and 25K 
PEI in (a) MB231, (b) Hela, (c)COS7 and (d) MCF7 cells in the presence of serum. Data 
represent mean±SD (n=3, *p<0.05, **p<0.01). 
In vitro gene transfection efficiency of the biocleavable cationic polyrotaxane 
was assessed using luciferase as a marker gene in 4 cell lines (MB231, Hela, COS7 
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and MCF7) in the presence of serum. Fig. 6.9 shows the luciferase protein expression 
of the bioreductive polyrotaxane PRSSP123 and PRSSP177 compared with non-
reductive analogue PRP123, PRP177 and gold standard PEI25k at various N/P ratios. 
As presented in Fig. 6.9, it could be seen that the luciferase expression mediated by 
cationic polyrotaxanes was greatly dependent on the N/P ratios. Remarkably, all 
polyrotaxanes showed excellent in vitro gene transfection efficiency, comparable to or 
even higher than that of branched PEI (25 K) at their optimal N/P ratios. In particular, 
the transfection efficiency mediated by PRSSP123 (N/P=50) was 9 times higher than 
that of PEI (25K) (N/P=10) in COS7 cells (Fig. 6.9c).  
Most importantly, it is worth of note that the reductive polyrotaxane PRSSP 
exhibited dramatically higher luciferase expression than the non-biodegradable 
polyrotaxane control (PRP). Generally, in four cell lines, non-cleavable PRP123 and 
PRP177 led to the highest luciferase protein expression at N/P ratio of 10. However, 
their gene transfection levels sharply decreased with the increase of N/P ratios, 
probably due to the significant cytotoxicity of the polyplexes (Fig. 6.8). Surprisingly, 
the luciferase expression of bioreducible polyrotaxane PRSSP123 and PRSSP177 
could maintain their highest transfection levels from N/P ratio of 10 to 70. In 
comparison, at N/P ratio of 50, the transfection ability mediated by PRSSP123 was 
observed about 1000 times higher than that of the non-reductive analogue PRP123 in 
all cell lines. It is hypothesized that cytotoxicity was related to gene transfection 
ability and might be caused by electrostatic interactions with negatively charged 
glycocalyx of the cell surface [35]. Since the bioreducible cationic polyrotaxane 
showed a remarkable decrease in cytotoxicity over the non-degradable control (Fig. 
6.8), the higher luciferase expression of degradable polyrotaxane may have benefited 
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from their lower toxicity inside cells, which might enable to enhance the transfection 
efficiency. Likewise, due to the higher cytotoxicity of PRSSP177 in contrast to 
PRSSP123, a lower gene expression levels were observed in PRSSP177/DNA 
complex, especially at high N/P ratios 
From the above results, we could conclude that the transfection efficiency of 
PDMAEMA was largely enhanced by the introduction of disulfide linkage. Evidently, 
the therapy windows of degradable PRSSP systems are noticeably wider comparing to 
the non-degradable analogue PRP, which is highly desirable for in vivo gene therapy. 
6.3.9 In vitro Green fluorescence protein expression 
 
Fig. 6.10 The fluorescence microscopy images of transfected COS 7 cells mediated by 
pEGFP-N1 complexes form by (a) PRP123, (b) PRSSP123, (c) PRP177 and (d) 
PRSSP177 at their optimal N/P ratios, comparing with PEI 25K at N/P=10. (40× and 100 
×) (f) Quantitative comparison of the percentage of cells expressing GFP (40×). 
Student’s unpaired t-test (**p<0.001).. (left: fluorescence light; right: bright light). 
We employ another reporter gene pEGFP-N1 plasmid DNA encoding green 
fluorescence protein (GFP) to further visualize transgenetic efficacies of the PRSSP 
carriers with its non-reductive analogue PRP as control. As shown in Fig. 6.10, strong 
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fluorescence signal could be observed in delivering EGFP-pDNA when transfections 
were mediated by the polyrotaxanes, exhibiting high levels of vector internalization 
and gene expression. Both PRSSP123 and PRSSP177 showed higher fluorescence 
than PEI, indicating higher gene GFP expression (Fig. 6.10b and 6.10d). It is in line 
with the results of luciferase assay. Furthermore, by comparing PRSSP and PRP at 
their optimal N/P ratios, a much stronger GFP fluorescence emission was observed 
for the bio-reductive vector. As a result of Fig. 6.10 (f), GFP transfection assay 
showed higher gene transfection efficiencies for PRSSP123 and PRSSP177 systems, 
and this trend agrees well with that measured by luciferase assay (Fig. 6.9).  
6.3.10 GSH inhibition 
 
Fig. 6.11  Effects of BSO (300μM) on luciferase expression levels in (a)MB231, (b)Hela 
and (c)COS7 cells at N/P ratio of 10 and 70. Polyplex formed by PRP and PRSSP were 
transfected in the presence of serum with/without BSO (300μM). Data represent mean ±SD 
(n=3). **p<0.01 
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In previous research, we confirmed the degradation behavior and DNA release 
ability of bioreductive cationic polyrotaxane in response to DTT, due to the cleavage 
of disulfide linkage (Fig. 6.5-6.6). And the transfection results and MTT assay further 
showed that the cell viability and gene transfer ability of biodegradable PRSSP 
systems were noticeably stronger than that of the non-reductive analogue PRP control 
(Fig. 6.7-6.10). However, we still not sure whether the degradation of the complexes 
occurred intracellularly reducing by glutathione (GSH), and whether the degradation 
and intracellular reductive environment GSH are responsive for the low cytotoxicity 
and high transfection efficiency. Therefore, in order to further determine the role of 
disulfide linkage of our system in improvement of gene transfection, D,L-Buthionine 
sulfoxamine (BSO), a known GSH inhibitor resulting in depletion of intracellular 
GSH, was used [36, 37]. Fig. 6.11 shows the effects of BSO (300μM) on luciferase 
expression levels in MB231, Hela and COS7 cells. The results showed that at low N/P 
ratios (N/P=10), no significant difference was observed for all polyrotaxanes before or 
after BSO treatment, probably because no appreciable cytotoxicity of all the test 
polyplexes at this N/P ratios and the effect of disulfide bond is the least, which is 
confirmed by our previous research (Fig. 6.8). However, at N/P ratio of 70, when cells 
were pre-incubated with BSO prior to transfection, the transfection efficiency of 
disulfide-linkage containing PRSSP123 and PRSSP177 sharply decreased as 
compared to the same polyplex without the treatment of GSH inhibitor (p<0.01). In 
contrast, the luciferase expression level of non-degradable analogue PRSSP was not 
affected by BSO (p>0.05). Therefore, it is evident that the observed inhibitions of 
transfection were not caused by cytotoxicity of BSO and the disulfide linkages were 
cleaved by intracellular GSH. It suggests that the degradation did play a role in 
reductive polyrotaxane transfection, presumably through the efficient unpacking of 
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DNA. Furthermore, after treating with BSO, no significant differences were observed 
in the transfection efficiency of PRSSP and PRP (p>0.05). This is in consistent with 
the research reported by other groups [36, 38], which indicating the intracellular 
cleavage of the disulfide bond in the PRSSP systems by GSH is responsible for their 
higher transfection efficiency observed previous in compared with PRP systems. 
 
Fig. 6.12 Effects of BSO (300μM) on cytotoxicity of polymers in (a) MB231 and (b) Hela 
cells. Cell viability was compared with various concentrations of polymers with/without 
BSO in the presence of serum. Data represent mean ± SD (n=5). 
 
Fig. 6.13 Effects of BSO (300μM) on cytotoxicity of polymer/DNA complex in (a) MB231 
and (b) Hela cells. Cell viability was compared with various N/P ratios with/without 
BSO in the presence of serum. Data represent mean ± SD (n=5).  
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Since we originally hypothesized that the reductive polyrotaxane would 
facilitate DNA release triggered by the intracellular degradation in response to GSH, 
we expected that the cytotoxicity of the biodegradable polyrotaxane would also be 
affected by the level of intracellular GSH level, which causes the degradation. To test 
this point, cell viabilities were compared between the cells treated with and without 
BSO. Treatment with BSO, an inhibitor of g-glutamylcysteine synthetase, would 
result in depletion of intracellular GSH. As shown in Fig. 6.12 and Fig. 6.13, in both 
cell lines, the cytotoxicity of PRSSP system significantly increased to the level of its 
non-degradable analogue PRP upon treatment with BSO (p<0.001). It should also be 
noted that the decreased of cell viability should not be associated with toxicity of BSO, 
because the cytotoxicity of non-reductive PRP123 was not affected by BSO treatment 
(p>0.05). The results showed that the GSH inhibitor led to the inability of polyplex to 
completely degradation, resulting limited DNA release and higher cytotoxicity. 
Evidently, lower the cytotoxicity of complexes is the one of the major contributions of 
disulfide bonds to gene transfection. The results are in accordance with our previous 
hypothesis.  
6.3.11 Stability of polymer/DNA complexes 
Serum stability is one of the most important barriers for gene delivery. 
PEGylation is a well studied method to stabilize the polyplexes by providing a steric 
hydrophilic shell around particles. Polyplexes with PEG shell could prevent the 
aggregation of particles, resist protein adsorption and cell adhesion, lower cytotoxicity 
and improve anti-serum ability [20, 21]. In our system, due to the unique self-
assembly behavior of star polyrotaxanes based on star PEG and partial threaded CDs, 
the naked PEG arms could form a sheddable hydrophilic shell by self-assembly, 
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which could stabilize the polyplex. This is another major advantage of our systems in 
contrast to other PDMAEMA based gene vectors [11, 39]. The 8 arm PEG not only 
can offer rotating backbone and moving axle for α-CD; more importantly they could 
also provide a hydrophilic shell with naked PEG brush layer. Furthermore, unlike 
traditional PEGylation via covalent or non-covalent attachment, the PEG shell was 
formed naturally and no more modification is needed, which could prevent the 
drawbacks due to the traditional PEG modification, such as lower transfection 
efficiency and reduced internalization of untargeted polyplexes [40], degradation of 
DNA by nucleases [41], and lower DNA binding ability [42].   
 
Fig. 6.14 Hydrodynamic size of polyplex formed by PEI25k, PDMAEMA-177, PRSSP 
and PRP systems at N/P ratio of 50 with different DNA content as a function of time in 
the presence of 150 mM PBS. (a) DNA content=5μg; (b) DNA content=10μg 
We studied the aggregation behaviors of the polyplex formed by polyrotaxane 
PRSSP and PRP with PEG shell under physiological salt condition (150 mM) (Fig. 
6.14). In order to verify the importance of PEG chain on the stability of polyplex, two 
control systems are used: PEI25k and PDMAEMA without PEG. PDMAEMA was 
synthesized via ATPR of DMAEMA with the same procedures as our test 
polyrotaxane and their structures are confirmed by 1H NMR, which showed that about 
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177 DMA repeat units were polymerized. As shown in Fig. 6.14, in the presence of 
PBS, the hydrodynamic diameters of our four test core-shell structures (PRSSP and 
PRP systems) remained sufficiently stable within 24hrs, but the complexes formed by 
pure PDMAEMA without PEG and PEI25k aggregated rapidly in PBS.  For example, 
the size of polyplexes formed by PRP177 with 10 μg DNA increased from 174 nm to 
222.2 nm in 24 hours with PBS incubation, and the size change ratio was 1.27 (Fig. 
6.14b). In contrast, without naked PEG shell, the trend of size changes of both PEI25k 
and PRDMAEMA-177 system were much steeper. The diameters of PEI25K/DNA 
and PDMAEMA/DNA complexes increased from 119.7 nm to 2063 nm and from 
132.9 nm to 2822 nm, respectively in 24 hours. Their size change ratio was 17.23 and 
21.23 respectively. These results demonstrates that the naked PEG in partial 
polyrotaxane PRSSP and PRP contributes to the formation of core-shell nanostructure 
with hydrophilic PEG brush layer in the exterior surface, which could stabilize the 
polyplex and prevent aggregation of particles under physiological salt conditions.  
 
Fig. 6.15 Evaluation of the change in particle size of polyplexes in PBS that contains 5% 
w/w of BSA at 37 °C, as determined by dynamic light scattering: (a) size change ratio (b) 
particle size. (All the N/P ratio of the polymer/DNA complex was fixed at 50.) 
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Ingredients in serum especially the proteins may affect the stability of the 
particles. In the case of in vivo gene delivery, the negatively charged plasma proteins 
in the blood may cause aggregation of the positively charged polymer/DNA 
complexes. Thus, many polyplexes are not likely to maintain their colloidal stability 
upon intravenous injection, like PEI25k, Lipofectamine 2000 et.al, and their 
applications in vivo are compromised [43]. Therefore, it is necessary to evaluate the 
stability of our polyrotaxane self-assembled nanostructures with PEG shell upon 
proteins. In this chapter, bovine serum albumin (BSA) was selected as the model 
protein to simulate the serum condition. We investigate the stability of the 
polymer/DNA complexes in BSA containing PBS. Fig. 6.15 showed the ratio of size 
change (a) and the size of polyplexes (b) in 5% BSA solution as a function of 
incubation time, with fixed N/P ratio of 50. Similar with the investigation of salt 
stability, the particle size of PRSSP/DNA and PRP/DNA complex was compared to 
PEI25k and PDMAEMA177 without PEG. As expected, it was found that all the four 
tested core-shell nanostructures (PRSSP and PRP) could prevent particle aggregation 
for 24h in the presence BSA. The sizes of PRSSP177/DNA complexes increased from 
245.6 nm to 279.4 nm in 24 hours, and the size change ratio was 1.14. All the other 
three polyrotaxane showed the similar phenomena and the size change ratio are all 
lower than 2. However, without the modification of PEG, the trend of size changes of 
both PEI/DNA and PDMAEMA/DNA system were much steeper. The ratios of size 
change at 24 h were 10.4 and 11.8, respectively. The diameter of 
PDMAEMA177/DNA complexes increased from 132.9 nm to 1565 nm in 24 hours 
and the size change ratio was 11.8. The results are in line with the previous salt 
stability studies. It is confirmed that the shielding effect of PEG could hinder the 
interaction with protein and aggregation of particles. Our polyrotaxane system based 
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on PDMAEMA in this chapter may be more stable and resistant to serum system than 
other polycationic gene systems, which is important for in vivo applications. 
6.4 CONCLUSIONS 
Aiming to increase the serum stability and improve the transfection efficiency 
of PDMAEMA systems with optimal DNA release and decreasing cytotoxicity, a 
novel reduction-sensitive and shell detachable gene delivery system was successfully 
developed based on star polyrotaxanes, which consists of partially threaded α-
cyclodextrin (α-CD), 8-arm PEG and low molecular weight PDMAEMA segments 
linked to the end of PEG arms with disulfide linkage. The resulted star 
supramolecular structure demonstrated good ability to condense DNA into 
nanoparticles. Particle size, zeta potential and gel retardation experiment confirmed 
their degradability and DNA release ability in response to DTT, a reductive 
environment analogous to that of the intracellular compartments such as cytosol and 
the cell nucleus. Remarkably, the results of MTT assay and luciferase expression 
confirmed that the biodegradable star polyrotaxane with disulfide linkage exhibited 
remarkable lower cytotoxicity and higher gene transfection efficiency in contrast to 
reduction insensitive control and polyethylenimine (PEI) 25k. They showed excellent 
in vitro transfection efficiency and noticeably wider therapy window than that of PEI 
25k and non-degradable control. Furthermore, in according to the glutathione (GSH) 
inhibition experiment, it was found that cell viability and transfection was markedly 
decreased, confirming that introduction of disulfide linkage to the system result in fast 
intracellular degradation and disassociation, efficient DNA release, decreased 
cytotoxicity and enhanced transfection.  
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More importantly, the hindrance effect of PEG shell allows the system to be 
stable and prevent aggregation in salt and protein solution. Taken together, our 
supramolecular self-assembled nanostructure boast many favorable properties as gene 
carriers, which include good DNA binding ability, reduction-sensitive 
biodegradability, intracellular DNA release, low cytotoxicity, high gene transfection 
efficiency and high stability in biological fluids. Moreover, due to the dual self-
assembly behavior of the polyrotaxane, the star polymer could also be very promising 
for the application of drug/gene codelivery.  
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CHAPTER 7 SELF-ASSEMBLED NANOSTRUCTURES 
BASED ON STAR POLYROTAXANE FOR CO-
DELIVERY OF DRUG AND GENE  
7.1 INTRODUCTION  
In cancer therapy, one of the major issues associated with current 
chemotherapy is multiple drug resistance (MDR), which is mainly due to the gene 
malfunction. [1] Combination therapy of gene and drug may provide a solution to this 
problem by correcting malfunctioned gene and sensitizing cancer cells to anticancer 
drugs.[2, 3]  Furthermore, codelivery of gene and drug with one delivery system may 
take the advantages of enhanced gene transfection efficiency by achieving the 
synergistic effects because the therapeutic agents are delivered into target cells 
simultaneously.[4-6] Over the past few years, many designs of novel co-delivery 
vectors have attracted much attention in delivery systems, including cationic 
micelles,[6-8], cationic liposomes, [9-11] and cationic supramolecular polymers [12]. 
For example, micelles capable of dual delivery of DNA and other therapeutics have 
also have been designed [6, 13, 14]. Specially, poly N-methyldietheneamine sebacate 
and (cholesteryl oxocarbonylamido ethyl) methyl bisethylene ammonium bromide 
sebacate (PMDS-co CES) form micelles with an inner hydrophobic core composed of 
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cholesterol surrounded by polycationic polymer. The co-delivery of the micelle 
containing paclitaxel and the plasmid DNA suppresses tumor growth in a 4T1 mouse 
breast cancer model more effectively than the delivery of micelles with either 
therapeutic alone [6]. In addition, biodegradable PDMAEMA-PCL-PDMAEMA 
triblock copolymer was also prepared for siRNA and paclitaxel codelivery. 
Significant enhanced gene silencing efficiency of the polycations micelles was 
observed as compared to 20K PDMAEMA or 25K PEI. Moreover, due to the 
improved cellular uptake, micelle loaded with paclitaxel displayed higher drug 
efficacy than free drug. These results suggested that cationic biodegradable micelles 
are highly promising for the combinatorial delivery of siRNA and lipophilic 
anticancer drugs [8]. 
DOX is one of the most potent anticancer drugs and used widely in the 
treatment of different types of solid malignant tumors [15, 16]. DOX is known to 
interact with DNA by intercalation and inhibition of macromolecular biosynthesis. It 
is crucial, therefore, to deliver and release DOX in the cytoplasm and/or right into the 
cell nucleus. However, the cardiotoxicity of this drug limits its direct administration 
and cumulative storage [17, 18]. In order to minimize the cardiotoxicity, reduction of 
DOX dose would be necessary in the future research. But low dose of anticancer 
drugs will be less effective to the treatment of cancers, especially to drug resistant 
cancers [19]. Therefore, it would be very useful to explore the combination therapy 
and achieve a high anticancer efficacy in low DOX dose.  
Our previous studies present a novel redox-responsive and shell detachable 
star shaped polyrotaxane nanostructure based on pDMAEMA, which could be very 
promising in reduction-sensitive intracellular gene delivery with the advantages of 
Chapter 7. Self-assembled nanostructures based on star PR for gene/drug codelivery 
220 
biodegradability, intracellular DNA release, low cytotoxicity, high gene transfection 
efficiency and high stability in biological fluids. In this work, we are interested in 
designing a series of these star shaped cationic polyrotaxanes based on pDMAEMA 
with different threading numbers of CDs (Scheme 7.1). Their self-assembly 
formations with PEG shell and polyrotaxane core would be confirmed. Furthermore, 
by taking the advantages of the core-shell structure, the cationic polyrotaxanes are 
expected to encapsulate DOX into the CD core and applied in drug delivery with high 
drug loading efficiency, higher cell uptake and improved drug efficacy. More 
importantly, in this star polyrotaxane, cationic PDMAEMA arms are expected to 
condense DNA efficiently into nanoparticles and this new cationic polyrotaxane 
nanostructure could be very promising in co-delivery therapeutics by combing the 
advantages of core-shell structures as drug vectors and reductive star polyrotaxanes as 
gene vectors.  
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Scheme 7.1 Illustration of (a) the preparation of bioreductive codelivery systems and (b) 
the intracellular drug and gene release 
7.2 MATERIALS AND METHODS 
7.2.1 Materials  
Star PEG (Mn=9468) were purchased from Fluka. α-CD was purchased from 
TCI. DMAEMA monomer, 2-bromopropionyl bromide, Cu(I)Br, HMTETA were 
supplied by Aldrich. Ethylenediamine, cystamine dihychloride, triethylamine (TEA), 
1,1’-Carbonyldiimidazole (CDI), dithiothreitol (DTT), doxorubincin (DOX) were 
received from Sigma-Aldrich and used as received. Diethyl ether, methanol, 
tetrahydrofuran (THF), n-hexane and dimethyl sulfoxide (DMSO) were purchased 
from Merck. Penicillin, streptomycin and MTT were obtained from Sigma. 
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7.2.2 Synthesis Methods  
The synthesis of partial cationic polyrotaxane based on PDMAEMA is as the 
same with the synthesis methods of star polyrotaxane PR-SS-PDMAEMA described 
in section 6.2.2.1~6.2.2.3 of chapter 6.  
7.2.3 Measurements and Characterization 
The details were described in section 3.2.3.1 of Chapter 3. 
7.2.3.1 Proton Nuclear Magnetic Resonance (1H-NMR)  
The details were described in section 5.2.3.2 of Chapter 5. 
7.2.3.2 Elemental analysis 
The resulted polyrotaxanes are soluble in water, and the core-shell 
nanostrucutres could be prepared by directly dissolving the polymer in water and 
allowing it to stay overnight to ensure complete dissolution [
7.2.3.3 Self-assembly and Critical aggregation concentration (CAC) determination 
20]. The resulted solution 
was then diluted to the desired concentration with proper amount of water. For TEM 
and particle size measurements, the solution was filtered through a 0.45 μm Whatman 
PVDF filter into a dust-free vial. 
The CAC values were determined by the dye solubilization method [21]. The 
hydrophobic dye 1,6-diphenyl-1,3,4-hexatriene (DPH) was dissolved in methanol 
with a stock concentration of 0.6mM. Star polyrotaxanes were dissolved in water with 
variable concentration in the range of 0.0001 to 10 mg/mL, while keeping the 
concentration of DPH constant. 1 mL of polyotaxane aqueous solution was mixed 
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with 10 μL DPH stock solution and equilibrated at room temperature overnight. A 
UV-vis spectra in the range of 330-430 nm were recorded at room temperature. And 
the CAC values were determined by the plot of the difference in absorbance at 378 
nm and at 400 nm (A378-A400) versus logarithmic concentration. 
The morphology of the formed core-shell nanostructures was conducted by 
TEM and DLS. The procedures described in section 3.2.3.4 and 3.2.3.5 of chapter 3.  
7.2.3.4 Transmission Electron Microscopy (TEM) and Dynamic light scattering (DLS)  
DOX was loaded into the star polyrotaxane followed by the method reported 
before [
7.2.3.5 DOX encapsulation and drug content determination 
22]. 20 mg soluble polyrotaxane was added to 1 mg Doxorubicin 
hydrochloride (DOX·HCl) and dissolved together with 1 mL DI water, and the 
solution was stirred overnight at room temperature. Solution of sodium hydroxide 
(NaOH) was added to the solution to adjust the pH to 8~9 and stirred for 3 h. Because 
DOX is insoluble in basic condition, the unloaded DOX molecular were precipitated 
and removed by ultracentrifugation. The obtained solution with loaded DOX was then 
lyophilized (Yield, 11 mg). 
The amount of DOX encapsulated in the nanoaggregates was analyzed by 
fluorescence measurement. For determination of drug loading content, 1 mL DMSO 
was added into 1mg DOX-loaded polyrotaxane, the core-shell structure were broken 
up and the DOX was dissolved in the solution. The characteristic emission absorbance 
of DOX at 588 nm was recorded and compared with a standard curve generated 
DOX/DMSO solutions with different DOX concentrations varying from 0 to 60 
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μg/mL. Drug loading content (DLC) and drug loading efficiency (DLE) were 
calculated according to the following formula: 
DLC (wt%) = (weight of loaded drug/weight of polymer) 100% 
DLE (wt%) = (weight of loaded drug /weight of drug in feed) 100% 
The methods of measuring the anticancer efficacy of the DOX loaded 
polyrotaxanes were described in section 3.2.3.9 of chapter 3.  
7.2.3.6 Cell viability assay 
The methods of measuring the cell uptake and distribution of the DOX loaded 
polyrotaxanes were described in section 3.2.3.10 of chapter 3.  
7.2.3.7 Intracellular cell uptake and distribution 
MB231 and Hela cells were seeded onto 24-well plate at a density of 5×104 
per well in 500 μL DMEM medium with 10% FBS 24h prior to transfection. After the 
confluence of the cells reaching to 70-80%, the culture medium was replaced with 
500 μL fresh complete medium with 10% FBS. Polyplexes with different N/P ratios 
containing 1 μg pDNA were added to each well and were further incubated with cells 
for 4h. Then the culture medium were changed to 500 μL medium containing 10% 
FBS and cells are incubated for further 20 hours. At the end of transfection, the cells 
were washed with PBS three times and the measuring method of luciferase expression 
levels are as the same with the protocols described in section 5.2.3.11 of chapter 5.  
7.2.3.8 In vitro transfection and luciferase assay 
7.2.3.9 Co-delivery of p53-encoding plasmid with DOX 
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Co-delivery of p53 (a therapeutic gene) and DOX was used to test the synergy 
in the anti-cancer abilities in MB231 cells. Cells were seeded onto 6-well plate at a 
density of 2×105 per well in 2 mL of culture medium with 10% FBS 24h prior to 
transfection. At the time of transfection, polyplexes containing 4 μg p53 were added 
to each well and were further incubated with cells for 4h. Then the culture media were 
changed to 2 mL medium containing 10% FBS. After 72 h of transfection, total RNA 
was isolated from the cells by using RNA Maxiprep Kit (Axygen). The RNA was 
reverse transcribed with OligodT (Promega) according to the manufacturer’s protocol. 
Real-time PCR was performed on 1μL of cDNA with the Brillian SYBR Green PCR 
Kit (Stratagene) according to the manufacturer’s recommended instruction. The 
sequences of p53 primers, β-actin primer and amplification conditions used for the 
RT-PCR experiment were the same as described elsewhere [7]. β-actin was used as an 
internal standard. Data were analyzed for relative mRNA expression using ΔΔCT 
method, and normalized against β-actin expression profile.  
7.3 RESULTS AND DISCUSSION 
7.3.1 Synthesis of cationic polyrotaxane via ATRP 
Scheme 7.1 shows the synthesis procedures of partial cationic polyrotaxane 
based on ATRP of PDMAEMA, which includes 4 steps. (1) Firstly, 8-arm PEG-SS-
NH2 was synthesized by the CDI reaction. Specifically, the hydroxyl groups at the 
end of 8-arm PEG were activated with CDI, followed by reaction with large excess of 
cystamine to give terminal amino groups. The reaction was completed in anhydrous 
DMF under nitrogen because the polarity of the reaction solvent has a strong 
influence on the conversion. To minimize intermolecular crosslinking, the molar ratio 
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of cystamine/ethylenediamine to PEG was more than 50 times in the conjugate 
reaction. (2) Next, 2-bromopropionyl bromide was grafted on the end of PEG arm to 
form corresponding ATRP macroinitriator (PEG-SS-Br). By controlling the feeding 
ratio of 2-bromopropionyl bromide/PEG, partially terminated initiator could be 
achieved (eg. 4 arm grafted). (3) The PPR initiator (PPR-SS-Br) for ATRP was 
obtained by threading different amounts of α-CDs onto PEG-SS-Br chain, and it was 
used to polymerize DMA. (4) Finally, star shaped polyrotaxane PRSSP was prepared 
via ATPR of DMAEMA using PPR-SS-Br as macroinitiator and the flanking chains 
of pDMAEMA were introduced as the stoppers to prevent CD dethreading. During 
the end capping process, water was used as ATRP solvent to avoid the α-CD rings 
dethreading [20, 23]. Furthermore, according to references regarding polyrtoaxane 
ATRP, the reaction was controlled to proceed at room temperature due to the fact that 
higher temperature would cause severe dethreading of α-CDs from the polymeric axle 
[24, 25]. In order to obtain polyrotaxanes with different CD threaded number, 
different molar ratios of CD/sPEG in feed was used varying from 20 to 160. 
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7.3.2 Characterization of cationic polyrotaxanes 
 
Fig. 7.1 1H-NMR spectrum of (a) α-CD, (b) PR1-CD6-SS4-PDMA123, (c) PR1-CD12-SS4-
PDMA123, (d) PR1-CD22-SS4-PDMA177  and (e) PR1-CD30-SS4-PDMA177 in d6-DMSO. (In 
PRxCDySSzPDMAn, in where x are number of PEG, y are the number of threaded CD, z are 
number of SS linkage, and n are number of DMA repeat units, calculated by 1H NMR)   
Fig.7.1 shows the 1H NMR of polyrotaxane in comparison with pristine α-CD. 
The peak of δ=2.7~2.8 was attributed to the SS-linkage. In Fig. 7.1(b)-7.1(e), the 
signals for α-CD, the threading 8-arm PEG (δ=3.5) and the end capping polymer 
PDMAEMA ((-N(CH3)2, δ=2.21 ppm) were all observed. Furthermore, it was found 
that the peaks of α-CDs in Fig. 7.1(a) were clearly sharp, but those of polyrotaxanes 
were broadened (Fig. 7.1b-7.1e). These results suggest that the mobility of α-CDs in 
polyrotaxane is restricted by the PEG chain after forming the supramolecular structure. 
These results provide us clear evidence for the physically interlocked supramolecular 
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structure of 8 arm PEG covered by α-CDs ended with PDMAEMA [26, 27]. The CD 
threaded number could be derived by quantitative comparison between the value for 
the area of the resonance peak due to H1 of α-CD (δ=4.79) and the peak due to the 
PEG (δ=3.50). Moreover, by comparing the integration of the signals for the 
pDMAEMA (-N(CH3)2, around 2.21 ppm) to those for the peak of PEG in the region 
of 3.50 ppm, the degree of polymerization was calculated. By calculation, the 
structure of the star polyrotaxanes is confirmed (Table 7.1). It was found that different 
numbers of CD rings, on average, were threaded on each molecule of 8-arm PEG and 
about 123 or 177 DMA repeat units were formed on the end of PEG (4-arm initiated).  


















PRCD6P123 1:20:160 1:6:123 4 arms 31 
PRCD12P123 1:40:160 1:12:123 4 arms 31 
PRCD12P177 1:40:200 1:12:177 4 arms 45 
PRCD22P177 1:80:200 1:22:177 4 arms 45 
PRCD30P177 1:160:200 1:30:177 4 arms 45 
aMolar ratio in feed= [8 arm PEG-Br4]:[α-CD]:[DMAEMA] 
bData was all calculated on the basis of 1H NMR in DMSO-D6 
The elemental analysis of the synthesized cationic polyrotaxane was presented 
in Table 7.2. By calculation, the compositions of the cationic polyrotaxane, which 
determined based on 1H NMR results (Table 7.1), are also in good agreement with the 
elemental analysis results. Therefore, from the results of 1H NMR and elemental 
analysis, it could be conclude that the cationic 8-arm polyrotaxane threaded with OEI 
grafted α-CD and end blocked with disulfide-linkage were successful synthesized. 
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N%  C%  H%  S%  N%  C%  H%  S%  
PRCD6P123  PEG1CD6SS4PD123 4.27  49.40  7.96  0.91  4.26 49.5 7.84 0.95 
PRCD12P123  PEG1CD12SS4PD123 4.25  49.07  8.35  1.26  4.27  49.00  8.39  1.38  
PRCD12P177  PEG1CD12SS4PD177 5.22  57.87  8.02  1.12  5.17 57.95  7.98  1.08  
PRCD22P177  PEG1CD22SS4PD177 3.46  47.23  7.01  0.79  3.75 46.18 6.96 0.82 
PRCD30P177  PEG1CD30SS4PD177 3.02  48.98  7.63  0.79  3.17 49.91 7.73 0.75  
a The compounds are denoted PEGxCDySSzPDn, in where x are number of PEG, y are the 
number of threaded CD, z are number of SS linkage and n are number of DMA repeat units, 
calculated by 1H NMR (Table 7.1).  
b Theoretical elemental analysis calculated for the corresponding compound.  
c Elemental analysis found. 
7.3.3 Self-assembly behavior and CAC determination 
 
Fig. 7.2 (a) and (c) UV-vis spectra changes of DPH with increasing PRCD22P177 and 
PRCD30P177 concentration in water at 25 °C. DPH concentration was fixed at 6 mM. (b) 
and (d) CAC determination by extrapolation of the difference in absorbance at 378 nm 
and 400 nm 
The star polyrotaxanes were soluble and the core-shell nanoaggregates were 
formed by directly dissolving in water. Their CAC were determined by DPH method 
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[28, 29]. This experiment was conducted by varying the aqueous polymer 
concentration in the range of 0.00001 mg/mL to 5 mg/mL, while keeping the 
concentration of DPH constant. DPH shows a higher absorption coefficient in a 
hydrophobic environment than in water. Thus, with increasing polymer concentration, 
the absorbance at 344, 358 and 378 nm increased (Fig. 7.2a). The point where the 
absorbance suddenly increases corresponds to the concentration at which 
nanoaggregates are formed. When the core-shell structure is formed, DPH partitions 
preferentially into the hydrophobic core formed in the aqueous solution [28, 29]. The 
CAC was determined by extrapolating the absorbance at 378 nm minus the 
absorbance at 400 nm (A378-A400) versus logarithmic concentration (Fig. 7.2b). It was 
found that the CAC values for PRCD22P177 are 0.1 mg/mL. Similarly, PRCD30P177 
showed a CAC of 0.3 mg/mL (Fig. 7.2c-d).  
7.3.4 TEM and Particle Size of the self-assembly 
 
Fig. 7.3 Particle size distribution (intensity distribution) and TEM images of the self-
assembly nanoaggregates of PRCD12P177 (a), PRCD22P177 (b) and PRCD30P177 (c). 
(conc.=1 mg/mL) 
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To convince the self-assembly and characterize the size and morphology of 
the polyrotaxane nanoaggregates, TEM and DLS experiments were conducted. These 
nano-scaled particles were imaged with staining of the polymer shell with sodium salt 
of phosphotungstic acid. As shown in Fig. 7.3, spherical particles were observed in 
the three kinds of polyrotaxanes, and the average size was confirmed by particle size 
with DLS measurement. It was found that all three polyrotaxane assembly exhibited 
very small size (<120 nm), and the small sizes of particles may enable them to 
prolong circulation in blood and slower elimination by the reticuloendothelium 
system (RES) [30]. Specifically, in Fig. 7.3 (a), DLS measurements showed that 
PRCD12P177 formed nanoaggregates with sizes of 65 nm and TEM micrograph 
revealed that these particles had a spherical morphology with an average size of ~60 
nm. The smaller size observed by TEM as compared to that determined by DLS is 
most likely due to shrinkage of the PEG shell. With increased number of CDs, the 
size distribution became monomodal due to the increase of hydrophobic segments. 
Furthermore, by comparison Fig. 7.3a, b and c, it could be found that with increase in 
the number of threaded α-CDs, the formed particles tend to be larger (from 65 nm to 
116 nm), showing that the presence of more CDs as hydrophobic segment in the CD 
core increases particle volume.  
Therefore, given the CAC, TEM and DLS analytical data as mentioned above, 
the self-assembly behavior of the synthesized star polyrotaxanes can be confirmed. 
Furthermore, by comparison with the DLS of 8 arm PEG-PDMAEMA without CDs 
(z average=5 nm), it can be concluded that the threading of α-CD into the PEG chain 
not only affects the chain conformation, but also attributes to the aggregation and self-
assembly of the novel polyrotaxane. 
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7.3.5 Drug loading and loading efficiency 
In this chapter, we use DOX as the model molecule and try to decrease the 
limitations and achieve high drug efficacy in low drug dose. The potential application 
of our star cationic polyrotaxane as anti-cancer drug carrier was evaluated. 
















PRCD6P123  7.56 μg  0.76 %  5%  16.6%  
PRCD12P123  16.6μg  1.66%  5%  39.9%  
PRCD12P177  19.1μg  1.91%  5%  42.1%  
PRCD22P177  26.9 μg  2.69%  5%  59.2%  
PRCD30P177  32.1μg  3.21%  5%  70.6%  
Pure DOX (control)  47.14 µg  -  -  4.7%  
a Drug loading content (wt%) = (weight of loaded drug/weight of polymer) 100% 
b Drug loading efficiency (wt%) = (weight of loaded drug / drug in feed) 100% 
Table 7.3 shows the drug loading contents and efficiency of the star 
polyrotaxanes. The theoretical drug loading content was set at 5 wt% and 
fluorescence was used to determine the DOX content in the polymer. The results 
showed that the drug loading efficiencies for the star polyrotaxanes with PDMAEMA 
were around 16%~70%. The loading content markedly increased with increasing of 
threading CDs. This can be explained that the more hydrophobic part in the polymer 
chain makes it possible to have more hydrophobic interaction points in the formed 
nanoaggregates, giving rise to a higher loading content [31, 32]. Pure DOX was used 
as control to further verify the drug loading ability of the polyrotaxanes. With the 
same procedure in the absence of polyrotaxanes, only 4.71 wt% free DOX were found 
in the final product. In contrast, in the presence of polyrotaxane, approximately 70 wt% 
DOX was observed. The result confirms the high drug load efficiency and capacity of 
the polyrotaxane nanostructures. In addition to the hydrophobic interaction, the high 
drug load efficiency may be attributed to the hydrogen-bond interaction between 
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hydroxyl group of CDs and amide group of DOX under neutral and basic conditions 
[22]. The results indicate that the threading of CDs into sPEG chains not only 
contributes to the self-assembly, but also to the drug loading ability of the 
polyrotaxane nanoaggregates. Therefore, a controllable drug loading efficiency could 
be achieved by controlling the threaded number of CDs in the polyrotaxanes. 
7.3.6 In vitro cytotoxicity 
 
Fig. 7.4 The cytotoxicity of DOX loaded (a) PRCD6P123, (b) PRCD12P123, (c) 
PRCD22P177 and (d) PRCD30P177 against MB231 after 24h incubation. Free DOX and 
polymer without DOX was set as control. Data represent mean ± standard deviation 
(n=3). 
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Fig. 7.5 The cytotoxicity of DOX loaded (a) PRCD6P123, (b) PRCD12P123, (c) 
PRCD22P177 and (d) PRCD30P177 against Hela after 24h incubation. Free DOX and 
polymer without DOX was set as control. Data represent mean ± standard deviation 
(n=3). 
Table 7.4 IC50 values (μg/mL) for DOX loaded PRP  
 MB231  Hela  
PRCD6P123/DOX  0.56  0.83  
PRCD12P123/DOX  0.52  0.87  
PRCD22P177/DOX  0.69  1.48  
PRCD30P177/DOX  0.49  1.06  
DOX  9.82  6.62  
The in vitro anticancer activity of the DOX loaded polyrotaxane was 
performed on MB231 and HeLa cancer cells using MTT assay (Fig. 7.4 and Fig. 7.5). 
As shown in Fig. 7.4 and Fig. 7.5, similar dose-response viability was observed in 
both cells for all DOX formulas, suggesting our polyrotaxane nano-aggregates could 
successfully delivery DOX into the cancer cell. It fitted with other researches based 
on the cytotoxicity of free DOX.[33, 34] Remarkably, all four tested DOX loaded star 
polyrotaxane showed much more cytotoxicity and higher potent in killing cancer cells 
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in comparison with free DOX in the low dose range from 0.1 to 2 μg/mL, and their 
IC50 was much lower than free DOX in two cancer cells (Table 7.4). The high 
cytotoxicity could be attributed to higher cell uptake when delivered by the core-shell 
aggregates (detail showed in Fig. 7.6-7.7). Additionally, there was no obvious cellular 
toxicity caused by the blank polyrotaxanes (without DOX) (Fig. 7.4-7,5) at the 
studied DOX concentration range, eliminating the possibility that polymer themselves 
were responsible for the cytotoxicity. From the above results, we could conclude that 
the encapsulation of DOX into our star polyrotaxane could result in a significant 
higher antitumor efficacy than equivalent free DOX, especially in low DOX dose. 
This unique property of our star polyrotaxane could be highly beneficial to reduce 
cardiotoxicity, which is a serious drawback for DOX as anti-cancer therapy.[17, 18] 
7.3.7 Intracellular uptake of DOX 
 
Fig. 7.6 Cellular uptake and internalization of (a) PRCD6P123/DOX, (b) 
PRCD12P123/DOX, (c) PRCD22P177/DOX and (d) Free DOX in MB231 cells at 2 h, 5 h, 
18h and 24 h followed by fluorescence microscopy. (DOX conc.=1 μg/mL). 
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Fig. 7.7 Cellular uptake and internalization of (a) PRCD6P123/DOX, (b) 
PRCD12P123/DOX, (c) PRCD22P177/DOX and (d) Free DOX in Hela cells at 2 h, 5 h, 
18h and 24 h followed by fluorescence microscopy. (DOX conc.=1 μg/mL). Scale 
length=100µm. 
Cellular uptake of DOX may play an important role in the contribution to its 
antitumor ability. DOX exhibits its own fluorescence with an excitation and emission 
wavelengths of 480 and 580 nm, respectively. Therefore, fluorescence microscopy 
was used to evaluate the cellular uptake and internalization behaviour of DOX loaded 
PRP using MB231 and Hela cell line (Fig. 7.6-7.7). As shown in Fig. 7.6-7.7, DOX 
loaded polyrotaxane could be rapidly uptaken by the cells and the uptake efficiency 
increased with time. Notably, in contrast to free DOX without transport carriers (Fig. 
7.6d), the PRP/DOX complexes exhibited a much faster and higher cell uptake, as 
reflected by the higher intensity of fluorescence within the exposed cells. The high 
internalization and cell uptake of our core-shell carriers may be due to the small size 
and water soluble PEG shell, which increased the cell-impermeability and stability of 
DOX.[30] Since it has been reported that fluorescence is observed only when DOX is 
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released due to the self-quenching effect of DOX in nanoparticles,[35, 36] it is clear 
from these fluorescence images that DOX has been efficiently released from star 
polyrotaxane nanoaggregates.  
7.3.8 Co-delivery of DOX and luciferase-encoding plasmid 
 
Fig. 7.8 Gene transfection efficiency of the polyplexes formed by PRCDP, PRCDP/DOX 
and 25K PEI in (a, b) MB231 and (c, d) Hela cells in the presence of serum. Data 
represent mean±SD (n=3). DOX concentration (μg/mL) in transfection medium (N/P=10): 
1.24 (PRCD12P123); 0.53 (PRCD12P177); 0.79 (PRCD22P177) and 0.83 (PRCD30P177) 
Based on the previous researches, reduction-sensitive star polyrotaxanes 
PRCDP are found to exhibit excellent gene transfection efficiency (chapter 6). 
Structure similarly with star polyrotaxane we studied before, PRCDP/DOX is also 
expected to mediate efficient gene delivery. In vitro gene transfection efficiency of 
the DOX loaded polyrotaxanes was assessed using luciferase as a marker gene in 
MB231 and Hela cells in the presence of serum (Fig. 7.8). 25k PEI and PRCDP 
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without DOX loading was set as control. As shown in Fig. 7.8, PRCDP/DOX still 
exhibited excellent gene transfection efficiency, which is comparable or even better 
than PEI 25k. At lower N/P ratios, the co-delivery of DOX into the polyrotaxane 
showed a slightly higher gene expression by comparing with single gene delivery 
system of PRCDP. However, when the N/P ratio increased, their transfection level 
appeared to be reduced. The reduced luciferase expression could be attributed to the 
cytotoxicity of DOX, which may inhibit macromolecular biosynthesis. This 
phenomenon was also reported by other groups.[7, 19] The results confirmed that 
drug encapsulation in the cyclodextrin core would not hamper gene transfection. 
Moreover, it seems that the endocytosis of the vector and gene expression was 
implemented quickly before DOX exerted endocellular function, which could 
probably resulted in enhanced transfection ability at lower N/P ratios.[37]  
7.3.9 Co-delivery of DOX and p53-encoding plasmid 
 
Fig. 7.9 RT-PCR detection of p53 mRNA expression levels in MB231 cells transfected 
with naked p53, PR/DOX, PR/p53, PR/DOX+PR/P53, and PR/DOX/p53 complexes at 
N/P of 10. (PR1 refers to PRCD12P123 and PR2 denotes PRCD12P177, **p<0.01, 
*p<0.05, n=3)  
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The p53 gene is a tumor suppressor gene, which can inhibit cell proliferation 
and affect various cellular pathways, such as DNA repair, cell cycle regulation and 
apoptosis [38]. It is also the most frequently mutated gene occurring mutations in 
around half of all human tumors, such as breast, liver and ovarian tumors [39]. The 
mutant p53 gene cannot suppress tumor growth and also results in drug resistance. 
Therefore, the reintroduction of wild-type p53 is crucial in tumor inhibition by 
inducing apoptosis and G1-cell cycle arrest in various carcinoma cells [40]. In this 
chapter, based on the above transfection results mediated by pRL-CMV, we further 
evaluated the synergistic cancer therapeutic effects of drug/gene co-delivery using 
wild-type p53. Because the p53 protein has a shorter half-life, mRNA levels were 
used as an indicator of gene expression and detected by RT-PCR. Fig. 7.9 shows the 
mRNA expression levels of p53 in MB231 transfected with DOX loaded star 
polyrotaxanes: PR1/DOX/p53 (Fig. 7.9a) and PR2/DOX/p53 (Fig. 7.9b). Their 
expressions were compared with various control groups, such as naked p53 plasmid, 
PR/DOX without p53, PR/p53 without DOX and physical mixture of PR/DOX and 
PR/p53 (PR/p53+PR/DOX). As shown in Fig. 7.9, the p53 mRNA expressions of 
both DOX load polyrotaxanes (PR/DOX/p53) were significantly higher than the 
control groups, indicating their excellent transfection efficiency. Importantly, by 
comparing PR/p53 and PR/DOX/p53, it can be seen that the presence of DOX made 
the vectors much more effective in causing p53 upregulation. For example, in Fig. 
7.9a, the PR1/DOX/p53 exhibited 4 times higher p53 transfection abilities than that 
without DOX (PR1/p53). The results suggested that the synergy between drug and 
gene therapeutics was supported by the increased p53 expression levels in the 
presence of DOX. Similar results were also found in other DOX based codelivery 
systems.[7, 19] The synergistic effect between p53 gene and DOX could be explained 
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by the mechanism of DOX antitumor activity. It was reported that p53 protein could 
be positively in response to some stress signals such as DNA damages caused by 
drugs, like DOX.[41, 42] Wang et al. further found that DOX induced apoptosis of 
tumor cells through the activation of p53-dependent apoptosis pathways.[43] 
Additionally, physical mixture of gene and drug is another therapeutic system. 
In Fig. 7.9b, the p53 mRNA expression with PR2/p53+PR2/DOX was found higher 
than those of p53, PR2/p53 and PR2/DOX, but the levels are still 50% lower than that 
of PR2/DOX/p53. It is probably because that the codelivery system PR2/DOX/p53 
can ensure both gene and drug to be delivered into the same cancer cells. However, 
the physical mixture may cause separated delivery pathways and result in 
incompletely or less effectively synergistic effects of drug and gene.[19] Therefore, it 
could be concluded that our design of star polyrotaxane nanoaggregates for co-
delivery of DOX and gene into one system did present the gene expression 
enhancement and higher anti-tumor ability.  
7.4 CONCLUSIONS 
In this chapter, a novel gene/drug co-delivery system was successfully 
designed and synthesized based on star cationic polyrotaxane, which consists of 
controlled threaded α-CD, star PEG and low molecular weight PDMAEMA segments 
linked to the end of PEG arms with disulfide linkage. This unique polyrotaxane could 
easily self-assembled in water to form cationic nanostructures with PEG/PDMAEMA 
shell and CD core. After encapsulating DOX, the nano-sized particles showed high 
drug loading efficiency around 16%~70% and the loading ability increased with the 
increase of CD threaded numbers in the core. Intracellularly, the core-shell structures 
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were capable of faster internalization, higher intracellular uptake and higher 
anticancer efficacy as compared to free DOX, especially in low drug dose. It could be 
helpful to reduce cardiotoxicity, which is a serious drawback for DOX as anti-cancer 
therapy. In addition, owning to the cationic end group PDMAEMA, the polyrotaxanes 
were capable of condensing and delivering DNA with high efficiency. More 
importantly, the co-delivery of DOX and p53 using the cationic nanostructures 
achieved a synergistic effects in suppressing the proliferation of cancer cells, which is 
much more effective than the single delivery systems. Therefore, given to the above 
results, our multifunctional PR/DOX/DNA delivery system should be very promising 
in delivering anticancer drug and gene simultaneously for improved cancer therapy.   




1. Marchisone C, Pfeffer U, Del Grosso F, Noonan DM, Santi L, Albini A. 
Progress towards gene therapy for cancer. J Exp Clin Cancer Res 2000 
Sep;19(3):261-270. 
2. Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S, et al. 
Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 
gene and bleomycin synergistically induced therapeutic immunity and 
suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003 
Nov;8(5):738-745. 
3. Aszalos A, Ladanyi A, Bocsi J, Szende B. Induction of apoptosis in MDR1 
expressing cells by daunorubicin with combinations of suboptimal 
concentrations of P-glycoprotein modulators. Cancer Lett 2001 Jun 
26;167(2):157-162. 
4. Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics 
and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. 
Biomaterials 2009 Oct;30(29):5660-5666. 
5. Cheng H, Li YY, Zeng X, Sun YX, Zhang XZ, Zhuo RX. Protamine 
sulfate/poly(L-aspartic acid) polyionic complexes self-assembled via 
electrostatic attractions for combined delivery of drug and gene. Biomaterials 
2009 Feb;30(6):1246-1253. 
6. Wang Y, Gao SJ, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and 
DNA from cationic core-shell nanoparticles self-assembled from a 
biodegradable copolymer. Nature Materials 2006 Oct;5(10):791-796. 
7. Wiradharma N, Tong YW, Yang YY. Self-assembled oligopeptide 
nanostructures for co-delivery of drug and gene with synergistic therapeutic 
effect. Biomaterials 2009 Jun;30(17):3100-3109. 
8. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, et al. Co-delivery of siRNA 
and paclitaxel into cancer cells by biodegradable cationic micelles based on 
PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010 
Mar;31(8):2408-2416. 
9. Xiao W, Chen X, Yang L, Mao Y, Wei Y, Chen L. Co-delivery of doxorubicin 
and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm 2010 
Jun 30;393(1-2):119-126. 
10. Liu F, Shollenberger LM, Huang L. Non-immunostimulatory nonviral vectors. 
FASEB J 2004 Nov;18(14):1779-1781. 
11. Xu Z, Zhang Z, Chen Y, Chen L, Lin L, Li Y. The characteristics and 
performance of a multifunctional nanoassembly system for the co-delivery of 
docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. 
Biomaterials 2010 Feb;31(5):916-922. 
12. Hu QD, Fan H, Ping Y, Liang WQ, Tang GP, Li J. Cationic supramolecular 
nanoparticles for co-delivery of gene and anticancer drug. Chem Commun 
(Camb) 2011 May 21;47(19):5572-5574. 
13. Wang Y, Ke CY, Beh CW, Liu SQ, Goh SH, Yang YY. The self-assembly of 
biodegradable cationic polymer micelles as vectors for gene transfection. 
Biomaterials 2007 Dec;28(35):5358-5368. 
Chapter 7. Self-assembled nanostructures based on star PR for gene/drug codelivery 
243 
14. Wang Y, Wang LS, Goh SH, Yang YY. Synthesis and characterization of 
cationic micelles self-assembled from a biodegradable copolymer for gene 
delivery. Biomacromolecules 2007 Mar;8(3):1028-1037. 
15. Akinc A, Anderson DG, Lynn DM, Langer R. Synthesis of poly(beta-amino 
ester)s optimized for highly effective gene delivery. Bioconjugate Chemistry 
2003 Sep-Oct;14(5):979-988. 
16. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for 
drug delivery. Journal of Pharmaceutical Sciences 2003 Jul;92(7):1343-1355. 
17. Brown MD, Schatzlein A, Brownlie A, Jack V, Wang W, Tetley L, et al. 
Preliminary characterization of novel amino acid based polymeric vesicles as 
gene and drug delivery agents. Bioconjugate Chemistry 2000 Nov-
Dec;11(6):880-891. 
18. Son YJ, Jang JS, Cho YW, Chung H, Park RW, Kwon IC, et al. 
Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan 
nanoaggregates by EPR effect. Journal of Controlled Release 2003 Aug;91(1-
2):135-145. 
19. Lu X, Wang QQ, Xu FJ, Tang GP, Yang WT. A cationic prodrug/therapeutic 
gene nanocomplex for the synergistic treatment of tumors. Biomaterials 2011 
Jul;32(21):4849-4856. 
20. Zhang XW, Zhu XQ, Ke FY, Ye L, Chen EQ, Zhang AY, et al. Preparation 
and self-assembly of amphiphilic triblock copolymers with polyrotaxane as a 
middle block and their application as carrier for the controlled release of 
Amphotericin B. Polymer 2009 Aug;50(18):4343-4351. 
21. Loh XJ, Goh SH, Li J. New biodegradable thermogelling copolymers having 
very low gelation concentrations. Biomacromolecules 2007 Feb;8(2):585-593. 
22. Yang XY, Chen LT, Huang B, Bai F, Yang XL. Synthesis of pH-sensitive 
hollow polymer microspheres and their application as drug carriers. Polymer 
2009 Jul;50(15):3556-3563. 
23. Ren LX, Ke FY, Chen YM, Liang DH, Huang J. Supramolecular ABA 
triblock copolymer with polyrotaxane as B block and its hierarchical self-
assembly. Macromolecules 2008 Jul;41(14):5295-5300. 
24. Liu J, Sondjaja HR, Tam KC. Alpha-cyclodextrin-induced self-assembly of a 
double-hydrophilic block copolymer in aqueous solution. Langmuir 2007 Apr 
24;23(9):5106-5109. 
25. Tong XM, Zhang XW, Ye L, Zhang AY, Feng ZG. Synthesis and 
characterization of block copolymers comprising a polyrotaxane middle block 
flanked by two brush-like PCL blocks. Soft Matter 2009;5(9):1848-1855. 
26. Li J, Yang C, Li HZ, Wang X, Goh SH, Ding JL, et al. Cationic 
supramolecules composed of multiple oligoethylenimine-grafted beta-
cyclodextrins threaded on a polymer chain for efficient gene delivery. 
Advanced Materials 2006 Nov;18(22):2969-+. 
27. Yang C, Li J. Thermoresponsive Behavior of Cationic Polyrotaxane 
Composed of Multiple Pentaethylenehexamine-grafted alpha-Cyclodextrins 
Threaded on Poly(propylene oxide)-Poly(ethylene oxide)-Poly(propylene 
oxide) Triblock Copolymer. Journal of Physical Chemistry B 2009 
Jan;113(3):682-690. 
28. Bae SJ, Suh JM, Sohn YS, Bae YH, Kim SW, Jeong B. Thermogelling 
poly(caprolactone-b-ethylene glycol-b-caprolactone) aqueous solutions. 
Macromolecules 2005 Jun;38(12):5260-5265. 
Chapter 7. Self-assembled nanostructures based on star PR for gene/drug codelivery 
244 
29. Hwang MJ, Suh JM, Bae YH, Kim SW, Jeong B. Caprolactonic poloxamer 
analog: PEG-PCL-PEG. Biomacromolecules 2005 Mar-Apr;6(2):885-890. 
30. Lee ALZ, Wang Y, Cheng HY, Pervaiz S, Yang YY. The co-delivery of 
paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 
2009 Feb;30(5):919-927. 
31. Lin JP, Zhang SN, Chen T, Lin SL, Jin HT. Micelle formation and drug 
release behavior of polypeptide graft copolymer and its mixture with 
polypeptide block copolymer. International Journal of Pharmaceutics 2007 
May;336(1):49-57. 
32. Oh I, Lee K, Kwon HY, Lee YB, Shin SC, Cho CS, et al. Release of 
adriamycin from poly(gamma-benzyl-L-glutamate)/poly(ethylene oxide) 
nanoparticles. International Journal of Pharmaceutics 1999 Apr;181(1):107-
115. 
33. Chen YC, Liao LC, Lu PL, Lo CL, Tsai HC, Huang CY, et al. The 
accumulation of dual pH and temperature responsive micelles in tumors. 
Biomaterials 2012 Jun;33(18):4576-4588. 
34. Li YL, Zhu L, Liu Z, Cheng R, Meng F, Cui JH, et al. Reversibly stabilized 
multifunctional dextran nanoparticles efficiently deliver doxorubicin into the 
nuclei of cancer cells. Angew Chem Int Ed Engl 2009;48(52):9914-9918. 
35. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive 
supramolecular assemblies for intracellular drug delivery: polymeric micelles 
that are responsive to intracellular pH change. Angew Chem Int Ed Engl 2003 
Oct 6;42(38):4640-4643. 
36. Sun HL, Guo BN, Li XQ, Cheng R, Meng FH, Liu HY, et al. Shell-Sheddable 
Micelles Based on Dextran-SS-Poly(epsilon-caprolactone) Diblock 
Copolymer for Efficient Intracellular Release of Doxorubicin. 
Biomacromolecules 2010;11(4):848-854. 
37. Qiu LY, Bae YH. Self-assembled polyethylenimine-graft-poly(epsilon-
caprolactone) micelles as potential dual carriers of genes and anticancer drugs. 
Biomaterials 2007 Oct;28(28):4132-4142. 
38. Yoshida K, Miki Y. The cell death machinery governed by the p53 tumor 
suppressor in response to DNA damage. Cancer Sci 2010 Apr;101(4):831-835. 
39. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human 
cancers. Science 1991 Jul 5;253(5015):49-53. 
40. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 
2001;82:55-84. 
41. Fornari FA, Jr., Jarvis DW, Grant S, Orr MS, Randolph JK, White FK, et al. 
Growth arrest and non-apoptotic cell death associated with the suppression of 
c-myc expression in MCF-7 breast tumor cells following acute exposure to 
doxorubicin. Biochem Pharmacol 1996 Apr 12;51(7):931-940. 
42. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference 
by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol 
Pharmacol 1994 Apr;45(4):649-656. 
43. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. 
Doxorubicin induces apoptosis in normal and tumor cells via distinctly 
different mechanisms. intermediacy of H(2)O(2)- and p53-dependent 
pathways. J Biol Chem 2004 Jun 11;279(24):25535-25543. 
 
 
Chapter 8 Conclusion and future research 
245 
CHAPTER 8 CONCLUSIONS AND FUTURE 
RESEARCH 
8.1 SUMMARY OF RESULTS AND CONCLUSION 
This research studied the synthesis of novel core-shell nanostructures self-
assembled from star polyrotaxane, based on star PEG, α-CD, triggered biodegradable 
linkage and cationic polymers (such as OEI or PDMAEMA), and investigated their 
applications to biomedical areas such as drug delivery and gene delivery.  
Firstly, a series of novel star polyrotaxanes is successful synthesized by 
controlled threading of α-CD on star PEG, and blocking the end of the polymer with 
both enzymatic biodegradable linkage. The SPR could further self-assembled into 
nanostructures in water with polyrotaxane core and hydrophilic PEG shell. Their self-
assembly behavior and enzymatic-triggered biodegradability was confirmed by CAC, 
TEM and particle size. The nano-sized particles provide high capacity for DOX 
loading with sustained in vitro release for more than 2 months. Furthermore, PR-
phe/DOX exhibited a faster release, suggesting their stimuli-responsible properties, 
which would be benefic to the controlled drug delivery. Intracellularly, the PR/DOX 
was capable of fast cell internalization and cell uptake to yield significantly enhanced 
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drug efficacy as compared to free DOX. And the DOX-loaded polyrotaxane which 
present a hydrophilic coating would be great interest in vivo due to the long-
circulating properties as compared to other structures.  
In order to meet the conflicting requirements of an ideal drug delivery system, 
we further developed a reduction-sensitive biodegradable system for rapid 
intracellular drug release based on the similar polyrotaxane self-assembled 
nanostructures. Disulfide linkage was introduced to the end of star PEG, which was 
threaded with α-CD. Similarly, this unique polyrotaxane could self-assembled into 
nanostructures with PR core and PEG shell. The biodegradability of polyrotaxane 
with disulfide bond in response to DTT was confirmed by TEM and particle size. 
After encapsulating DOX, the nano-sized particles exhibited sustained and reduction-
sensitive in vitro release profile within 30 days even in the presence of DTT. It is 
much longer than the in vitro release results reported by Sun and coworkers [1]. The 
unique property could be important for intravenous delivery in order to prolong the 
therapeutic effect and reduce cardiotoxicity, which is a serious drawback for DOX as 
an anti-cancer therapy. Furthermore, the core-shell nanostructures were capable of 
faster internalization, rapid intracellular uptake and higher anticancer efficacy as 
compared to reduction insensitive control and free DOX. Taken together, our SPR 
nanostructures boast many favorable properties as a drug carries, which include 
excellent biocompatibility and reduction-sensitive biodegradability, adequate drug 
loading capacity, sustained drug release, higher cell uptake and highly drug efficacy.  
Besides drug delivery, this research also developed a series of disulfide-
containing cationic polyrotaxanes as reduction-sensitive gene carriers and investigated 
their applications in gene delivery. Multiple OEI arms of different chain length were 
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conjugated onto α-CD rings in the polyrotaxane, which is end blocked with disulfide 
linkage. The cationic polyrotaxane displayed degradability and DNA release 
capability in response to DTT. Importantly, due to the introduction of low MW OEI 
with α-CD and disulfide linkage into the polyrotaxane, significant lower in vitro 
cytotoxicity and higher gene transfection were achieved in contrast to reduction 
insensitive control and polyethylenimine (PEI) 25k. They showed excellent in vitro 
transfection efficiency which was comparable to or even higher than that of PEI 25k. 
Furthermore, the hindrance effect of PEG shell allows the system to be stable in salt 
and protein solution, and thus improve their serum stability.  This research is helpful 
as it creates a new approach to design a reduction-sensitive delivery system by 
introducing disulfide linkage into polyrotaxane, which achieves rapid intracellular 
release, effective unpacking ability, low cytotoxicity, high transfection efficiency and 
high stability in biological fluids.   
Cytotoxicity, lack of cell specificity and serum-induced aggregation are the 
major obstacles for pDMAEMA-based polyplexes in application in gene delivery [2]. 
Aiming to increase the serum stability and improve the transfection efficiency of 
PDMAEMA systems with optimal DNA release and decreasing cytotoxicity, a novel 
reduction-sensitive and shell detachable gene delivery system was successfully 
developed based on star polyrotaxanes, which consists of partially threaded α-
cyclodextrin (α-CD), 8-arm PEG and low molecular weight PDMAEMA segments 
linked to the end of PEG arms with disulfide linkage. Their degradability and DNA 
release ability in response to DTT was confirmed. Remarkably, the biodegradable star 
polyrotaxane with disulfide linkage exhibited remarkable lower cytotoxicity and 
higher gene transfection efficiency in contrast to reduction insensitive control and PEI 
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25k with noticeably wider therapy window, which is highly desirable for in vivo gene 
therapy. More importantly, owning to the shell sheddable effect of hydrophilic PEG 
shell, the system could prevent aggregation in salt and protein solution.  
Based on the similar structures with above star cationic polyrotaxanes, a novel 
gene/drug co-delivery system was further designed, which consists of controlled 
threaded α-CD, star PEG and low molecular weight PDMAEMA segments linked to 
the end of PEG arms with disulfide linkage. This unique polyrotaxane could easily 
self-assembled in water to form cationic nanostructures with PEG/PDMAEMA shell 
and CD core. After encapsulating DOX, the nano-sized particles showed high drug 
loading efficiency around 16%~70% and the loading ability increased with the 
increase of CD threaded numbers in the core. Intracellularly, the core-shell structures 
were capable of faster internalization, higher intracellular uptake and higher 
anticancer efficacy as compared to free DOX, especially in low drug dose. In addition, 
owning to the cationic end group PDMAEMA, the polyrotaxanes were capable of 
condensing and delivering DNA with high efficiency. More importantly, the co-
delivery of DOX and p53 using the cationic nanostructures achieved a synergistic 
effects in suppressing the proliferation of cancer cells, which is much more effective 
than the single delivery systems. Therefore, given to the above results, our 
multifunctional PR/DOX/DNA delivery system should be very promising in 
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  The different versions of polymers were compared in Table 8.1. In short, the 
result of the present study exploited the applications of supramolecular self-assembled 
core-shell nanostructures based on star PEG and CDs to the field of drug delivery and 
gene therapy. This research is helpful in creating a new approach to design of 
reduction-sensitive delivery system by introducing disulfide linkage into polyrotaxane, 
which could achieve rapid intracellular release, low cytotoxicity, high transfection 
efficiency and effective unpacking ability.  
8.2 POSSIBLE FUTURE RESEARCH 
  The work presented in this thesis opens new avenues for the development of 
core-shell nanostructures derived from star polyrotaxanes and it can be utilized for 
effective drug and gene delivery due to the “smart design” and flexibility of the 
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polyrotaxane. However, this study did not explore the application of the 
biodegradable nanostructures as drug and gene carriers through in vivo tests since the 
in vivo animal tests are very complicated and involve many biological issues. Further 
research is therefore needed to investigate their advantages as drug and gene carriers 
by using in-vivo animal tests, which can be better suited for observing the overall 
effects of a novel material on a living subject.  
In addition, our unique core-shell nanostructures could also be applied in 
target drug/gene delivery. In the future, owning to the flexibility and easy 
modification of the supramolecular systems, the possible modifications, such as 
conjugating folic acid and peptide will be introduced to the CD rings in polyrotaxane 
to obtain targeting carriers. The proposed functional nanoparticels would show higher 
tumor uptake and concomitant enhanced tumor reduction. Furthermore, when folic 
acid is conjugated to the exterior of PEG shell, the nanostructures are targeted to 
cancer cells, and upon binding to the receptor, the particles will be endocytosed [3-5].  
Another possible avenue of future work is drug/gene codelivery. We have 
reported a strategy of gene/drug codelivery by combing the advantages of core-shell 
systems as drug carriers and cationic bioreductive polyrotaxane systems as gene 
carrier. The strategy was developed in our shell detachable core-shell nanostructures 
self-assembled from star polyrotaxanes with PDMAEMA. DOX was encapsulated in 
this system and some preliminary results were obtained. In the future research, based 
on the similar principles of drug delivery with core-shell nanostructures, our cationic 
polyrotaxane nanoaggregates could be utilized in co-delivery of other anticancer 
drugs (e.g. PTX, DTX) and therapeutic genes (e.g. siRNA), which could enhance 
gene transfection and antitumor efficacy in both in vitro and in vivo studies [6-10].  
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